data_6lms_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6lms _Structure_validation_residue.Date_analyzed 2020-07-17 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' THR . . . . . 0.467 ' HG1' HD22 ' A' ' 78' ' ' ASN . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.574 HG23 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB3' ' HB2' ' A' ' 70' ' ' ASN . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.574 HG12 HG23 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.467 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.58 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.58 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.464 ' HG ' ' H ' ' A' ' 136' ' ' SER . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.464 ' H ' ' HG ' ' A' ' 102' ' ' SER . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG22 ' A' ' 57' ' ' THR . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.566 HG23 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.417 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.406 HG23 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.485 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 HG23 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.528 ' HD1' ' H ' ' A' ' 89' ' ' THR . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.528 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.491 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . 0.664 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.664 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.406 ' HB3' HG23 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . 0.491 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.8 mttm . . . . . 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.559 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.662 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.662 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.431 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG23 ' A' ' 57' ' ' THR . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.645 HG23 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.419 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.645 HG12 HG23 ' A' ' 63' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 HG13 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.725 ' HD1' ' H ' ' A' ' 89' ' ' THR . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.725 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.414 HD23 ' HB2' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.419 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.431 ' CG2' ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.431 ' H ' ' CG2' ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.402 HG21 HD11 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.414 ' HB2' HD23 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.682 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.682 HG12 HG22 ' A' ' 63' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.491 HG23 HG13 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.43 HG23 ' H ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG23 ' A' ' 57' ' ' THR . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.496 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 63' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.62 ' HD1' ' H ' ' A' ' 89' ' ' THR . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.62 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.501 ' CD1' ' HB1' ' A' ' 122' ' ' ALA . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . 0.501 ' HB1' ' CD1' ' A' ' 111' ' ' PHE . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt . . . . . 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.474 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.4 ' H ' HG23 ' A' ' 57' ' ' THR . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.545 HG23 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.453 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.453 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.592 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.592 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.421 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . 0.421 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG23 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.427 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 61.5 mtpt . . . . . 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . 0.499 HG22 HG13 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.407 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.471 HD13 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . 0.407 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.457 ' O ' HG23 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.471 ' HB3' HD13 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt . . . . . 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG12 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG12 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.492 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.459 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.429 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.492 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.596 ' HD1' ' H ' ' A' ' 89' ' ' THR . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.596 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.421 ' CG2' ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . 0.421 ' H ' ' CG2' ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt . . . . . 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.4 ' H ' HG23 ' A' ' 57' ' ' THR . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.572 HG12 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.491 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.491 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.4 ' O ' ' HB2' ' A' ' 81' ' ' LYS . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 80' ' ' THR . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.408 ' HG ' ' HB1' ' A' ' 139' ' ' ALA . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.408 ' HB1' ' HG ' ' A' ' 102' ' ' SER . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.597 HG23 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.491 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.481 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.481 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.491 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.597 HG12 HG23 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.749 ' HD1' ' H ' ' A' ' 89' ' ' THR . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.749 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt . . . . . 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.622 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.461 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.461 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.622 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.538 ' HD1' ' H ' ' A' ' 89' ' ' THR . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.538 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt . . . . . 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.428 ' H ' HG22 ' A' ' 57' ' ' THR . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.58 HG12 HG23 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.495 HD22 ' HB2' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.465 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.408 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.495 ' HB2' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.47 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.553 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.457 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . 0.41 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.465 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.465 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.453 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.727 ' HD1' ' H ' ' A' ' 89' ' ' THR . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.727 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG22 ' A' ' 57' ' ' THR . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.613 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . 0.419 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . 0.419 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.509 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.514 HG23 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.613 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.588 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.588 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . 0.489 HD11 ' HA3' ' A' ' 135' ' ' GLY . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.514 ' HB3' HG23 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . 0.489 ' HA3' HD11 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . 0.439 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.438 ' H ' HG22 ' A' ' 57' ' ' THR . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.486 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.456 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.456 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 HG23 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.468 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.624 ' HD1' ' H ' ' A' ' 89' ' ' THR . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.624 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.436 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.563 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.446 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.563 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . 0.51 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.703 ' HD1' ' H ' ' A' ' 89' ' ' THR . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.703 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.418 ' H ' HG23 ' A' ' 57' ' ' THR . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.649 HG23 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.462 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.454 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.454 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.649 HG12 HG23 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.603 ' HD1' ' H ' ' A' ' 89' ' ' THR . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.603 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.411 HG21 HG11 ' A' ' 109' ' ' VAL . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.411 HG11 HG21 ' A' ' 103' ' ' VAL . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.41 ' HB ' ' HD2' ' A' ' 132' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.41 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp . . . . . 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.539 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.433 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.572 ' HD1' ' H ' ' A' ' 89' ' ' THR . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.572 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.497 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.497 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . 0.41 ' H ' HG22 ' A' ' 57' ' ' THR . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.587 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.431 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' TYR . . . . . 0.431 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.451 ' CD2' ' H ' ' A' ' 88' ' ' GLN . 9.0 t-160 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLN . . . . . 0.451 ' H ' ' CD2' ' A' ' 87' ' ' HIS . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.44 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.4 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.4 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ASN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.855 0.36 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 64.74 -173.98 0.17 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-O 121.459 0.647 . . . . 0.0 109.455 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -125.17 137.13 54.14 Favored 'General case' 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' THR . . . . . 0.467 ' HG1' HD22 ' A' ' 78' ' ' ASN . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.574 HG23 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB3' ' HB2' ' A' ' 70' ' ' ASN . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.574 HG12 HG23 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.467 HD22 ' HG1' ' A' ' 62' ' ' THR . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.58 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.58 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.464 ' HG ' ' H ' ' A' ' 136' ' ' SER . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.464 ' H ' ' HG ' ' A' ' 102' ' ' SER . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.88 173.41 6.51 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.6 139.54 45.6 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG22 ' A' ' 57' ' ' THR . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.566 HG23 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.417 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.417 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.406 HG23 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.485 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.566 HG12 HG23 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.528 ' HD1' ' H ' ' A' ' 89' ' ' THR . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.528 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.491 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . 0.664 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.664 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.406 ' HB3' HG23 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . 0.491 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG23 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 121.054 0.454 . . . . 0.0 110.358 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.677 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -87.53 154.87 20.29 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.677 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.8 mttm -118.5 138.78 52.27 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.559 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.559 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.662 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.662 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.431 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.031 0.443 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.0 ttpt -71.81 139.5 48.99 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -130.37 135.9 48.52 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG23 ' A' ' 57' ' ' THR . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.645 HG23 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.419 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.645 HG12 HG23 ' A' ' 63' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 HG13 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.725 ' HD1' ' H ' ' A' ' 89' ' ' THR . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.725 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.414 HD23 ' HB2' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.419 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.431 ' CG2' ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.431 ' H ' ' CG2' ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.402 HG21 HD11 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.414 ' HB2' HD23 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 120.957 0.408 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.66 172.56 6.88 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -74.06 139.77 44.89 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.592 HG12 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.682 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.682 HG12 HG22 ' A' ' 63' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.491 HG23 HG13 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.6 t0 . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.054 0.454 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.36 173.15 6.49 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.5 140.01 46.11 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.43 HG23 ' H ' ' A' ' 58' ' ' LYS . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG23 ' A' ' 57' ' ' THR . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.554 HG23 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.496 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.451 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.451 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.554 HG12 HG23 ' A' ' 63' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.62 ' HD1' ' H ' ' A' ' 89' ' ' THR . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.62 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.501 ' CD1' ' HB1' ' A' ' 122' ' ' ALA . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . 0.501 ' HB1' ' CD1' ' A' ' 111' ' ' PHE . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.999 0.428 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.64 170.69 8.25 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt -73.64 143.99 46.07 Favored 'General case' 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.474 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.4 ' H ' HG23 ' A' ' 57' ' ' THR . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.485 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.545 HG23 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.453 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.453 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.592 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.592 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.421 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . 0.421 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG23 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.427 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 120.794 0.33 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.515 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.37 -170.11 0.2 Allowed 'General case' 0 C--N 1.358 0.936 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.515 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 61.5 mtpt -85.72 141.77 29.48 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.742 HG23 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.742 HG12 HG23 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . 0.499 HG22 HG13 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.407 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.471 HD13 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . 0.407 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.457 ' O ' HG23 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.457 HG23 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.471 ' HB3' HD13 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 . . . . . 0 N--CA 1.487 1.408 0 CA-C-O 120.987 0.423 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.424 ' HZ2' ' CG2' ' A' ' 114' ' ' VAL . 0.0 OUTLIER -92.25 157.0 16.91 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -179.984 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -93.65 131.04 39.34 Favored 'General case' 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG12 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG12 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.492 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.459 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.429 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.429 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.492 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.596 ' HD1' ' H ' ' A' ' 89' ' ' THR . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.596 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.421 ' CG2' ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . 0.421 ' H ' ' CG2' ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . 0.424 ' CG2' ' HZ2' ' A' ' 52' ' ' LYS . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.32 170.58 7.79 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -73.55 142.44 46.66 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.4 ' H ' HG23 ' A' ' 57' ' ' THR . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.572 HG12 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.491 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.491 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.4 ' O ' ' HB2' ' A' ' 81' ' ' LYS . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . 0.4 ' HB2' ' O ' ' A' ' 80' ' ' THR . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.408 ' HG ' ' HB1' ' A' ' 139' ' ' ALA . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.408 ' HB1' ' HG ' ' A' ' 102' ' ' SER . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 121.142 0.496 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.446 ' HZ1' HG22 ' A' ' 54' ' ' VAL . 0.0 OUTLIER -151.92 167.69 27.55 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.967 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -129.93 142.38 50.66 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.446 HG22 ' HZ1' ' A' ' 52' ' ' LYS . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.597 HG23 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.491 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.481 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.481 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.491 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.597 HG12 HG23 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.749 ' HD1' ' H ' ' A' ' 89' ' ' THR . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.749 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.019 0.438 . . . . 0.0 110.661 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -152.45 -155.16 0.58 Allowed 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.75 136.77 57.28 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.622 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.461 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.461 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.622 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.538 ' HD1' ' H ' ' A' ' 89' ' ' THR . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.538 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.8 t0 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.38 170.66 7.79 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -73.42 147.71 43.96 Favored 'General case' 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.428 ' H ' HG22 ' A' ' 57' ' ' THR . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.58 HG23 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.58 HG12 HG23 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.495 HD22 ' HB2' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.465 ' O ' HG23 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.408 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.495 ' HB2' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 121.128 0.49 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.94 157.69 16.21 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -96.23 130.36 43.32 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.47 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.553 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.457 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . 0.41 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.465 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.465 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.553 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.453 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.727 ' HD1' ' H ' ' A' ' 89' ' ' THR . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.727 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.068 0.461 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.478 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -82.16 141.99 32.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.924 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.478 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.6 mttm -81.92 134.57 35.4 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.427 ' H ' HG22 ' A' ' 57' ' ' THR . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.613 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . 0.419 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . 0.419 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.509 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.514 HG23 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.613 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.588 ' HD1' ' H ' ' A' ' 89' ' ' THR . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.588 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . 0.489 HD11 ' HA3' ' A' ' 135' ' ' GLY . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.514 ' HB3' HG23 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . 0.489 ' HA3' HD11 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . 0.439 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 121.041 0.448 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 11.3 tptt -103.71 134.41 47.08 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -70.93 135.95 48.25 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.438 ' H ' HG22 ' A' ' 57' ' ' THR . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.602 HG12 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.521 HG23 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.486 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.456 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.456 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.486 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.521 HG12 HG23 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.468 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.624 ' HD1' ' H ' ' A' ' 89' ' ' THR . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.624 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.436 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 . . . . . 0 N--CA 1.489 1.484 0 CA-C-O 120.952 0.406 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.03 172.33 6.86 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.68 139.83 45.66 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.563 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.446 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.563 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . 0.51 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.703 ' HD1' ' H ' ' A' ' 89' ' ' THR . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.703 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.742 0.306 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . 0.51 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.13 -169.49 0.2 Allowed 'General case' 0 C--N 1.358 0.963 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . 0.51 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 98.7 mttt -85.37 137.26 33.06 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.418 ' H ' HG23 ' A' ' 57' ' ' THR . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.649 HG23 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.462 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.454 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.454 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.649 HG12 HG23 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.603 ' HD1' ' H ' ' A' ' 89' ' ' THR . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.603 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.411 HG21 HG11 ' A' ' 109' ' ' VAL . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.411 HG11 HG21 ' A' ' 103' ' ' VAL . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.41 ' HB ' ' HD2' ' A' ' 132' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.41 ' HD2' ' HB ' ' A' ' 131' ' ' VAL . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 121.01 0.433 . . . . 0.0 110.399 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.84 172.18 6.95 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -74.0 139.67 44.94 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.539 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.433 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.463 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.463 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.572 ' HD1' ' H ' ' A' ' 89' ' ' THR . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.572 ' H ' ' HD1' ' A' ' 87' ' ' HIS . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.497 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.497 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.074 0.464 . . . . 0.0 110.625 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.36 171.43 7.34 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -73.91 142.76 45.94 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . 0.556 ' O ' HG12 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . 0.41 ' H ' HG22 ' A' ' 57' ' ' THR . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.556 HG12 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.587 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.472 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.431 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . 0.431 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.587 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.451 ' CD2' ' H ' ' A' ' 88' ' ' GLN . 9.0 t-160 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLN . . . . . 0.451 ' H ' ' CD2' ' A' ' 87' ' ' HIS . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.44 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.4 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.4 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ASN . . . . . 0.44 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 132' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.543 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.628 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 57' ' ' THR . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.513 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.48 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.48 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.457 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.457 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLN . . . . . 0.4 ' HB2' ' HB3' ' A' ' 101' ' ' ARG . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.679 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.4 ' HB3' ' HB2' ' A' ' 88' ' ' GLN . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.679 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.413 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.413 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.518 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.425 HG22 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.489 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . 0.662 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.662 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.425 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.454 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.8 mttm . . . . . 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.524 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.644 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.558 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.659 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.437 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.659 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 87' ' ' HIS . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.402 ' N ' HG22 ' A' ' 86' ' ' VAL . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.595 ' O ' HD23 ' A' ' 100' ' ' LEU . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.595 HD23 ' O ' ' A' ' 99' ' ' TYR . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.509 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.644 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.571 HG13 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.639 HG22 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.683 HD12 HG21 ' A' ' 86' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 HD12 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.437 HD22 ' HB3' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.413 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG22 ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.688 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.457 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 131' ' ' VAL . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.437 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.667 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.417 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.717 HD12 HG21 ' A' ' 86' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.717 HG21 HD12 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 54' ' ' VAL . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.61 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 57' ' ' THR . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.541 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.448 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.448 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.882 HD12 HG11 ' A' ' 86' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.518 HH21 HG11 ' A' ' 59' ' ' VAL . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.945 HG12 ' HB3' ' A' ' 122' ' ' ALA . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.945 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt . . . . . 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.473 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.604 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.519 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.545 HG22 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.449 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.449 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.604 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.478 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.426 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.513 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ARG . . . . . 0.426 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG22 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.428 ' H ' HG22 ' A' ' 133' ' ' VAL . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.513 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 61.5 mtpt . . . . . 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.537 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.778 ' O ' HG23 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 57' ' ' THR . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.74 HG22 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.74 HG12 HG22 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.477 ' HE ' HG11 ' A' ' 59' ' ' VAL . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.73 HG21 HD12 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.689 HD22 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.587 HG22 ' H ' ' A' ' 104' ' ' GLY . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.587 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.543 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASN . . . . . 0.402 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.689 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt . . . . . 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.666 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG13 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.498 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 87' ' ' HIS . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.53 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.723 HG22 ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.723 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.666 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt . . . . . 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.645 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.486 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.486 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.574 HD22 ' CB ' ' A' ' 139' ' ' ALA . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.476 ' CE2' HG21 ' A' ' 75' ' ' ILE . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.645 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.574 ' CB ' HD22 ' A' ' 100' ' ' LEU . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.545 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.641 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 57' ' ' THR . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG22 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.502 HG22 ' N ' ' A' ' 87' ' ' HIS . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.502 ' N ' HG22 ' A' ' 86' ' ' VAL . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.526 HD22 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 131' ' ' VAL . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.526 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt . . . . . 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.494 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.614 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.614 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.473 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.473 ' N ' HG22 ' A' ' 86' ' ' VAL . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' HB1' ' A' ' 139' ' ' ALA . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.407 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt . . . . . 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.547 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.572 HG22 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.428 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.572 HG12 HG22 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.505 ' CE2' HG21 ' A' ' 75' ' ' ILE . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.631 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.466 ' O ' HG22 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.456 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.461 ' N ' HG22 ' A' ' 86' ' ' VAL . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.553 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.686 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.415 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.554 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.457 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.457 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.484 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 139' ' ' ALA . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.518 ' HB3' HG22 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.686 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' GLY . . . . . 0.451 ' HA3' HD12 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 54' ' ' VAL . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.55 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.679 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.516 HG22 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.526 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.526 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.516 HG12 HG22 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.471 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.439 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.439 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.459 ' O ' HD23 ' A' ' 100' ' ' LEU . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.85 HD22 ' HB3' ' A' ' 139' ' ' ALA . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.679 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.473 ' O ' HG22 ' A' ' 131' ' ' VAL . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.473 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.494 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ARG . . . . . 0.513 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.497 HG22 ' N ' ' A' ' 87' ' ' HIS . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.497 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 139' ' ' ALA . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.41 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.419 ' O ' HD22 ' A' ' 100' ' ' LEU . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.637 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.641 HG22 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.495 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.609 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.641 HG12 HG22 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.48 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.48 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.631 HD22 ' HB3' ' A' ' 139' ' ' ALA . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.609 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 104' ' ' GLY . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.522 ' O ' HG22 ' A' ' 131' ' ' VAL . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.522 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.412 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.631 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp . . . . . 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.521 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.657 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.529 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.469 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.529 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.484 HG22 ' O ' ' A' ' 80' ' ' THR . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 87' ' ' HIS . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.491 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.727 HD22 ' HB1' ' A' ' 139' ' ' ALA . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.496 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.657 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.53 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.496 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.727 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 54' ' ' VAL . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.533 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . 0.555 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.575 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LEU . . . . . 0.498 HD22 ' HB1' ' A' ' 139' ' ' ALA . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' PHE . . . . . 0.471 ' CE2' HG21 ' A' ' 75' ' ' ILE . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.656 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ASN . . . . . 0.421 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.533 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ALA . . . . . 0.498 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.855 0.36 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 64.74 -173.98 0.17 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-O 121.459 0.647 . . . . 0.0 109.455 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -125.17 137.13 54.14 Favored 'General case' 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.543 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.628 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 57' ' ' THR . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.513 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.48 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.48 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.457 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.457 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLN . . . . . 0.4 ' HB2' ' HB3' ' A' ' 101' ' ' ARG . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.679 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.4 ' HB3' ' HB2' ' A' ' 88' ' ' GLN . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.679 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.88 173.41 6.51 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.6 139.54 45.6 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.413 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.413 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.518 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.425 HG22 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.489 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . 0.662 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.662 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.425 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.454 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 121.054 0.454 . . . . 0.0 110.358 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.665 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -87.53 154.87 20.29 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.665 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.8 mttm -118.5 138.78 52.27 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.524 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.644 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.558 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.659 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.437 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.659 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 87' ' ' HIS . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.402 ' N ' HG22 ' A' ' 86' ' ' VAL . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.595 ' O ' HD23 ' A' ' 100' ' ' LEU . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.595 HD23 ' O ' ' A' ' 99' ' ' TYR . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.509 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.644 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.031 0.443 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.0 ttpt -71.81 139.5 48.99 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -130.37 135.9 48.52 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.571 HG13 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.639 HG22 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.683 HD12 HG21 ' A' ' 86' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 HD12 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.437 HD22 ' HB3' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.413 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG22 ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.688 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.457 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 131' ' ' VAL . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.437 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 120.957 0.408 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.66 172.56 6.88 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -74.06 139.77 44.89 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.667 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.417 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.717 HD12 HG21 ' A' ' 86' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.717 HG21 HD12 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.6 t0 . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.054 0.454 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.36 173.15 6.49 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.5 140.01 46.11 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 54' ' ' VAL . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.61 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 57' ' ' THR . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.541 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.448 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.448 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.882 HD12 HG11 ' A' ' 86' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.518 HH21 HG11 ' A' ' 59' ' ' VAL . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.945 HG12 ' HB3' ' A' ' 122' ' ' ALA . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.945 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.999 0.428 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.64 170.69 8.25 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt -73.64 143.99 46.07 Favored 'General case' 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.473 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.604 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.519 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.545 HG22 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.449 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.449 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.604 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.478 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.426 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.513 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ARG . . . . . 0.426 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG22 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.428 ' H ' HG22 ' A' ' 133' ' ' VAL . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.513 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 120.794 0.33 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.531 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.37 -170.11 0.2 Allowed 'General case' 0 C--N 1.358 0.936 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.531 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 61.5 mtpt -85.72 141.77 29.48 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.537 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.778 ' O ' HG23 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 57' ' ' THR . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.74 HG22 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.74 HG12 HG22 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.477 ' HE ' HG11 ' A' ' 59' ' ' VAL . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.73 HG21 HD12 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.689 HD22 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.587 HG22 ' H ' ' A' ' 104' ' ' GLY . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.587 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.543 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASN . . . . . 0.402 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.689 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 . . . . . 0 N--CA 1.487 1.408 0 CA-C-O 120.987 0.423 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.25 157.0 16.91 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -93.65 131.04 39.34 Favored 'General case' 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.666 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG13 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.498 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 87' ' ' HIS . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.53 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.723 HG22 ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.723 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.666 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.32 170.58 7.79 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -73.55 142.44 46.66 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.645 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.486 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.486 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.574 HD22 ' CB ' ' A' ' 139' ' ' ALA . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.476 ' CE2' HG21 ' A' ' 75' ' ' ILE . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.645 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.574 ' CB ' HD22 ' A' ' 100' ' ' LEU . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 121.142 0.496 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.92 167.69 27.55 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -129.93 142.38 50.66 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.545 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.641 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 57' ' ' THR . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG22 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.502 HG22 ' N ' ' A' ' 87' ' ' HIS . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.502 ' N ' HG22 ' A' ' 86' ' ' VAL . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.526 HD22 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 131' ' ' VAL . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.526 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.019 0.438 . . . . 0.0 110.661 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -152.45 -155.16 0.58 Allowed 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.75 136.77 57.28 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.494 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.614 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.614 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.473 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.473 ' N ' HG22 ' A' ' 86' ' ' VAL . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' HB1' ' A' ' 139' ' ' ALA . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.407 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.8 t0 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.38 170.66 7.79 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -73.42 147.71 43.96 Favored 'General case' 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.547 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.572 HG22 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.428 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.572 HG12 HG22 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.505 ' CE2' HG21 ' A' ' 75' ' ' ILE . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.631 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.466 ' O ' HG22 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 121.128 0.49 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.94 157.69 16.21 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -96.23 130.36 43.32 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.456 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.461 ' N ' HG22 ' A' ' 86' ' ' VAL . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.553 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.068 0.461 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.484 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -82.16 141.99 32.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.924 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.484 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.6 mttm -81.92 134.57 35.4 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.686 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.415 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.554 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.457 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.457 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.484 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 139' ' ' ALA . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.518 ' HB3' HG22 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.686 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' GLY . . . . . 0.451 ' HA3' HD12 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 121.041 0.448 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 11.3 tptt -103.71 134.41 47.08 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -70.93 135.95 48.25 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 54' ' ' VAL . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.55 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.679 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.516 HG22 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.526 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.526 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.516 HG12 HG22 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.471 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.439 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.439 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.459 ' O ' HD23 ' A' ' 100' ' ' LEU . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.85 HD22 ' HB3' ' A' ' 139' ' ' ALA . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.679 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.473 ' O ' HG22 ' A' ' 131' ' ' VAL . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.473 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 . . . . . 0 N--CA 1.489 1.484 0 CA-C-O 120.952 0.406 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.03 172.33 6.86 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.68 139.83 45.66 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.494 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.513 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.497 HG22 ' N ' ' A' ' 87' ' ' HIS . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.497 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 139' ' ' ALA . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.41 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.419 ' O ' HD22 ' A' ' 100' ' ' LEU . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.742 0.306 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 52' ' ' LYS . . . . . 0.523 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.13 -169.49 0.2 Allowed 'General case' 0 C--N 1.358 0.963 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LYS . . . . . 0.523 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 98.7 mttt -85.37 137.26 33.06 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.637 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.641 HG22 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.495 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.609 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.641 HG12 HG22 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.48 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.48 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.631 HD22 ' HB3' ' A' ' 139' ' ' ALA . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.609 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 104' ' ' GLY . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.522 ' O ' HG22 ' A' ' 131' ' ' VAL . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.522 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.412 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.631 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 121.01 0.433 . . . . 0.0 110.399 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.84 172.18 6.95 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -74.0 139.67 44.94 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.521 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.657 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.529 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.469 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.529 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.484 HG22 ' O ' ' A' ' 80' ' ' THR . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 87' ' ' HIS . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.491 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.727 HD22 ' HB1' ' A' ' 139' ' ' ALA . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.496 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.657 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.53 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.496 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.727 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.074 0.464 . . . . 0.0 110.625 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.36 171.43 7.34 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -73.91 142.76 45.94 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 54' ' ' VAL . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.533 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . 0.555 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.575 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LEU . . . . . 0.498 HD22 ' HB1' ' A' ' 139' ' ' ALA . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' PHE . . . . . 0.471 ' CE2' HG21 ' A' ' 75' ' ' ILE . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.656 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ASN . . . . . 0.421 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.533 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ALA . . . . . 0.498 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt . . . . . 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.543 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.628 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 57' ' ' THR . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.513 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.48 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.48 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.457 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.457 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.4 ' HB2' ' HB3' ' A' ' 101' ' ' ARG . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.679 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.4 ' HB3' ' HB2' ' A' ' 88' ' ' GLN . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.679 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.413 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.413 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.518 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.425 HG22 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.489 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . 0.662 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.662 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.425 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.454 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.8 mttm . . . . . 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.524 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.644 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.558 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.659 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.437 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.659 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 87' ' ' HIS . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.402 ' N ' HG22 ' A' ' 86' ' ' VAL . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.595 ' O ' HD23 ' A' ' 100' ' ' LEU . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.595 HD23 ' O ' ' A' ' 99' ' ' TYR . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.509 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.644 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.571 HG13 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.639 HG22 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.683 HD12 HG21 ' A' ' 86' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 HD12 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.437 HD22 ' HB3' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.413 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.688 HG22 ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.688 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.457 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 131' ' ' VAL . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.437 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.667 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.417 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.717 HD12 HG21 ' A' ' 86' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.717 HG21 HD12 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt . . . . . 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 54' ' ' VAL . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.61 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 57' ' ' THR . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.541 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.448 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.448 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.882 HD12 HG11 ' A' ' 86' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.518 HH21 HG11 ' A' ' 59' ' ' VAL . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.945 HG12 ' HB3' ' A' ' 122' ' ' ALA . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.945 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt . . . . . 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.473 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.604 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.519 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.545 HG22 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.449 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.449 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.604 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.478 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.426 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.513 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . 0.426 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG22 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.428 ' H ' HG22 ' A' ' 133' ' ' VAL . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.513 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 61.5 mtpt . . . . . 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.537 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.778 ' O ' HG23 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 57' ' ' THR . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.74 HG22 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.74 HG12 HG22 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.477 ' HE ' HG11 ' A' ' 59' ' ' VAL . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.73 HG21 HD12 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.689 HD22 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.587 HG22 ' H ' ' A' ' 104' ' ' GLY . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.587 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.543 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . 0.402 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.689 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt . . . . . 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.666 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.529 HG13 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.498 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 87' ' ' HIS . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.53 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.723 HG22 ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.723 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.666 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt . . . . . 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.645 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.486 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.486 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.574 HD22 ' CB ' ' A' ' 139' ' ' ALA . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.476 ' CE2' HG21 ' A' ' 75' ' ' ILE . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.645 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.574 ' CB ' HD22 ' A' ' 100' ' ' LEU . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt . . . . . 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.545 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.641 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 57' ' ' THR . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.586 HG22 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.502 HG22 ' N ' ' A' ' 87' ' ' HIS . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.502 ' N ' HG22 ' A' ' 86' ' ' VAL . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.526 HD22 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 131' ' ' VAL . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.526 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt . . . . . 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.494 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.614 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.614 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.473 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.473 ' N ' HG22 ' A' ' 86' ' ' VAL . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' HB1' ' A' ' 139' ' ' ALA . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.407 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt . . . . . 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.547 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.572 HG22 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.428 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.572 HG12 HG22 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.505 ' CE2' HG21 ' A' ' 75' ' ' ILE . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.631 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.466 ' O ' HG22 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.456 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.461 ' N ' HG22 ' A' ' 86' ' ' VAL . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.553 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm . . . . . 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.686 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.415 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.554 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.457 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.457 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.484 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 139' ' ' ALA . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.518 ' HB3' HG22 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.686 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . 0.451 ' HA3' HD12 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt . . . . . 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 54' ' ' VAL . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.55 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.679 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.516 HG22 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.526 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.526 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.516 HG12 HG22 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.471 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.439 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.439 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.459 ' O ' HD23 ' A' ' 100' ' ' LEU . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.85 HD22 ' HB3' ' A' ' 139' ' ' ALA . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.679 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.473 ' O ' HG22 ' A' ' 131' ' ' VAL . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.473 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.494 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . 0.513 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.497 HG22 ' N ' ' A' ' 87' ' ' HIS . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.497 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 139' ' ' ALA . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.41 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.419 ' O ' HD22 ' A' ' 100' ' ' LEU . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt . . . . . 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.637 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.641 HG22 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.495 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.609 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.641 HG12 HG22 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.48 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.48 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.631 HD22 ' HB3' ' A' ' 139' ' ' ALA . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.609 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 104' ' ' GLY . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.522 ' O ' HG22 ' A' ' 131' ' ' VAL . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.522 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.412 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.631 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp . . . . . 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.521 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.657 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.529 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.469 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.529 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.484 HG22 ' O ' ' A' ' 80' ' ' THR . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 87' ' ' HIS . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.491 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.727 HD22 ' HB1' ' A' ' 139' ' ' ALA . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.496 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.657 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.53 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.496 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.727 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp . . . . . 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 54' ' ' VAL . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.533 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . 0.555 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.575 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.404 ' CD2' ' H ' ' A' ' 88' ' ' GLN . 9.0 t-160 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLN . . . . . 0.404 ' H ' ' CD2' ' A' ' 87' ' ' HIS . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LEU . . . . . 0.498 HD22 ' HB1' ' A' ' 139' ' ' ALA . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' PHE . . . . . 0.471 ' CE2' HG21 ' A' ' 75' ' ' ILE . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.656 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ASN . . . . . 0.421 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.533 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ALA . . . . . 0.498 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 120.855 0.36 . . . . 0.0 110.514 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 64.74 -173.98 0.17 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-O 121.459 0.647 . . . . 0.0 109.455 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -125.17 137.13 54.14 Favored 'General case' 0 CA--C 1.49 -1.339 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.5 t -108.38 121.13 60.94 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.439 0 N-CA-C 105.267 -2.123 . . . . 0.0 105.267 179.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.543 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.22 -35.91 7.87 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.871 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.502 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.04 152.83 40.74 Favored 'General case' 0 N--CA 1.434 -1.24 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 -179.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.628 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.1 t -94.71 -174.53 3.32 Favored 'General case' 0 CA--C 1.492 -1.274 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 21.2 pttm -42.19 108.09 0.09 Allowed 'General case' 0 N--CA 1.445 -0.716 0 CA-C-O 122.27 1.033 . . . . 0.0 110.725 -179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.628 HG13 ' O ' ' A' ' 57' ' ' THR . 19.4 m -121.06 160.59 21.87 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 N-CA-C 106.027 -1.842 . . . . 0.0 106.027 178.288 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 78.0 mt -104.05 139.64 38.88 Favored 'General case' 0 N--CA 1.433 -1.295 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -148.15 160.38 28.32 Favored Glycine 0 CA--C 1.489 -1.583 0 N-CA-C 107.876 -2.09 . . . . 0.0 107.876 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 99.3 m -105.91 129.98 53.95 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.568 HG22 HG12 ' A' ' 75' ' ' ILE . 96.0 t -73.77 116.24 15.9 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.102 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.9 mtpt -70.13 -43.97 69.86 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 179.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.6 p-90 -172.57 155.38 3.34 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.513 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 53.2 t80 -142.68 120.97 12.29 Favored 'General case' 0 N--CA 1.434 -1.247 0 N-CA-C 105.602 -1.999 . . . . 0.0 105.602 179.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 59.2 t-20 -95.82 116.05 28.33 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 70.6 t -62.74 -40.33 88.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -179.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.77 -39.75 95.02 Favored 'General case' 0 C--N 1.352 0.703 0 O-C-N 122.182 -0.323 . . . . 0.0 110.14 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.48 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.4 m-20 -74.07 -30.98 62.65 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -179.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.99 14.79 71.45 Favored Glycine 0 C--N 1.349 1.303 0 N-CA-C 107.976 -2.05 . . . . 0.0 107.976 -179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.48 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.3 p90 -157.35 165.78 34.87 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.05 -166.13 19.17 Favored Glycine 0 CA--C 1.489 -1.582 0 N-CA-C 107.164 -2.374 . . . . 0.0 107.164 -179.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -128.68 141.09 51.45 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.568 HG12 HG22 ' A' ' 63' ' ' VAL . 88.8 mt -120.65 129.11 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.137 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 179.706 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.96 125.48 34.55 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -74.31 127.19 32.38 Favored 'General case' 0 N--CA 1.431 -1.411 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 179.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -90.47 0.82 57.16 Favored 'General case' 0 CA--C 1.503 -0.859 0 C-N-CA 119.831 -0.747 . . . . 0.0 109.736 -178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -98.57 -36.69 9.82 Favored 'General case' 0 CA--C 1.505 -0.766 0 C-N-CA 119.557 -0.857 . . . . 0.0 109.971 -178.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.7 m -115.91 -9.97 11.72 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? 67.28 37.37 3.63 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -116.78 146.38 42.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 179.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.77 141.35 42.59 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.31 141.4 46.62 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -91.59 132.3 36.41 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -178.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.457 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.86 152.36 31.09 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.17 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.457 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.9 t-80 -133.44 158.79 42.18 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.4 ' HB2' ' HB3' ' A' ' 101' ' ' ARG . 21.2 pt20 -65.71 -17.4 64.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 O-C-N 122.039 -0.413 . . . . 0.0 110.244 -179.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.3 p -87.78 1.56 53.56 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 -179.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.6 -4.84 33.12 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 69.6 mt -86.31 105.5 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.021 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.9 -42.5 63.5 Favored 'General case' 0 CA--C 1.507 -0.698 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.738 -178.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.67 141.24 48.62 Favored 'General case' 0 CA--C 1.496 -1.102 0 C-N-CA 119.837 -0.745 . . . . 0.0 109.178 -177.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -117.68 162.82 17.42 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 106.317 -1.734 . . . . 0.0 106.317 179.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.0 t-20 -65.34 132.72 95.27 Favored Pre-proline 0 N--CA 1.444 -0.75 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -71.72 -25.04 20.93 Favored 'Trans proline' 0 C--N 1.317 -1.097 0 C-N-CA 121.626 1.551 . . . . 0.0 114.727 -179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 27.2 mmm180 -70.09 -41.88 73.46 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -178.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 30.6 mtpp -141.64 134.72 29.11 Favored 'General case' 0 CA--C 1.493 -1.239 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 13.9 p90 -79.15 114.94 18.5 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.679 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.4 mt -128.48 146.54 50.78 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.4 ' HB3' ' HB2' ' A' ' 88' ' ' GLN . 90.2 mmt-85 -107.01 15.11 25.66 Favored 'General case' 0 CA--C 1.499 -0.992 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 99.9 p -100.92 164.56 11.77 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 -178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 22.2 t -125.0 145.66 31.94 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.049 0 N-CA-C 105.092 -2.188 . . . . 0.0 105.092 179.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -72.34 131.32 16.94 Favored Glycine 0 C--N 1.345 1.065 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -178.367 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -78.74 137.82 37.94 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.17 90.5 Favored Glycine 0 C--N 1.354 1.541 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -92.69 149.05 21.56 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.6 m -94.9 125.49 39.6 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 105.423 -2.065 . . . . 0.0 105.423 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 25.4 m -129.36 163.35 34.79 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -178.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.4 pt-20 -109.63 141.51 42.07 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 -179.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -157.86 160.27 37.52 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.061 -1.056 . . . . 0.0 109.77 -179.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -96.33 153.03 18.04 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.2 t -113.12 125.13 70.33 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.18 0 N-CA-C 106.727 -1.582 . . . . 0.0 106.727 -179.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.8 m -124.31 161.66 27.0 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.478 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 178.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.78 134.89 51.77 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 -178.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.68 170.88 17.55 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.8 pt-20 -70.69 -17.78 62.83 Favored 'General case' 0 N--CA 1.443 -0.786 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -98.73 8.04 45.4 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 116.8 -79.4 0.29 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 108.0 -2.04 . . . . 0.0 108.0 179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.96 135.95 55.09 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -128.57 136.19 50.38 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.77 145.89 30.23 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.24 153.63 40.81 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.17 52.95 4.71 Favored 'General case' 0 C--N 1.359 0.994 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.6 t -83.61 118.3 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.99 0 N-CA-C 107.775 -1.195 . . . . 0.0 107.775 -179.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.4 p -139.0 166.27 24.93 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.56 174.36 55.14 Favored Glycine 0 C--N 1.349 1.259 0 N-CA-C 106.958 -2.457 . . . . 0.0 106.958 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.437 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.4 Cg_exo -57.42 130.04 37.04 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 121.593 1.529 . . . . 0.0 112.711 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.59 1.63 87.49 Favored Glycine 0 C--N 1.349 1.305 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.96 17.24 67.94 Favored Glycine 0 C--N 1.352 1.469 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -81.2 156.47 71.65 Favored Pre-proline 0 N--CA 1.441 -0.892 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_exo -60.17 149.0 87.52 Favored 'Trans proline' 0 CA--C 1.501 -1.139 0 C-N-CA 122.039 1.826 . . . . 0.0 112.64 179.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.403 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.3 m -80.25 143.49 12.32 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.823 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 72.1 tp60 -67.52 -40.0 85.1 Favored 'General case' 0 CA--C 1.502 -0.901 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.74 -174.8 34.96 Favored Glycine 0 C--N 1.348 1.25 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 -179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 38.3 t -78.04 161.72 27.25 Favored 'General case' 0 CA--C 1.505 -0.782 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -60.14 -43.29 95.82 Favored 'General case' 0 C--N 1.356 0.886 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.6 t80 -122.97 128.31 50.06 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.679 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.72 159.2 43.78 Favored 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 -179.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.768 0 CA-C-O 117.967 -1.016 . . . . 0.0 108.638 179.636 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.384 0 CA-C-O 121.052 0.453 . . . . 0.0 110.424 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -100.88 173.41 6.51 Favored 'General case' 0 CA--C 1.499 -1.007 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.6 139.54 45.6 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.5 t -103.25 120.08 52.67 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.368 0 N-CA-C 105.017 -2.216 . . . . 0.0 105.017 178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.536 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.61 -36.42 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.811 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 -178.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.79 151.82 38.55 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.575 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.28 -174.12 3.27 Favored 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 -179.373 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.4 ptpt -43.04 105.92 0.06 Allowed 'General case' 0 CA--C 1.505 -0.762 0 CA-C-O 121.968 0.889 . . . . 0.0 110.638 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG13 ' O ' ' A' ' 57' ' ' THR . 16.6 m -123.32 162.81 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.371 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.2 mt -102.86 137.41 41.1 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.64 159.1 27.22 Favored Glycine 0 CA--C 1.487 -1.69 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.7 m -104.6 129.35 52.73 Favored 'General case' 0 CA--C 1.499 -1.018 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 -179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 88.4 t -78.04 105.83 7.67 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.199 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.413 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 64.9 tttp -72.34 -45.25 60.71 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.413 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.6 m95 -149.92 140.31 22.35 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -179.46 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.518 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 46.0 t80 -144.4 117.16 8.71 Favored 'General case' 0 N--CA 1.436 -1.172 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 177.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -101.44 115.12 29.78 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 -179.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.425 HG22 ' HB3' ' A' ' 102' ' ' SER . 71.6 t -66.08 -39.87 85.62 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 37.6 ptt-85 -64.6 -25.82 68.13 Favored 'General case' 0 C--N 1.352 0.677 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.09 -178.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.489 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 33.0 m120 -95.12 -24.03 17.04 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -179.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.24 16.3 72.1 Favored Glycine 0 C--N 1.348 1.21 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.3 p90 -157.24 166.12 34.03 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.06 -165.91 23.14 Favored Glycine 0 N--CA 1.433 -1.521 0 N-CA-C 107.345 -2.302 . . . . 0.0 107.345 -179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.96 138.34 51.91 Favored 'General case' 0 CA--C 1.497 -1.095 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 87.3 mt -120.98 129.25 75.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.062 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 12.3 m120 -93.39 128.0 39.26 Favored 'General case' 0 CA--C 1.494 -1.177 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -69.78 134.31 48.42 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.023 -1.473 . . . . 0.0 107.023 179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.37 -6.59 59.4 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -100.66 -35.08 9.61 Favored 'General case' 0 N--CA 1.443 -0.78 0 C-N-CA 119.9 -0.72 . . . . 0.0 110.557 -178.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 1.9 m -114.56 -15.14 12.05 Favored 'General case' 0 CA--C 1.506 -0.721 0 C-N-CA 119.855 -0.738 . . . . 0.0 110.325 -177.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 68.74 23.51 6.98 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 179.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -95.32 152.67 18.18 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -86.36 138.84 31.49 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.1 t -128.68 141.03 47.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.4 -1.704 . . . . 0.0 106.4 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -89.5 131.88 35.32 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.3 p -122.31 154.16 27.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.737 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.7 t-80 -141.65 166.53 24.49 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 -178.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -66.25 -21.94 66.3 Favored 'General case' 0 CA--C 1.505 -0.773 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 58.9 p -82.2 1.12 37.96 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.97 -4.6 43.01 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.726 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 36.2 mm -78.23 121.54 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 107.561 -1.274 . . . . 0.0 107.561 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.475 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 87.7 tttt -93.18 -45.34 7.91 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.351 -0.54 . . . . 0.0 109.575 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -117.37 144.12 45.27 Favored 'General case' 0 CA--C 1.497 -1.093 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 -177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.7 m120 -118.53 156.23 29.48 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.0 t-20 -67.72 135.53 92.47 Favored Pre-proline 0 N--CA 1.445 -0.711 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -67.5 -25.83 40.94 Favored 'Trans proline' 0 C--N 1.318 -1.077 0 C-N-CA 121.599 1.533 . . . . 0.0 114.31 -179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.91 -40.09 83.48 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . 0.662 ' HE2' HD11 ' A' ' 100' ' ' LEU . 21.4 pttm -157.78 142.76 16.68 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 106.621 -1.622 . . . . 0.0 106.621 179.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.4 p90 -80.87 117.19 21.3 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-O 121.67 0.747 . . . . 0.0 109.214 -177.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.662 HD11 ' HE2' ' A' ' 98' ' ' LYS . 89.7 mt -123.22 140.03 53.44 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 106.447 -1.686 . . . . 0.0 106.447 178.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -109.95 17.2 21.36 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.425 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.4 p -115.87 164.32 14.57 Favored 'General case' 0 CA--C 1.497 -1.071 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -178.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.579 HG12 HG11 ' A' ' 133' ' ' VAL . 33.5 m -124.47 161.31 27.92 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -79.23 139.97 22.41 Favored Glycine 0 C--N 1.35 1.332 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -178.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -78.24 137.03 37.91 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.19 1.94 90.46 Favored Glycine 0 C--N 1.351 1.37 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -92.32 161.49 14.66 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -105.3 128.53 53.51 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 105.939 -1.874 . . . . 0.0 105.939 179.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 29.0 m -127.78 161.01 36.55 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.92 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 -178.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.43 129.08 55.56 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 106.489 -1.671 . . . . 0.0 106.489 -179.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.454 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.1 p90 -155.56 161.62 40.83 Favored 'General case' 0 CA--C 1.504 -0.817 0 C-N-CA 118.73 -1.188 . . . . 0.0 110.326 -178.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -96.54 152.78 18.3 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 105.674 -1.973 . . . . 0.0 105.674 179.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.1 t -114.84 124.46 71.52 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.175 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 -179.537 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.8 m -125.07 159.59 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.057 -1.831 . . . . 0.0 106.057 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.5 mt-10 -69.01 142.26 54.66 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -179.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.78 -177.84 17.32 Favored Glycine 0 C--N 1.347 1.186 0 N-CA-C 108.497 -1.841 . . . . 0.0 108.497 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.13 -34.72 79.08 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.31 10.78 11.64 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.26 -70.72 0.26 Allowed Glycine 0 CA--C 1.489 -1.544 0 N-CA-C 107.708 -2.157 . . . . 0.0 107.708 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.07 129.91 53.54 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -122.46 134.79 54.58 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 179.497 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -80.79 145.59 31.38 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.42 151.06 38.7 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . 0.475 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 83.9 m-20 58.05 57.52 4.02 Favored 'General case' 0 C--N 1.358 0.943 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.7 t -82.83 121.28 35.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.6 p -137.27 166.23 24.27 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.14 175.32 53.82 Favored Glycine 0 C--N 1.347 1.159 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.417 ' O ' HG22 ' A' ' 131' ' ' VAL . 51.5 Cg_endo -69.17 135.7 32.56 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 C-N-CA 121.231 1.287 . . . . 0.0 112.035 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.23 -5.72 81.15 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.342 -1.903 . . . . 0.0 108.342 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.53 10.3 63.71 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.802 -1.719 . . . . 0.0 108.802 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -76.11 154.35 84.56 Favored Pre-proline 0 N--CA 1.442 -0.86 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -70.77 159.95 51.0 Favored 'Trans proline' 0 CA--C 1.499 -1.241 0 C-N-CA 121.72 1.614 . . . . 0.0 112.453 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.579 HG11 HG12 ' A' ' 103' ' ' VAL . 2.2 m -71.12 129.51 34.99 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 108.212 -1.032 . . . . 0.0 108.212 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -70.87 -40.26 72.4 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 124.01 -165.84 16.75 Favored Glycine 0 CA--C 1.494 -1.261 0 N-CA-C 107.409 -2.276 . . . . 0.0 107.409 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -118.04 -163.7 0.96 Allowed 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.092 -1.447 . . . . 0.0 107.092 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -62.3 -43.05 99.73 Favored 'General case' 0 CA--C 1.503 -0.842 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -137.57 135.76 36.95 Favored 'General case' 0 N--CA 1.437 -1.118 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 179.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.7 155.1 43.4 Favored 'General case' 0 N--CA 1.435 -1.187 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.798 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 121.054 0.454 . . . . 0.0 110.358 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.665 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -87.53 154.87 20.29 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 107.915 -1.142 . . . . 0.0 107.915 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.665 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.8 mttm -118.5 138.78 52.27 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 107.602 -1.258 . . . . 0.0 107.602 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.5 t -106.31 119.59 55.97 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.397 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 178.642 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.524 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.49 9.75 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.844 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -178.244 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.644 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.19 150.0 35.96 Favored 'General case' 0 CA--C 1.491 -1.299 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.558 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -174.6 3.44 Favored 'General case' 0 N--CA 1.432 -1.361 0 N-CA-C 107.248 -1.39 . . . . 0.0 107.248 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 18.4 pttp -46.3 105.73 0.07 Allowed 'General case' 0 N--CA 1.442 -0.854 0 CA-C-O 122.091 0.948 . . . . 0.0 110.414 -179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.558 HG13 ' O ' ' A' ' 57' ' ' THR . 28.2 m -124.93 164.78 23.14 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.496 0 N-CA-C 106.592 -1.632 . . . . 0.0 106.592 178.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -99.47 142.98 30.25 Favored 'General case' 0 N--CA 1.431 -1.422 0 N-CA-C 106.711 -1.589 . . . . 0.0 106.711 179.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -146.28 155.23 26.42 Favored Glycine 0 CA--C 1.485 -1.798 0 N-CA-C 107.63 -2.188 . . . . 0.0 107.63 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -104.31 129.15 52.19 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 107.443 -1.317 . . . . 0.0 107.443 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.659 HG22 HG12 ' A' ' 75' ' ' ILE . 61.8 t -78.87 103.92 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.235 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.52 -44.46 62.16 Favored 'General case' 0 N--CA 1.436 -1.141 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -147.06 143.65 28.5 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.437 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.8 t80 -149.05 120.68 8.02 Favored 'General case' 0 N--CA 1.437 -1.088 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 177.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 57.2 t-20 -95.94 117.07 29.91 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.4 t -63.75 -39.24 84.67 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.7 ttp180 -60.36 -43.93 96.05 Favored 'General case' 0 CA--C 1.507 -0.709 0 O-C-N 122.37 -0.206 . . . . 0.0 111.013 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -85.17 -29.42 24.77 Favored 'General case' 0 CA--C 1.501 -0.94 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.121 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.44 16.71 70.53 Favored Glycine 0 C--N 1.347 1.157 0 N-CA-C 108.013 -2.035 . . . . 0.0 108.013 -179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.7 m-85 -129.36 157.1 42.86 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.808 -1.552 . . . . 0.0 106.808 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.437 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.27 -177.17 34.13 Favored Glycine 0 CA--C 1.487 -1.674 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.533 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -124.15 134.0 53.43 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 -179.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.659 HG12 HG22 ' A' ' 63' ' ' VAL . 85.8 mt -121.46 128.89 75.96 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 106.506 -1.665 . . . . 0.0 106.506 179.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.2 m120 -99.08 128.79 45.28 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.1 mtp180 -68.28 134.02 49.71 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.4 p-10 -87.13 1.11 54.03 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.129 -179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -103.44 -38.94 6.97 Favored 'General case' 0 N--CA 1.441 -0.902 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.955 -179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -110.87 -15.09 13.87 Favored 'General case' 0 C--N 1.352 0.705 0 C-N-CA 120.232 -0.587 . . . . 0.0 110.08 -177.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.05 25.34 5.89 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -97.66 148.06 23.7 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.537 -1.283 . . . . 0.0 107.537 179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -88.18 141.33 28.65 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 -179.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -130.74 143.29 41.35 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.066 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -91.17 135.77 33.55 Favored 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.402 HG22 ' N ' ' A' ' 87' ' ' HIS . 4.5 p -123.28 149.02 27.0 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.043 0 CA-C-O 121.96 0.886 . . . . 0.0 108.647 -178.636 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.402 ' N ' HG22 ' A' ' 86' ' ' VAL . 65.1 m170 -120.16 158.49 26.83 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -70.52 -17.65 62.95 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 179.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.5 p -90.22 2.16 55.7 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.77 -8.92 42.35 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -81.9 114.06 22.22 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.156 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -83.35 -42.67 16.8 Favored 'General case' 0 N--CA 1.443 -0.79 0 C-N-CA 120.533 -0.467 . . . . 0.0 110.348 -177.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -115.62 140.47 49.15 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.8 m120 -119.21 154.36 33.5 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 15.7 t-20 -70.23 132.25 88.16 Favored Pre-proline 0 N--CA 1.443 -0.804 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.73 -28.16 20.94 Favored 'Trans proline' 0 C--N 1.317 -1.086 0 C-N-CA 121.59 1.527 . . . . 0.0 114.347 -179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -71.17 -39.45 71.86 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.0 mmtm -134.53 113.43 11.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.595 ' O ' HD23 ' A' ' 100' ' ' LEU . 8.5 m-85 -81.78 112.54 19.03 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 106.184 -1.784 . . . . 0.0 106.184 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.595 HD23 ' O ' ' A' ' 99' ' ' TYR . 62.9 mt -131.83 144.59 51.01 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 -178.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -102.07 15.34 29.36 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.147 -1.427 . . . . 0.0 107.147 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 42.5 t -119.08 150.69 39.56 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 107.292 -1.373 . . . . 0.0 107.292 -178.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 23.2 m -97.3 172.04 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.92 0 N-CA-C 107.294 -1.372 . . . . 0.0 107.294 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.34 128.5 9.11 Favored Glycine 0 CA--C 1.494 -1.265 0 N-CA-C 107.777 -2.129 . . . . 0.0 107.777 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -78.24 139.24 38.92 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 83.3 -0.25 89.78 Favored Glycine 0 C--N 1.352 1.422 0 N-CA-C 108.991 -1.644 . . . . 0.0 108.991 179.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.6 mm-40 -93.43 163.26 13.65 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.3 m -106.77 128.59 54.36 Favored 'General case' 0 N--CA 1.436 -1.159 0 N-CA-C 105.935 -1.876 . . . . 0.0 105.935 179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.3 m -127.6 161.8 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 -178.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -109.45 130.07 55.52 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 -179.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.509 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.7 p90 -156.62 162.04 39.88 Favored 'General case' 0 CA--C 1.503 -0.861 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.203 -178.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -99.52 153.0 19.38 Favored 'General case' 0 CA--C 1.495 -1.153 0 N-CA-C 105.744 -1.947 . . . . 0.0 105.744 179.15 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.644 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.6 t -115.35 126.08 72.79 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.172 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 -179.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -124.07 161.11 27.32 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.526 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -67.6 134.94 52.11 Favored 'General case' 0 N--CA 1.431 -1.397 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.012 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -125.25 173.08 17.34 Favored Glycine 0 CA--C 1.493 -1.327 0 N-CA-C 107.453 -2.259 . . . . 0.0 107.453 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -69.56 -28.64 66.16 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -88.97 4.47 48.03 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 120.56 -80.38 0.33 Allowed Glycine 0 CA--C 1.492 -1.376 0 N-CA-C 108.529 -1.828 . . . . 0.0 108.529 178.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.67 135.08 55.22 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.9 tt0 -128.26 135.36 49.55 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -84.82 146.83 27.14 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.07 154.93 40.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.078 -1.452 . . . . 0.0 107.078 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.7 t30 60.46 53.12 4.34 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.73 117.53 29.58 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.004 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.0 p -138.75 166.85 23.32 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.19 166.79 46.58 Favored Glycine 0 C--N 1.349 1.265 0 N-CA-C 106.789 -2.525 . . . . 0.0 106.789 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.446 ' O ' HG22 ' A' ' 131' ' ' VAL . 40.6 Cg_exo -59.15 135.2 64.47 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 121.669 1.58 . . . . 0.0 112.526 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.5 -7.07 80.39 Favored Glycine 0 C--N 1.351 1.368 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.02 9.13 64.11 Favored Glycine 0 C--N 1.353 1.503 0 N-CA-C 108.636 -1.786 . . . . 0.0 108.636 179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.446 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.8 m -76.96 156.55 82.29 Favored Pre-proline 0 N--CA 1.442 -0.873 0 N-CA-C 107.284 -1.376 . . . . 0.0 107.284 179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -67.6 154.62 72.98 Favored 'Trans proline' 0 CA--C 1.5 -1.2 0 C-N-CA 121.398 1.399 . . . . 0.0 112.158 179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -71.67 144.79 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.884 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 -178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.4 mt-30 -66.44 -40.35 89.43 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 90.44 -174.21 39.66 Favored Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 107.724 -2.15 . . . . 0.0 107.724 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 51.7 m -79.84 174.22 11.8 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 107.092 -1.448 . . . . 0.0 107.092 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.13 -44.99 94.5 Favored 'General case' 0 C--N 1.357 0.896 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 85.1 t80 -149.85 127.95 11.98 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -147.28 64.51 1.15 Allowed 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -179.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.741 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.031 0.443 . . . . 0.0 110.418 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 2.0 ttpt -71.81 139.5 48.99 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -130.37 135.9 48.52 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 11.7 p -88.62 127.83 41.24 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 105.544 -2.021 . . . . 0.0 105.544 178.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -100.36 -35.44 4.53 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -178.64 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.89 150.28 35.82 Favored 'General case' 0 CA--C 1.492 -1.287 0 N-CA-C 107.61 -1.255 . . . . 0.0 107.61 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.571 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -173.5 3.08 Favored 'General case' 0 CA--C 1.49 -1.351 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 -179.411 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -44.34 105.44 0.05 Allowed 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 121.613 0.72 . . . . 0.0 110.179 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.571 HG13 ' O ' ' A' ' 57' ' ' THR . 17.1 m -123.57 161.92 25.05 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.323 0 N-CA-C 106.428 -1.693 . . . . 0.0 106.428 178.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -101.4 138.84 37.88 Favored 'General case' 0 N--CA 1.433 -1.312 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.81 160.88 27.78 Favored Glycine 0 CA--C 1.487 -1.693 0 N-CA-C 108.084 -2.007 . . . . 0.0 108.084 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.58 131.06 54.76 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 -179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.639 HG22 HG12 ' A' ' 75' ' ' ILE . 93.5 t -68.99 116.2 9.12 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.063 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -71.59 -43.37 66.38 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -174.2 155.52 2.44 Favored 'General case' 0 N--CA 1.438 -1.028 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 179.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.449 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.7 t80 -148.68 122.59 9.37 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.386 -2.079 . . . . 0.0 105.386 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -105.39 122.61 46.33 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 -179.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.413 HG22 ' HB2' ' A' ' 102' ' ' SER . 69.3 t -65.46 -40.8 89.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.631 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -63.27 -39.72 95.38 Favored 'General case' 0 C--N 1.353 0.718 0 CA-C-N 116.668 -0.242 . . . . 0.0 110.412 -178.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.459 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.3 m120 -73.02 -30.65 63.92 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.568 -0.901 . . . . 0.0 108.568 -178.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.22 15.53 71.68 Favored Glycine 0 N--CA 1.438 -1.209 0 N-CA-C 108.202 -1.959 . . . . 0.0 108.202 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.459 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -158.18 166.02 33.46 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -156.62 -171.65 23.05 Favored Glycine 0 CA--C 1.487 -1.677 0 N-CA-C 107.542 -2.223 . . . . 0.0 107.542 -179.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -132.9 137.41 46.63 Favored 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.683 HD12 HG21 ' A' ' 86' ' ' VAL . 96.3 mt -123.79 127.03 73.6 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.22 0 N-CA-C 105.642 -1.985 . . . . 0.0 105.642 179.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 59.9 m-20 -94.89 136.12 35.58 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.7 mtp180 -68.79 136.28 52.52 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -85.74 -1.57 57.33 Favored 'General case' 0 N--CA 1.443 -0.797 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 -99.44 -35.79 9.78 Favored 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.91 -0.716 . . . . 0.0 109.932 -179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.9 p -114.68 -12.78 12.14 Favored 'General case' 0 C--N 1.353 0.756 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.502 -178.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.7 mptt 67.82 22.04 8.91 Favored 'General case' 0 CA--C 1.5 -0.944 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -97.78 139.99 32.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -79.44 146.88 32.52 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -132.05 142.38 43.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -79.74 131.53 35.95 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.542 -1.281 . . . . 0.0 107.542 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.683 HG21 HD12 ' A' ' 75' ' ' ILE . 53.3 t -125.75 140.52 48.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 -179.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 37.3 t-80 -124.36 166.07 16.6 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -178.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -62.34 -37.4 85.51 Favored 'General case' 0 CA--C 1.503 -0.845 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.6 t -72.47 2.0 7.06 Favored 'General case' 0 CA--C 1.507 -0.693 0 O-C-N 122.088 -0.383 . . . . 0.0 110.566 -178.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -93.17 -10.96 33.94 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -83.81 115.94 26.89 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -87.09 -42.67 12.87 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 120.574 -0.45 . . . . 0.0 110.219 -177.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -116.65 142.42 46.91 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 -178.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.4 m120 -118.53 159.75 22.99 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 14.4 t-20 -66.58 133.74 94.28 Favored Pre-proline 0 N--CA 1.445 -0.715 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.19 -23.47 24.46 Favored 'Trans proline' 0 C--N 1.318 -1.035 0 C-N-CA 121.756 1.637 . . . . 0.0 114.472 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -67.33 -39.74 85.87 Favored 'General case' 0 CA--C 1.502 -0.866 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 22.0 pttm -152.78 139.04 18.39 Favored 'General case' 0 CA--C 1.495 -1.151 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.7 p90 -88.24 115.91 26.08 Favored 'General case' 0 N--CA 1.438 -1.026 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -178.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.437 HD22 ' HB3' ' A' ' 139' ' ' ALA . 90.3 mt -128.34 145.76 50.97 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 178.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -100.4 15.61 27.23 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.413 ' HB2' HG22 ' A' ' 68' ' ' VAL . 45.0 t -115.93 145.9 42.53 Favored 'General case' 0 CA--C 1.497 -1.094 0 N-CA-C 107.433 -1.321 . . . . 0.0 107.433 -178.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.688 HG22 ' H ' ' A' ' 104' ' ' GLY . 9.5 p -96.64 171.33 1.18 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.688 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -80.06 139.77 21.58 Favored Glycine 0 CA--C 1.496 -1.104 0 N-CA-C 108.823 -1.711 . . . . 0.0 108.823 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -78.18 120.03 22.4 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.558 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 85.62 6.05 83.69 Favored Glycine 0 C--N 1.354 1.529 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -81.36 141.14 34.28 Favored 'General case' 0 N--CA 1.428 -1.543 0 N-CA-C 108.112 -1.07 . . . . 0.0 108.112 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.0 m -87.91 127.73 35.36 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.461 HG21 HD13 ' A' ' 75' ' ' ILE . 27.9 m -129.58 161.13 39.71 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -178.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -110.03 129.05 55.74 Favored 'General case' 0 CA--C 1.5 -0.976 0 N-CA-C 105.906 -1.887 . . . . 0.0 105.906 179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -155.18 161.64 41.16 Favored 'General case' 0 CA--C 1.505 -0.779 0 C-N-CA 118.55 -1.26 . . . . 0.0 110.839 -178.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.4 m-20 -95.94 154.92 16.98 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.758 -1.941 . . . . 0.0 105.758 178.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.2 t -118.44 126.14 74.87 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 -179.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.6 m -127.21 158.09 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 8.3 mt-10 -72.78 136.33 45.44 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -136.8 -171.99 12.4 Favored Glycine 0 C--N 1.348 1.244 0 N-CA-C 108.467 -1.853 . . . . 0.0 108.467 -179.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -65.12 -34.86 79.42 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.23 11.0 10.85 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.86 -69.96 0.44 Allowed Glycine 0 CA--C 1.488 -1.63 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.04 130.36 53.75 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -127.56 136.3 51.51 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.457 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.08 148.33 27.58 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.475 -1.305 . . . . 0.0 107.475 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.48 151.36 37.26 Favored 'General case' 0 N--CA 1.438 -1.065 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.6 m-20 58.45 52.91 6.66 Favored 'General case' 0 C--N 1.358 0.952 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 179.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 98.3 t -79.94 119.64 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.3 p -137.72 170.64 15.71 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.86 176.97 54.55 Favored Glycine 0 C--N 1.348 1.234 0 N-CA-C 106.956 -2.458 . . . . 0.0 106.956 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 131' ' ' VAL . 50.2 Cg_endo -68.46 136.01 35.4 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 121.253 1.302 . . . . 0.0 112.143 -179.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.91 1.09 89.01 Favored Glycine 0 C--N 1.348 1.238 0 N-CA-C 108.357 -1.897 . . . . 0.0 108.357 -179.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.98 14.33 75.33 Favored Glycine 0 C--N 1.355 1.586 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -80.57 157.63 72.14 Favored Pre-proline 0 N--CA 1.438 -1.034 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_exo -59.32 149.05 83.49 Favored 'Trans proline' 0 CA--C 1.5 -1.223 0 C-N-CA 121.993 1.795 . . . . 0.0 112.522 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.9 m -73.34 147.1 9.86 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.888 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -65.28 -42.02 93.59 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.058 -1.089 . . . . 0.0 108.058 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 86.15 -180.0 49.69 Favored Glycine 0 C--N 1.349 1.267 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 40.7 t -80.82 160.52 24.79 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 23.5 pttp -61.89 -27.46 68.82 Favored 'General case' 0 C--N 1.354 0.791 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -157.11 129.3 7.3 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 178.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.437 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -147.22 64.91 1.15 Allowed 'General case' 0 N--CA 1.439 -1.002 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.697 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 120.957 0.408 . . . . 0.0 110.583 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.66 172.56 6.88 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -74.06 139.77 44.89 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.0 t -103.55 120.18 53.21 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.316 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.49 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.92 -36.06 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.788 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 -178.401 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.67 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.69 151.06 38.36 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.592 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.74 -173.33 3.13 Favored 'General case' 0 CA--C 1.491 -1.311 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -179.15 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 61.7 mtpt -47.76 104.7 0.06 Allowed 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 121.677 0.751 . . . . 0.0 109.508 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.592 HG13 ' O ' ' A' ' 57' ' ' THR . 24.1 m -123.88 163.83 22.85 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.0 mt -98.65 141.64 31.23 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.51 28.24 Favored Glycine 0 CA--C 1.489 -1.555 0 N-CA-C 107.584 -2.206 . . . . 0.0 107.584 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.6 m -107.67 128.93 54.99 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.667 HG22 HG12 ' A' ' 75' ' ' ILE . 57.9 t -74.61 116.66 17.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.146 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.6 mtpt -69.97 -43.9 70.55 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 107.262 -1.384 . . . . 0.0 107.262 179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.7 p-90 -178.03 158.25 1.21 Allowed 'General case' 0 CA--C 1.497 -1.06 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 179.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.417 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 33.8 t80 -142.51 122.58 13.7 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 104.756 -2.313 . . . . 0.0 104.756 178.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.8 t-20 -104.05 121.34 42.99 Favored 'General case' 0 CA--C 1.5 -0.98 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -179.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -63.5 -39.79 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.861 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 mtp85 -63.37 -39.71 95.27 Favored 'General case' 0 C--N 1.354 0.789 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -178.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.437 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.5 m120 -73.3 -31.01 63.77 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.76 13.17 73.11 Favored Glycine 0 CA--C 1.494 -1.236 0 N-CA-C 108.189 -1.964 . . . . 0.0 108.189 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.437 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 49.9 p90 -157.27 165.97 34.42 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.417 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -150.53 -175.32 22.45 Favored Glycine 0 N--CA 1.432 -1.622 0 N-CA-C 107.43 -2.268 . . . . 0.0 107.43 -179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -132.23 139.8 48.43 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.513 -1.291 . . . . 0.0 107.513 -178.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.717 HD12 HG21 ' A' ' 86' ' ' VAL . 96.7 mt -123.58 127.87 74.27 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.217 0 N-CA-C 106.454 -1.684 . . . . 0.0 106.454 179.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -88.91 125.51 34.98 Favored 'General case' 0 CA--C 1.493 -1.244 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -178.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.6 ttm180 -68.53 127.88 34.62 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 107.005 -1.48 . . . . 0.0 107.005 179.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.0 t30 -84.94 5.4 29.26 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 119.966 -0.694 . . . . 0.0 109.411 -178.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -104.42 -49.34 3.59 Favored 'General case' 0 CA--C 1.505 -0.778 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.864 -179.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -103.04 -10.15 19.16 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.3 mptt 68.52 27.04 6.32 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -105.9 140.7 38.51 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.415 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -75.29 145.2 42.03 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.0 t -126.99 141.74 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.93 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 31.1 t80 -83.53 135.93 34.46 Favored 'General case' 0 CA--C 1.502 -0.868 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 -179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.717 HG21 HD12 ' A' ' 75' ' ' ILE . 52.4 t -122.27 138.21 53.23 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.061 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 -178.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.04 168.82 9.59 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.8 mp0 -71.33 -23.22 61.88 Favored 'General case' 0 CA--C 1.503 -0.827 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.8 p -85.72 1.92 47.51 Favored 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 -178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -90.82 -13.17 34.31 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.2 mt -83.37 118.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 -179.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -92.15 -41.8 10.26 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 120.5 -0.48 . . . . 0.0 110.242 -178.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -110.57 140.91 44.44 Favored 'General case' 0 CA--C 1.499 -1.002 0 CA-C-O 121.647 0.737 . . . . 0.0 109.44 -177.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.4 m120 -132.82 158.55 42.2 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 87.6 m-20 -72.42 141.47 83.11 Favored Pre-proline 0 C--N 1.353 0.743 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -72.5 -24.91 18.5 Favored 'Trans proline' 0 CA--C 1.502 -1.115 0 C-N-CA 121.746 1.63 . . . . 0.0 113.231 179.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -66.36 -40.47 89.79 Favored 'General case' 0 CA--C 1.502 -0.885 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -158.46 136.65 10.75 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -91.74 123.18 34.94 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 87.9 mt -121.19 142.57 49.77 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 178.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.9 mmt180 -99.2 15.85 24.74 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 48.4 t -120.12 140.46 51.05 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 8.8 m -98.12 165.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.958 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -82.33 136.41 15.52 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 108.463 -1.855 . . . . 0.0 108.463 -179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -79.12 143.25 35.68 Favored 'General case' 0 N--CA 1.441 -0.909 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.02 2.3 90.53 Favored Glycine 0 C--N 1.354 1.552 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -93.08 152.01 19.53 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.9 m -97.05 126.12 41.98 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 105.256 -2.128 . . . . 0.0 105.256 178.371 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.2 m -128.67 161.11 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.983 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 -178.331 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 75.6 tt0 -109.87 130.23 55.55 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 -179.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.8 p90 -156.15 161.22 40.36 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.419 -178.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -95.73 154.25 17.32 Favored 'General case' 0 CA--C 1.493 -1.215 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 178.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.67 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.3 t -117.49 125.19 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 106.487 -1.672 . . . . 0.0 106.487 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.5 m -125.85 159.23 34.29 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.414 0 N-CA-C 105.936 -1.876 . . . . 0.0 105.936 178.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -70.47 143.02 51.88 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 -179.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.5 -178.41 16.57 Favored Glycine 0 CA--C 1.494 -1.227 0 N-CA-C 108.09 -2.004 . . . . 0.0 108.09 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.95 -25.44 64.55 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -89.97 9.49 27.64 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 -179.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.11 -72.2 0.26 Allowed Glycine 0 CA--C 1.489 -1.579 0 N-CA-C 107.452 -2.259 . . . . 0.0 107.452 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 131.27 54.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 -179.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -123.75 134.5 53.66 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.27 148.49 27.36 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.47 151.33 36.22 Favored 'General case' 0 N--CA 1.438 -1.03 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.3 m-20 58.14 53.23 6.8 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.0 t -81.05 119.8 31.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -179.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.8 p -137.17 166.55 23.47 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 106.588 -1.634 . . . . 0.0 106.588 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.51 175.82 54.8 Favored Glycine 0 C--N 1.349 1.26 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 179.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -67.18 133.48 30.84 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 121.084 1.189 . . . . 0.0 111.821 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.44 -5.97 80.56 Favored Glycine 0 C--N 1.349 1.28 0 N-CA-C 108.067 -2.013 . . . . 0.0 108.067 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.56 11.36 66.32 Favored Glycine 0 C--N 1.356 1.655 0 N-CA-C 108.724 -1.75 . . . . 0.0 108.724 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 35.5 m -77.34 155.13 81.96 Favored Pre-proline 0 N--CA 1.44 -0.959 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -60.42 150.2 82.15 Favored 'Trans proline' 0 CA--C 1.499 -1.229 0 C-N-CA 122.116 1.877 . . . . 0.0 112.832 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 27.6 m -74.18 138.28 21.48 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.878 0 N-CA-C 107.707 -1.219 . . . . 0.0 107.707 -179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.9 mm-40 -69.02 -39.43 79.27 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 92.94 -171.89 33.3 Favored Glycine 0 C--N 1.345 1.077 0 N-CA-C 107.699 -2.16 . . . . 0.0 107.699 -179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.1 t -85.43 -171.34 3.56 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -61.74 -45.11 95.32 Favored 'General case' 0 CA--C 1.504 -0.794 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 49.0 t80 -156.82 136.51 12.39 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 106.154 -1.795 . . . . 0.0 106.154 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.97 65.28 1.27 Allowed 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.726 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 179.604 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.6 t0 . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.054 0.454 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -102.36 173.15 6.49 Favored 'General case' 0 N--CA 1.439 -1.009 0 N-CA-C 107.701 -1.222 . . . . 0.0 107.701 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.5 140.01 46.11 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -179.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 54' ' ' VAL . 9.2 p -102.47 126.69 56.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.264 0 N-CA-C 105.086 -2.19 . . . . 0.0 105.086 178.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -95.55 -35.09 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -178.327 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.653 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.42 152.86 40.49 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.61 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.3 -173.34 3.05 Favored 'General case' 0 CA--C 1.492 -1.266 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 -179.073 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -44.33 107.46 0.09 Allowed 'General case' 0 CA--C 1.503 -0.844 0 CA-C-O 121.823 0.821 . . . . 0.0 110.609 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 57' ' ' THR . 30.7 m -121.37 161.24 21.8 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.443 0 N-CA-C 105.663 -1.977 . . . . 0.0 105.663 177.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 77.9 mt -101.29 139.24 37.23 Favored 'General case' 0 N--CA 1.434 -1.258 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 -179.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.64 159.29 27.54 Favored Glycine 0 CA--C 1.489 -1.57 0 N-CA-C 107.932 -2.067 . . . . 0.0 107.932 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.0 m -111.9 131.66 55.22 Favored 'General case' 0 CA--C 1.499 -0.983 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 93.8 t -71.52 116.01 12.54 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.208 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -87.43 -45.08 10.84 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.9 m-90 -145.11 139.1 27.09 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.541 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.9 t80 -150.16 118.96 6.6 Favored 'General case' 0 CA--C 1.494 -1.205 0 N-CA-C 105.727 -1.953 . . . . 0.0 105.727 177.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -105.61 122.32 45.8 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -179.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -65.41 -40.75 89.32 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.771 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 60.3 ttp180 -61.59 -42.84 99.43 Favored 'General case' 0 C--N 1.352 0.707 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 -178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.448 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.02 -30.81 65.58 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -178.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.06 15.34 72.58 Favored Glycine 0 C--N 1.348 1.248 0 N-CA-C 108.088 -2.005 . . . . 0.0 108.088 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.448 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -158.22 166.57 32.06 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.541 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -161.83 -168.16 23.32 Favored Glycine 0 N--CA 1.432 -1.599 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -127.06 137.41 53.04 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.882 HD12 HG11 ' A' ' 86' ' ' VAL . 89.3 mt -116.96 126.84 74.6 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.112 0 N-CA-C 105.967 -1.864 . . . . 0.0 105.967 179.421 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -91.59 130.15 37.45 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 107.41 -1.329 . . . . 0.0 107.41 -178.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.518 HH21 HG11 ' A' ' 59' ' ' VAL . 77.5 mtp180 -72.29 132.0 43.45 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 -179.847 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -81.92 -9.74 59.49 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.57 -33.18 10.42 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.779 -178.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.0 m -109.4 -17.05 13.88 Favored 'General case' 0 CA--C 1.506 -0.735 0 C-N-CA 119.891 -0.724 . . . . 0.0 110.302 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.2 mptt 67.27 32.28 6.08 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -117.42 143.02 46.43 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 179.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -82.72 142.52 31.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.9 t -125.79 144.12 36.97 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.013 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 179.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.1 t80 -90.64 133.09 35.37 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -178.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.945 HG12 ' HB3' ' A' ' 122' ' ' ALA . 23.3 m -126.99 163.36 29.85 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.261 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -133.67 170.89 14.88 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 98.0 mt-30 -61.67 -36.16 80.06 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 7.1 t -73.69 1.53 10.1 Favored 'General case' 0 N--CA 1.443 -0.794 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.587 -178.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.16 -11.63 37.85 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.9 mt -84.59 116.9 29.02 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.063 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -87.99 -42.1 12.68 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 120.552 -0.459 . . . . 0.0 110.388 -177.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -117.77 144.41 45.35 Favored 'General case' 0 CA--C 1.498 -1.052 0 C-N-CA 119.787 -0.765 . . . . 0.0 109.334 -177.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -124.94 157.89 34.93 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 106.053 -1.832 . . . . 0.0 106.053 179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -64.75 131.32 95.12 Favored Pre-proline 0 C--N 1.352 0.712 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -74.3 -12.77 23.13 Favored 'Trans proline' 0 C--N 1.319 -1.019 0 C-N-CA 122.191 1.928 . . . . 0.0 115.296 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.6 mtp180 -95.73 -17.54 21.16 Favored 'General case' 0 CA--C 1.494 -1.204 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -157.58 108.0 2.22 Favored 'General case' 0 N--CA 1.428 -1.55 0 N-CA-C 106.015 -1.846 . . . . 0.0 106.015 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -87.23 117.42 25.97 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-O 121.781 0.8 . . . . 0.0 109.444 -177.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.1 mt -125.26 147.83 48.93 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 177.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.5 mmt180 -97.79 15.48 23.6 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 65.4 m -120.76 152.55 38.17 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.1 m -98.2 168.81 1.61 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -84.85 138.42 16.76 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 108.034 -2.026 . . . . 0.0 108.034 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -77.75 121.29 23.85 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 107.34 -1.355 . . . . 0.0 107.34 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.43 6.02 63.02 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.144 -1.582 . . . . 0.0 109.144 179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -84.86 150.21 25.16 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 108.082 -1.081 . . . . 0.0 108.082 179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.8 m -99.55 126.28 45.48 Favored 'General case' 0 CA--C 1.494 -1.202 0 N-CA-C 105.224 -2.139 . . . . 0.0 105.224 178.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.9 m -131.62 162.41 39.48 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -111.24 141.21 45.06 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 40.7 p90 -159.27 161.16 35.93 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.576 -178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -94.7 152.84 18.13 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 105.543 -2.021 . . . . 0.0 105.543 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.653 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.5 t -114.65 125.12 71.88 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.194 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.7 m -126.31 160.03 34.39 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -70.29 142.84 52.21 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -140.73 -176.54 15.36 Favored Glycine 0 CA--C 1.495 -1.158 0 N-CA-C 108.561 -1.816 . . . . 0.0 108.561 -179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -64.97 -34.67 78.99 Favored 'General case' 0 CA--C 1.504 -0.791 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -85.35 11.32 10.47 Favored 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.76 -69.26 0.32 Allowed Glycine 0 CA--C 1.489 -1.562 0 N-CA-C 107.582 -2.207 . . . . 0.0 107.582 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.94 131.67 54.48 Favored 'General case' 0 N--CA 1.436 -1.13 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.22 138.19 51.55 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.945 ' HB3' HG12 ' A' ' 86' ' ' VAL . . . -86.61 150.13 24.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.78 150.22 36.83 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 60.17 53.56 4.43 Favored 'General case' 0 C--N 1.357 0.923 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.8 t -81.22 119.31 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.961 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -138.99 170.31 16.22 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 106.152 -1.795 . . . . 0.0 106.152 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.07 176.59 54.65 Favored Glycine 0 C--N 1.348 1.202 0 N-CA-C 106.726 -2.55 . . . . 0.0 106.726 179.392 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.19 134.63 32.07 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 C-N-CA 121.193 1.262 . . . . 0.0 112.168 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.35 2.27 89.16 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 87.26 7.86 75.92 Favored Glycine 0 C--N 1.353 1.518 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.48 132.47 83.72 Favored Pre-proline 0 N--CA 1.445 -0.695 0 N-CA-C 107.427 -1.323 . . . . 0.0 107.427 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -55.9 145.85 71.11 Favored 'Trans proline' 0 CA--C 1.504 -1.011 0 C-N-CA 121.767 1.645 . . . . 0.0 112.866 179.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.3 m -71.47 143.23 14.53 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -178.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.5 tt0 -67.54 -39.97 85.01 Favored 'General case' 0 CA--C 1.501 -0.937 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 93.09 -172.91 34.05 Favored Glycine 0 C--N 1.349 1.25 0 N-CA-C 107.843 -2.103 . . . . 0.0 107.843 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 68.6 m -76.47 170.93 15.46 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -60.17 -44.76 94.77 Favored 'General case' 0 C--N 1.355 0.847 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -148.8 129.55 14.17 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 106.16 -1.792 . . . . 0.0 106.16 178.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -146.37 65.54 1.19 Allowed 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 -178.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.703 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 179.704 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.487 1.404 0 CA-C-O 120.999 0.428 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.64 170.69 8.25 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 16.1 mmmt -73.64 143.99 46.07 Favored 'General case' 0 CA--C 1.497 -1.091 0 CA-C-O 121.795 0.807 . . . . 0.0 108.915 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.8 t -105.46 120.43 56.19 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.26 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 179.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.19 -36.63 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.635 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.29 153.07 42.39 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.473 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.86 -174.44 3.43 Favored 'General case' 0 N--CA 1.432 -1.329 0 N-CA-C 107.559 -1.275 . . . . 0.0 107.559 -178.849 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.8 mtmt -50.85 107.08 0.15 Allowed 'General case' 0 N--CA 1.44 -0.936 0 CA-C-O 121.787 0.803 . . . . 0.0 109.782 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 57' ' ' THR . 16.9 m -119.93 166.3 14.49 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.252 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.6 mt -102.56 134.73 45.42 Favored 'General case' 0 N--CA 1.434 -1.259 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 179.459 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.72 156.28 25.28 Favored Glycine 0 CA--C 1.486 -1.731 0 N-CA-C 107.624 -2.19 . . . . 0.0 107.624 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -108.26 128.63 54.9 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 -179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.604 HG22 HG12 ' A' ' 75' ' ' ILE . 82.1 t -74.92 117.11 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.295 0 N-CA-C 106.89 -1.522 . . . . 0.0 106.89 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 24.2 tptm -87.64 -46.53 9.44 Favored 'General case' 0 N--CA 1.432 -1.363 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 6.8 m-90 -143.94 138.73 28.71 Favored 'General case' 0 CA--C 1.497 -1.083 0 C-N-CA 119.477 -0.889 . . . . 0.0 108.942 -178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.519 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 39.1 t80 -145.64 117.7 8.32 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 56.0 t-20 -97.67 122.74 41.1 Favored 'General case' 0 CA--C 1.499 -0.995 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 -179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.545 HG22 ' OG ' ' A' ' 102' ' ' SER . 72.3 t -63.12 -41.17 91.82 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 N-CA-C 108.658 -0.868 . . . . 0.0 108.658 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.1 mmt-85 -64.23 -40.08 95.3 Favored 'General case' 0 C--N 1.352 0.709 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.719 -178.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.449 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.2 m120 -74.07 -31.44 62.85 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 -178.714 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.94 13.89 78.5 Favored Glycine 0 C--N 1.348 1.236 0 N-CA-C 107.641 -2.184 . . . . 0.0 107.641 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.449 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 42.8 p90 -157.14 166.57 32.88 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.16 -159.65 10.41 Favored Glycine 0 CA--C 1.491 -1.422 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 -179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -129.44 139.34 51.66 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.252 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.604 HG12 HG22 ' A' ' 63' ' ' VAL . 91.0 mt -121.41 129.09 75.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.9 m120 -95.24 127.57 41.39 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 60.3 mtm180 -70.09 140.37 52.7 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -95.13 3.2 54.99 Favored 'General case' 0 N--CA 1.438 -1.044 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.8 m-20 -110.79 -41.5 4.26 Favored 'General case' 0 C--N 1.356 0.869 0 C-N-CA 119.967 -0.693 . . . . 0.0 109.967 -179.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.5 m -103.02 -16.39 15.81 Favored 'General case' 0 CA--C 1.499 -0.986 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -178.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 65.68 41.02 4.16 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -128.69 152.37 48.48 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 178.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -81.59 147.75 29.44 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -178.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 23.7 t -132.95 144.8 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.078 0 N-CA-C 106.009 -1.849 . . . . 0.0 106.009 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.7 t80 -86.87 130.84 34.3 Favored 'General case' 0 N--CA 1.441 -0.888 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -179.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.478 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.9 p -122.16 154.54 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.24 0 N-CA-C 106.973 -1.491 . . . . 0.0 106.973 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.478 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.21 158.63 43.83 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 -178.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -65.05 -17.58 64.57 Favored 'General case' 0 CA--C 1.509 -0.612 0 O-C-N 122.252 -0.28 . . . . 0.0 110.254 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.2 p -88.53 1.65 54.48 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -98.27 -5.45 33.08 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 72.5 mt -83.65 117.67 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.073 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 -179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.7 tptt -89.74 -44.83 9.72 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -178.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -113.96 149.41 35.32 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 -177.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -146.25 172.75 12.99 Favored 'General case' 0 N--CA 1.434 -1.242 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 59.1 t-20 -70.88 121.72 84.79 Favored Pre-proline 0 N--CA 1.444 -0.771 0 N-CA-C 107.957 -1.127 . . . . 0.0 107.957 -178.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -61.09 -28.08 85.25 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 121.943 1.762 . . . . 0.0 113.785 178.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -64.41 -39.8 94.55 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 -178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 16.4 ptpt -146.11 130.76 17.91 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.426 ' HB2' HH12 ' A' ' 101' ' ' ARG . 21.5 p90 -82.33 119.11 23.72 Favored 'General case' 0 N--CA 1.437 -1.085 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 -179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.513 HD22 ' HB3' ' A' ' 139' ' ' ALA . 88.7 mt -122.24 152.44 40.02 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . 0.426 HH12 ' HB2' ' A' ' 99' ' ' TYR . 90.0 mmt-85 -107.94 16.36 23.54 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.545 ' OG ' HG22 ' A' ' 68' ' ' VAL . 49.4 m -128.94 163.21 25.8 Favored 'General case' 0 CA--C 1.497 -1.058 0 CA-C-O 121.614 0.721 . . . . 0.0 109.223 -177.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 29.8 m -122.58 164.14 20.22 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.01 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -85.88 137.41 15.15 Favored Glycine 0 CA--C 1.493 -1.298 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -178.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.7 m-20 -77.3 146.37 36.85 Favored 'General case' 0 N--CA 1.44 -0.947 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.79 1.28 89.04 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 179.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.75 144.37 25.37 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 95.9 m -94.9 127.12 40.7 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 178.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.0 m -127.23 161.12 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.134 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -109.47 128.09 54.91 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 106.757 -1.571 . . . . 0.0 106.757 -178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.419 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.6 p90 -156.29 160.14 39.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.159 -1.016 . . . . 0.0 109.24 -178.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.81 162.05 13.2 Favored 'General case' 0 CA--C 1.494 -1.211 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.1 t -117.29 127.14 74.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.268 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 -178.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.8 m -119.75 158.88 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.521 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -68.43 132.48 47.09 Favored 'General case' 0 N--CA 1.429 -1.511 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -91.12 -170.44 42.75 Favored Glycine 0 C--N 1.352 1.439 0 N-CA-C 107.974 -2.05 . . . . 0.0 107.974 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -64.39 -43.81 93.29 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -140.93 31.6 1.8 Allowed 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -174.88 -136.4 2.26 Favored Glycine 0 N--CA 1.43 -1.75 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 179.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.49 142.69 49.8 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 -179.113 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -132.82 137.16 46.66 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.36 149.55 27.65 Favored 'General case' 0 CA--C 1.502 -0.872 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.58 153.86 39.96 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 63.8 t30 58.52 53.05 6.44 Favored 'General case' 0 C--N 1.361 1.095 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 64.7 t -82.47 118.81 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.026 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -178.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.1 p -138.16 166.15 24.86 Favored 'General case' 0 CA--C 1.5 -0.961 0 N-CA-C 106.23 -1.767 . . . . 0.0 106.23 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 176.07 54.68 Favored Glycine 0 C--N 1.349 1.292 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 179.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.6 135.59 33.77 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 C-N-CA 121.183 1.255 . . . . 0.0 111.916 -179.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 83.46 2.17 90.17 Favored Glycine 0 C--N 1.35 1.338 0 N-CA-C 108.653 -1.779 . . . . 0.0 108.653 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 84.62 12.86 74.22 Favored Glycine 0 C--N 1.355 1.605 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 73.8 t -76.02 126.73 86.48 Favored Pre-proline 0 N--CA 1.446 -0.669 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_exo -59.15 148.65 84.77 Favored 'Trans proline' 0 CA--C 1.502 -1.084 0 C-N-CA 121.857 1.705 . . . . 0.0 113.084 179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.428 ' H ' HG22 ' A' ' 133' ' ' VAL . 2.6 m -73.11 137.42 23.43 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.798 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.8 tt0 -68.5 -41.07 80.56 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 127.86 -168.13 19.94 Favored Glycine 0 C--N 1.35 1.329 0 N-CA-C 106.869 -2.493 . . . . 0.0 106.869 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.5 t -103.32 -174.24 2.5 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.45 -43.24 99.3 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 179.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -133.61 134.19 42.93 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 179.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.513 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.05 156.06 43.71 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.712 0 CA-C-O 117.797 -1.097 . . . . 0.0 108.298 179.804 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 27.3 t0 . . . . . 0 N--CA 1.487 1.421 0 CA-C-O 120.794 0.33 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.531 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.37 -170.11 0.2 Allowed 'General case' 0 C--N 1.358 0.936 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.531 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 61.5 mtpt -85.72 141.77 29.48 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 66.8 t -102.94 119.6 51.57 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 179.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.537 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.25 -36.36 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.863 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.64 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.95 151.99 39.5 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.778 ' O ' HG23 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -93.3 -173.35 3.21 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 -179.611 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.1 ptpt -36.87 104.27 0.03 OUTLIER 'General case' 0 C--N 1.35 0.599 0 CA-C-O 121.892 0.853 . . . . 0.0 111.51 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.778 HG23 ' O ' ' A' ' 57' ' ' THR . 57.5 t -117.0 141.98 32.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.265 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 178.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.3 mt -92.4 137.53 32.29 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -147.8 164.1 28.83 Favored Glycine 0 CA--C 1.49 -1.48 0 N-CA-C 107.954 -2.058 . . . . 0.0 107.954 -179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.1 m -107.43 129.97 54.87 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 -179.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.74 HG22 HG12 ' A' ' 75' ' ' ILE . 60.6 t -75.29 114.17 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 -179.447 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -70.72 -42.39 70.63 Favored 'General case' 0 N--CA 1.437 -1.079 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 179.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -168.57 158.97 9.8 Favored 'General case' 0 N--CA 1.438 -1.068 0 N-CA-C 108.145 -1.058 . . . . 0.0 108.145 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -147.49 124.09 11.1 Favored 'General case' 0 N--CA 1.433 -1.315 0 N-CA-C 105.027 -2.212 . . . . 0.0 105.027 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 68.8 m-80 -96.93 113.46 25.0 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.4 t -65.32 -41.63 91.82 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.681 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -63.14 -39.71 95.46 Favored 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 122.321 -0.237 . . . . 0.0 110.739 -178.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -82.28 -29.93 30.89 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 17.27 71.15 Favored Glycine 0 C--N 1.349 1.275 0 N-CA-C 108.015 -2.034 . . . . 0.0 108.015 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 18.8 m-85 -130.21 152.78 49.27 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 107.072 -1.455 . . . . 0.0 107.072 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -152.05 173.08 31.31 Favored Glycine 0 CA--C 1.488 -1.62 0 N-CA-C 107.552 -2.219 . . . . 0.0 107.552 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -130.43 136.66 49.26 Favored 'General case' 0 CA--C 1.491 -1.293 0 N-CA-C 106.841 -1.541 . . . . 0.0 106.841 -179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.74 HG12 HG22 ' A' ' 63' ' ' VAL . 98.1 mt -124.3 128.58 73.89 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.216 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -91.28 126.15 36.27 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.477 ' HE ' HG11 ' A' ' 59' ' ' VAL . 77.4 mtp180 -75.22 126.27 30.68 Favored 'General case' 0 CA--C 1.495 -1.159 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 178.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.7 m120 -83.81 -9.77 58.54 Favored 'General case' 0 CA--C 1.505 -0.772 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 32.4 t70 -81.81 -42.74 19.26 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 120.553 -0.459 . . . . 0.0 110.051 -179.022 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 6.5 m -112.86 -13.51 13.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.362 -176.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 66.53 45.29 2.11 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 75.4 mm-40 -120.48 160.79 22.43 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -94.39 140.87 29.25 Favored 'General case' 0 CA--C 1.502 -0.893 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 40.8 t -129.92 140.56 48.66 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 106.271 -1.751 . . . . 0.0 106.271 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -88.78 131.76 34.92 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.73 HG21 HD12 ' A' ' 75' ' ' ILE . 46.9 t -123.87 141.15 45.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.096 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -178.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -115.58 160.79 19.53 Favored 'General case' 0 CA--C 1.498 -1.026 0 N-CA-C 106.637 -1.616 . . . . 0.0 106.637 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.1 pt20 -70.22 -12.06 61.33 Favored 'General case' 0 CA--C 1.506 -0.738 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.8 p -89.17 1.43 55.67 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -88.83 -8.83 53.63 Favored 'General case' 0 N--CA 1.439 -0.986 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 24.3 mm -74.71 119.34 22.03 Favored 'Isoleucine or valine' 0 C--N 1.354 0.778 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.402 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 39.6 ttpt -94.19 -47.0 6.84 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -179.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -110.8 140.37 45.29 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -178.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.4 m120 -118.18 157.16 27.47 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 -179.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 31.9 t-20 -70.63 128.15 91.27 Favored Pre-proline 0 N--CA 1.441 -0.886 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 179.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -56.98 -35.87 99.02 Favored 'Trans proline' 0 C--N 1.318 -1.073 0 C-N-CA 121.934 1.756 . . . . 0.0 114.343 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -66.37 -41.88 88.79 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -178.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.7 mtmm -142.83 124.3 14.79 Favored 'General case' 0 CA--C 1.494 -1.184 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 -179.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 9.4 p90 -82.05 115.51 21.22 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.689 HD22 ' HB3' ' A' ' 139' ' ' ALA . 89.7 mt -125.57 141.12 52.2 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.1 mmt180 -102.3 16.52 25.96 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.494 -1.298 . . . . 0.0 107.494 -179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 59.5 m -124.55 150.25 46.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 107.367 -1.345 . . . . 0.0 107.367 -178.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.587 HG22 ' H ' ' A' ' 104' ' ' GLY . 7.6 p -105.42 166.69 3.27 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.587 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -88.78 140.63 16.01 Favored Glycine 0 CA--C 1.492 -1.359 0 N-CA-C 108.353 -1.899 . . . . 0.0 108.353 -178.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -78.81 146.28 33.82 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.45 0.81 90.22 Favored Glycine 0 C--N 1.353 1.477 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -93.73 149.86 20.88 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -96.73 125.78 41.42 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 105.041 -2.207 . . . . 0.0 105.041 178.143 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 21.2 m -129.57 163.34 35.11 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.982 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -177.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -109.58 129.82 55.55 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 -179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -152.37 159.85 43.38 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.379 -179.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -96.65 149.92 21.25 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 105.886 -1.894 . . . . 0.0 105.886 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.64 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -107.73 124.02 63.53 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.162 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.1 m -124.42 157.94 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.455 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.2 tt0 -71.23 133.46 46.13 Favored 'General case' 0 N--CA 1.428 -1.534 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.55 -177.65 15.02 Favored Glycine 0 C--N 1.35 1.353 0 N-CA-C 107.943 -2.063 . . . . 0.0 107.943 -179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.21 -23.8 63.0 Favored 'General case' 0 CA--C 1.504 -0.792 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -90.29 9.4 28.87 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 101.97 -70.52 0.36 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 107.421 -2.272 . . . . 0.0 107.421 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.71 131.54 54.59 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -128.15 136.72 51.51 Favored 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.543 ' HB3' HG22 ' A' ' 86' ' ' VAL . . . -83.23 143.61 30.32 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.44 151.23 40.1 Favored 'General case' 0 N--CA 1.438 -1.025 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . 0.402 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.2 m-20 58.86 58.11 3.36 Favored 'General case' 0 C--N 1.358 0.976 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 84.7 t -83.29 121.06 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.984 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 69.3 p -136.87 167.24 21.84 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.37 174.89 55.0 Favored Glycine 0 C--N 1.35 1.349 0 N-CA-C 106.99 -2.444 . . . . 0.0 106.99 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.456 ' O ' HG22 ' A' ' 131' ' ' VAL . 43.1 Cg_endo -68.48 135.86 34.9 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.356 1.371 . . . . 0.0 111.824 -179.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.64 -5.34 82.36 Favored Glycine 0 C--N 1.349 1.277 0 N-CA-C 108.02 -2.032 . . . . 0.0 108.02 -179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.64 12.61 68.98 Favored Glycine 0 C--N 1.356 1.661 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.456 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.7 m -80.22 156.69 73.89 Favored Pre-proline 0 N--CA 1.439 -0.988 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -60.0 150.39 78.77 Favored 'Trans proline' 0 CA--C 1.499 -1.249 0 C-N-CA 122.032 1.821 . . . . 0.0 112.594 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 30.2 m -74.81 140.85 16.82 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.854 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 -66.36 -40.79 90.01 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 101.75 -179.72 27.79 Favored Glycine 0 C--N 1.348 1.221 0 N-CA-C 108.259 -1.936 . . . . 0.0 108.259 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 82.5 p -79.23 170.0 17.3 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -60.92 -43.39 98.65 Favored 'General case' 0 C--N 1.358 0.961 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 90.9 t80 -135.92 129.34 32.08 Favored 'General case' 0 N--CA 1.435 -1.218 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.689 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -145.74 162.35 37.82 Favored 'General case' 0 N--CA 1.437 -1.121 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.81 0 CA-C-O 117.829 -1.081 . . . . 0.0 108.487 179.91 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 . . . . . 0 N--CA 1.487 1.408 0 CA-C-O 120.987 0.423 . . . . 0.0 110.551 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.25 157.0 16.91 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 39.1 ttmt -93.65 131.04 39.34 Favored 'General case' 0 CA--C 1.492 -1.257 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -102.72 119.72 51.49 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.306 0 N-CA-C 104.885 -2.265 . . . . 0.0 104.885 178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -87.5 -36.36 9.58 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.761 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -178.232 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.666 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.14 152.17 39.61 Favored 'General case' 0 CA--C 1.494 -1.2 0 N-CA-C 107.651 -1.241 . . . . 0.0 107.651 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.529 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.0 t -94.6 -173.96 3.17 Favored 'General case' 0 CA--C 1.491 -1.294 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 -179.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.6 mtmt -47.72 104.44 0.06 Allowed 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.699 0.762 . . . . 0.0 109.534 -179.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.529 HG13 ' O ' ' A' ' 57' ' ' THR . 18.4 m -124.78 163.95 24.29 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.279 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -98.91 139.17 34.98 Favored 'General case' 0 N--CA 1.433 -1.321 0 N-CA-C 107.302 -1.37 . . . . 0.0 107.302 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.87 160.73 27.5 Favored Glycine 0 CA--C 1.488 -1.655 0 N-CA-C 107.486 -2.246 . . . . 0.0 107.486 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.7 m -107.05 129.53 54.8 Favored 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.484 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -78.08 102.71 4.57 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.113 0 N-CA-C 107.156 -1.424 . . . . 0.0 107.156 -179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -72.34 -44.26 62.9 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 97.4 m95 -145.18 139.31 27.14 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -179.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.498 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 61.9 t80 -151.29 119.55 6.35 Favored 'General case' 0 CA--C 1.493 -1.227 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 177.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -104.61 121.43 43.51 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.1 t -65.35 -40.25 87.85 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.735 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 25.2 tpp180 -61.32 -44.0 97.93 Favored 'General case' 0 C--N 1.353 0.718 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 -178.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.3 m120 -72.2 -31.69 66.1 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -178.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.82 14.51 75.25 Favored Glycine 0 C--N 1.347 1.151 0 N-CA-C 107.908 -2.077 . . . . 0.0 107.908 -179.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 47.2 p90 -158.32 167.07 30.73 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -167.07 -158.49 11.48 Favored Glycine 0 CA--C 1.49 -1.478 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.207 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -129.57 137.73 50.91 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.484 HG12 HG22 ' A' ' 63' ' ' VAL . 90.1 mt -123.9 129.97 74.1 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.134 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -93.25 120.64 33.77 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -76.19 128.39 34.85 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.43 -1.13 49.19 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -178.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -67.77 -39.82 84.07 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.8 t -142.44 8.65 1.79 Allowed 'General case' 0 C--N 1.354 0.761 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 -178.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt 61.47 49.2 5.34 Favored 'General case' 0 CA--C 1.497 -1.093 0 CA-C-O 121.777 0.799 . . . . 0.0 110.785 179.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -115.62 161.97 17.9 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -91.22 137.27 32.5 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 34.9 t -127.67 140.54 48.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 106.078 -1.823 . . . . 0.0 106.078 179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -89.55 132.23 35.18 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 87' ' ' HIS . 15.0 p -121.13 158.39 23.87 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.166 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.53 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.4 t-80 -144.62 157.42 44.22 Favored 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -178.575 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -64.39 -17.43 63.75 Favored 'General case' 0 CA--C 1.508 -0.639 0 O-C-N 122.252 -0.28 . . . . 0.0 110.468 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 66.5 p -88.47 1.85 53.99 Favored 'General case' 0 CA--C 1.497 -1.073 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -97.21 -5.66 36.49 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.6 mt -82.02 118.44 29.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.0 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -88.44 -43.83 11.17 Favored 'General case' 0 N--CA 1.444 -0.765 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.617 -178.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -109.77 141.23 42.71 Favored 'General case' 0 CA--C 1.497 -1.064 0 C-N-CA 119.838 -0.745 . . . . 0.0 109.525 -177.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.7 m120 -129.57 162.51 28.06 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 86.2 m-20 -71.32 140.56 85.14 Favored Pre-proline 0 C--N 1.352 0.709 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -74.62 -27.42 10.8 Favored 'Trans proline' 0 C--N 1.313 -1.301 0 C-N-CA 121.581 1.521 . . . . 0.0 113.311 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -67.44 -43.62 80.7 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 61.8 mtpt -144.76 138.8 27.42 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 17.5 p90 -85.62 115.69 23.46 Favored 'General case' 0 N--CA 1.437 -1.089 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 -179.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 94.5 mt -125.13 142.12 51.69 Favored 'General case' 0 CA--C 1.493 -1.25 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 2.0 mpt_? -105.76 15.62 26.51 Favored 'General case' 0 CA--C 1.499 -1.013 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.8 m -93.99 155.95 16.86 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -178.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.723 HG22 ' H ' ' A' ' 104' ' ' GLY . 6.6 p -125.34 172.23 13.13 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.12 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.723 ' H ' HG22 ' A' ' 103' ' ' VAL . . . -83.26 118.41 4.63 Favored Glycine 0 CA--C 1.496 -1.123 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -178.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -78.27 122.16 25.36 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 86.82 3.06 83.73 Favored Glycine 0 C--N 1.352 1.44 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -93.31 163.75 13.48 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.3 m -99.84 128.51 45.93 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.019 -1.845 . . . . 0.0 106.019 179.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -127.74 161.74 34.95 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 34.7 tt0 -109.52 130.03 55.53 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 -178.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.7 160.76 39.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 118.775 -1.17 . . . . 0.0 110.42 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -96.15 153.46 17.78 Favored 'General case' 0 CA--C 1.494 -1.178 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.666 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 58.5 t -116.79 125.77 73.9 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.081 0 N-CA-C 106.801 -1.555 . . . . 0.0 106.801 -179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.5 m -126.82 163.43 29.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.401 0 N-CA-C 105.988 -1.856 . . . . 0.0 105.988 179.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 79.7 mt-10 -67.49 145.63 54.77 Favored 'General case' 0 CA--C 1.496 -1.108 0 C-N-CA 119.222 -0.991 . . . . 0.0 109.358 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.5 173.43 23.45 Favored Glycine 0 CA--C 1.493 -1.297 0 N-CA-C 107.679 -2.168 . . . . 0.0 107.679 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.7 pt-20 -71.01 -16.86 62.64 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.3 mmtm -94.57 7.81 44.39 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 107.726 -1.213 . . . . 0.0 107.726 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 107.73 -73.8 0.21 Allowed Glycine 0 CA--C 1.49 -1.499 0 N-CA-C 107.08 -2.408 . . . . 0.0 107.08 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.42 131.61 54.27 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -121.67 134.0 54.97 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.98 146.96 29.46 Favored 'General case' 0 N--CA 1.44 -0.962 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.77 153.24 39.98 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 29.9 m120 58.24 52.36 7.52 Favored 'General case' 0 C--N 1.359 0.986 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.7 t -79.38 122.23 34.18 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.917 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 -179.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.1 p -137.5 166.52 23.68 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.54 173.53 54.02 Favored Glycine 0 C--N 1.349 1.29 0 N-CA-C 106.749 -2.54 . . . . 0.0 106.749 179.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.46 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.64 135.55 31.03 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.245 1.297 . . . . 0.0 112.114 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.85 -5.6 82.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.466 -1.854 . . . . 0.0 108.466 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.81 9.56 64.03 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -77.62 154.37 81.24 Favored Pre-proline 0 N--CA 1.441 -0.918 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 179.74 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.35 157.54 58.91 Favored 'Trans proline' 0 CA--C 1.498 -1.322 0 C-N-CA 121.629 1.553 . . . . 0.0 112.208 179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -73.5 128.51 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.885 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 -179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -68.14 -39.61 82.62 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 108.428 -0.953 . . . . 0.0 108.428 -179.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 111.09 -158.96 14.04 Favored Glycine 0 CA--C 1.493 -1.293 0 N-CA-C 107.423 -2.271 . . . . 0.0 107.423 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -108.48 -176.9 3.17 Favored 'General case' 0 CA--C 1.501 -0.913 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 62.5 mtpt -63.73 -39.19 93.68 Favored 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 -179.899 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -123.64 134.23 53.8 Favored 'General case' 0 N--CA 1.437 -1.099 0 N-CA-C 106.571 -1.64 . . . . 0.0 106.571 179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.33 153.78 42.34 Favored 'General case' 0 N--CA 1.436 -1.143 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 -179.446 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.821 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 179.85 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.584 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.32 170.58 7.79 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 179.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 62.1 mtpt -73.55 142.44 46.66 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.8 t -104.77 120.5 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.356 0 N-CA-C 105.018 -2.216 . . . . 0.0 105.018 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.526 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.51 -36.12 8.32 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 -178.358 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.645 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.15 153.01 40.93 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.572 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.08 -173.49 3.12 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 64.4 mttp -46.25 107.33 0.1 Allowed 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.754 0.787 . . . . 0.0 109.924 -179.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 57' ' ' THR . 20.5 m -123.69 161.44 26.01 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.398 0 N-CA-C 106.252 -1.758 . . . . 0.0 106.252 178.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 74.2 mt -99.85 138.92 36.25 Favored 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 106.914 -1.513 . . . . 0.0 106.914 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.97 157.64 26.92 Favored Glycine 0 CA--C 1.488 -1.609 0 N-CA-C 107.988 -2.045 . . . . 0.0 107.988 -179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.2 m -104.63 130.26 52.66 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.486 HG22 HG12 ' A' ' 75' ' ' ILE . 95.2 t -75.09 115.33 16.27 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.979 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -70.71 -41.28 72.12 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.13 154.75 4.15 Favored 'General case' 0 N--CA 1.436 -1.147 0 N-CA-C 107.378 -1.341 . . . . 0.0 107.378 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.403 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 60.9 t80 -150.89 124.04 8.8 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 105.631 -1.989 . . . . 0.0 105.631 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.99 115.46 27.46 Favored 'General case' 0 CA--C 1.498 -1.051 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 69.9 t -65.44 -39.78 86.26 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.307 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 mtp85 -62.45 -38.76 91.05 Favored 'General case' 0 CA--C 1.508 -0.667 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.697 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 33.5 m120 -86.32 -30.15 22.47 Favored 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.05 16.66 71.63 Favored Glycine 0 C--N 1.348 1.217 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 27.7 m-85 -131.28 155.77 46.58 Favored 'General case' 0 CA--C 1.495 -1.147 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.5 -178.05 38.28 Favored Glycine 0 CA--C 1.489 -1.531 0 N-CA-C 107.475 -2.25 . . . . 0.0 107.475 -179.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -126.7 138.33 53.38 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 -179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.486 HG12 HG22 ' A' ' 63' ' ' VAL . 84.6 mt -121.69 129.2 75.71 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.004 0 N-CA-C 106.691 -1.596 . . . . 0.0 106.691 179.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -96.3 124.27 40.24 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -69.75 135.48 49.8 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -89.21 2.54 54.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -98.09 -50.84 4.23 Favored 'General case' 0 N--CA 1.44 -0.938 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 -179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 2.4 m -105.29 -11.79 16.34 Favored 'General case' 0 CA--C 1.506 -0.718 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.106 -177.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.5 mptt 69.25 24.83 5.82 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -98.83 150.93 21.37 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -90.42 138.64 31.39 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.8 t -126.35 143.51 39.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.058 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -90.36 132.94 35.31 Favored 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.0 p -119.26 147.83 22.58 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 -179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 79.6 m80 -118.83 157.51 27.44 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 -179.173 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 24.4 pt20 -68.74 -21.32 64.39 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 11.0 t -87.8 2.13 52.13 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.79 -8.45 37.45 Favored 'General case' 0 CA--C 1.5 -0.973 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 67.3 mt -82.6 118.31 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.084 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.8 tttm -95.77 -40.58 9.28 Favored 'General case' 0 N--CA 1.443 -0.825 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.4 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 13.5 mptt -92.82 125.7 37.55 Favored 'General case' 0 CA--C 1.5 -0.964 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -131.82 157.16 44.61 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.394 -1.706 . . . . 0.0 106.394 179.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 73.2 m-80 -74.89 135.02 74.46 Favored Pre-proline 0 N--CA 1.442 -0.841 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.97 -24.82 12.52 Favored 'Trans proline' 0 C--N 1.314 -1.24 0 C-N-CA 121.589 1.526 . . . . 0.0 113.714 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 83.5 mtp180 -68.3 -41.64 80.63 Favored 'General case' 0 CA--C 1.505 -0.784 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 59.5 mtmt -140.91 139.27 34.32 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 -179.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -80.42 115.85 20.17 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.574 HD22 ' CB ' ' A' ' 139' ' ' ALA . 81.9 mt -127.29 137.31 52.8 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.6 mpt_? -109.31 14.66 23.61 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 107.066 -1.457 . . . . 0.0 107.066 179.432 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.4 p -93.33 164.73 13.1 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 32.8 m -127.53 168.74 20.1 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -71.4 119.95 8.08 Favored Glycine 0 C--N 1.351 1.387 0 N-CA-C 108.521 -1.832 . . . . 0.0 108.521 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -78.86 115.61 18.66 Favored 'General case' 0 N--CA 1.439 -0.994 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.72 5.03 86.95 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 108.953 -1.659 . . . . 0.0 108.953 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -93.2 163.91 13.44 Favored 'General case' 0 CA--C 1.494 -1.203 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -99.71 127.14 45.84 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 31.3 m -129.47 162.1 37.65 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.958 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -110.2 140.89 43.86 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 -179.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.476 ' CE2' HG21 ' A' ' 75' ' ' ILE . 44.9 p90 -160.01 161.58 34.09 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 119.029 -1.069 . . . . 0.0 109.784 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -97.4 151.61 19.78 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 105.659 -1.978 . . . . 0.0 105.659 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.645 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 52.9 t -113.1 125.19 70.32 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 -178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -125.08 159.28 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.494 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 178.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 90.8 mt-10 -68.93 145.15 53.88 Favored 'General case' 0 CA--C 1.492 -1.265 0 C-N-CA 119.385 -0.926 . . . . 0.0 108.679 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.96 177.3 20.09 Favored Glycine 0 CA--C 1.493 -1.342 0 N-CA-C 108.134 -1.987 . . . . 0.0 108.134 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -64.35 -37.48 87.67 Favored 'General case' 0 CA--C 1.506 -0.724 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -83.59 5.68 23.37 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 109.587 -0.523 . . . . 0.0 109.587 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.66 -75.48 0.26 Allowed Glycine 0 CA--C 1.492 -1.374 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 179.022 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.47 132.58 55.28 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -125.7 136.05 52.77 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.73 146.29 29.1 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.61 152.47 38.96 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.03 53.46 4.61 Favored 'General case' 0 C--N 1.361 1.097 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 99.8 t -83.54 120.01 33.88 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.091 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 75.6 p -136.95 165.79 25.16 Favored 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.31 172.29 54.52 Favored Glycine 0 C--N 1.349 1.299 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.423 ' O ' HG22 ' A' ' 131' ' ' VAL . 38.1 Cg_endo -67.01 127.85 17.63 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 C-N-CA 121.122 1.215 . . . . 0.0 112.117 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.82 -5.03 79.31 Favored Glycine 0 C--N 1.349 1.278 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.99 10.3 64.73 Favored Glycine 0 C--N 1.356 1.662 0 N-CA-C 108.73 -1.748 . . . . 0.0 108.73 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.423 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.0 m -78.76 157.17 77.08 Favored Pre-proline 0 N--CA 1.439 -1.022 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.87 150.9 75.02 Favored 'Trans proline' 0 CA--C 1.5 -1.199 0 C-N-CA 122.197 1.931 . . . . 0.0 112.504 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 3.2 m -73.86 140.97 16.81 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.806 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 71.7 tp60 -65.41 -40.2 93.11 Favored 'General case' 0 CA--C 1.503 -0.864 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.16 -177.1 34.89 Favored Glycine 0 C--N 1.347 1.184 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 74.6 m -97.69 174.44 6.62 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 65.0 tttp -60.6 -44.57 96.13 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -111.25 129.17 56.06 Favored 'General case' 0 N--CA 1.438 -1.05 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 178.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.574 ' CB ' HD22 ' A' ' 100' ' ' LEU . . . -146.32 160.36 42.12 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 -178.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.693 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.383 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.486 1.348 0 CA-C-O 121.142 0.496 . . . . 0.0 110.5 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.92 167.69 27.55 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -129.93 142.38 50.66 Favored 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 89.8 t -84.24 121.01 36.05 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.692 -1.966 . . . . 0.0 105.692 179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.545 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.66 -36.65 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.934 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 -178.85 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.97 153.49 40.13 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.641 ' O ' HG13 ' A' ' 59' ' ' VAL . 8.2 t -95.45 -173.54 2.93 Favored 'General case' 0 CA--C 1.493 -1.217 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.9 mtmt -42.34 106.15 0.06 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.396 -179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 57' ' ' THR . 25.1 m -123.34 160.69 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.417 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 178.306 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 75.3 mt -99.91 139.74 35.14 Favored 'General case' 0 N--CA 1.431 -1.387 0 N-CA-C 107.186 -1.412 . . . . 0.0 107.186 -179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.62 159.42 27.55 Favored Glycine 0 CA--C 1.488 -1.619 0 N-CA-C 107.689 -2.165 . . . . 0.0 107.689 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.5 m -108.48 129.06 55.29 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.586 HG22 HG12 ' A' ' 75' ' ' ILE . 89.8 t -76.8 115.41 18.48 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.262 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 -179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -87.93 -46.04 9.72 Favored 'General case' 0 N--CA 1.433 -1.318 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 7.4 m-90 -143.02 139.62 30.65 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 -178.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 47.4 t80 -151.27 119.5 6.34 Favored 'General case' 0 CA--C 1.493 -1.245 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 177.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -105.5 118.91 37.77 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 107.168 -1.419 . . . . 0.0 107.168 -179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 72.6 t -65.28 -40.31 88.17 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.753 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 -179.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.71 -42.81 99.44 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.479 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 99.2 m-20 -72.71 -31.15 64.78 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -178.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.04 14.0 73.22 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.2 p90 -156.6 166.24 33.97 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 -179.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -165.46 -163.15 18.21 Favored Glycine 0 CA--C 1.491 -1.464 0 N-CA-C 107.541 -2.224 . . . . 0.0 107.541 -179.204 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -129.04 136.42 50.25 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 63' ' ' VAL . 91.2 mt -120.14 128.65 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.086 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 179.541 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -89.98 116.05 27.74 Favored 'General case' 0 CA--C 1.494 -1.19 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 15.4 ptm180 -76.78 128.99 35.66 Favored 'General case' 0 CA--C 1.495 -1.166 0 N-CA-C 106.245 -1.761 . . . . 0.0 106.245 -179.465 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.8 m120 -79.01 -6.28 55.98 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 -177.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 34.5 t70 -70.93 -43.25 68.58 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 72.0 p -122.88 -4.49 8.59 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.378 -178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 13.8 mptt 69.21 21.66 7.06 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -98.62 164.84 12.08 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -92.12 143.29 26.6 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.2 t -128.16 141.9 45.24 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.033 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.7 t80 -85.73 132.94 34.04 Favored 'General case' 0 N--CA 1.441 -0.915 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.502 HG22 ' N ' ' A' ' 87' ' ' HIS . 12.4 p -127.46 155.42 38.66 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.502 ' N ' HG22 ' A' ' 86' ' ' VAL . 46.8 t-80 -138.43 156.82 47.22 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 -178.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -63.95 -20.05 65.59 Favored 'General case' 0 CA--C 1.509 -0.629 0 O-C-N 122.062 -0.399 . . . . 0.0 110.526 -178.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -82.12 2.01 33.41 Favored 'General case' 0 CA--C 1.502 -0.877 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.5 -1.78 34.8 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.137 -1.061 . . . . 0.0 108.137 -179.374 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 71.9 mt -85.09 106.62 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.998 0 N-CA-C 107.035 -1.468 . . . . 0.0 107.035 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -72.7 -42.23 64.44 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.104 -177.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -122.97 145.07 48.81 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 119.679 -0.809 . . . . 0.0 109.573 -177.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 29.7 m120 -119.99 158.73 26.16 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 106.403 -1.703 . . . . 0.0 106.403 179.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.2 t-20 -70.04 122.92 87.67 Favored Pre-proline 0 N--CA 1.445 -0.685 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -58.9 -34.65 99.18 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.825 1.683 . . . . 0.0 113.879 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -66.34 -40.91 90.17 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.2 mtmm -138.46 118.48 13.41 Favored 'General case' 0 CA--C 1.494 -1.175 0 N-CA-C 107.114 -1.439 . . . . 0.0 107.114 -179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.7 m-85 -90.97 115.52 28.05 Favored 'General case' 0 CA--C 1.49 -1.329 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 -179.048 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.526 HD22 ' HB3' ' A' ' 139' ' ' ALA . 0.2 OUTLIER -135.47 167.12 21.66 Favored 'General case' 0 N--CA 1.43 -1.471 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 179.965 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.8 mmt180 -106.37 15.44 26.05 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 85.8 p -97.4 166.26 11.62 Favored 'General case' 0 CA--C 1.501 -0.918 0 CA-C-O 121.626 0.727 . . . . 0.0 109.433 -178.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 33.3 m -125.16 166.4 20.91 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.001 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.59 118.01 5.36 Favored Glycine 0 C--N 1.349 1.281 0 N-CA-C 108.513 -1.835 . . . . 0.0 108.513 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -78.46 131.85 37.05 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.79 0.91 89.96 Favored Glycine 0 C--N 1.354 1.576 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -93.9 163.57 13.45 Favored 'General case' 0 CA--C 1.491 -1.309 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.4 m -102.84 127.48 50.01 Favored 'General case' 0 N--CA 1.434 -1.274 0 N-CA-C 105.877 -1.897 . . . . 0.0 105.877 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 23.8 m -129.28 162.02 37.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.987 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -109.93 141.0 43.29 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 44.8 p90 -159.03 161.67 36.61 Favored 'General case' 0 CA--C 1.501 -0.925 0 C-N-CA 118.834 -1.146 . . . . 0.0 110.271 -179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 97.3 m-20 -93.51 151.38 19.75 Favored 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 178.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.4 t -114.21 124.92 71.33 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 -179.662 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.4 m -127.19 156.45 38.7 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.463 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 -179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -69.82 131.09 43.96 Favored 'General case' 0 N--CA 1.429 -1.497 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -131.04 -173.27 13.32 Favored Glycine 0 C--N 1.35 1.346 0 N-CA-C 108.106 -1.997 . . . . 0.0 108.106 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -69.67 -25.86 64.1 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 49.9 mmtm -90.22 10.37 24.91 Favored 'General case' 0 CA--C 1.501 -0.929 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 -179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 100.22 -70.09 0.48 Allowed Glycine 0 CA--C 1.49 -1.507 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.93 130.39 53.85 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -129.01 137.24 51.21 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -82.74 145.31 29.64 Favored 'General case' 0 N--CA 1.439 -1.017 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.47 152.5 40.71 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 31.2 m120 58.5 52.48 7.01 Favored 'General case' 0 C--N 1.361 1.076 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 92.2 t -80.15 119.88 30.49 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.937 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 -178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.8 p -138.18 167.46 21.79 Favored 'General case' 0 CA--C 1.499 -0.998 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.67 175.33 55.04 Favored Glycine 0 C--N 1.35 1.308 0 N-CA-C 107.22 -2.352 . . . . 0.0 107.22 179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.455 ' O ' HG22 ' A' ' 131' ' ' VAL . 47.2 Cg_exo -58.17 132.21 47.82 Favored 'Trans proline' 0 C--N 1.311 -1.418 0 C-N-CA 121.782 1.654 . . . . 0.0 112.784 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.33 1.28 88.2 Favored Glycine 0 C--N 1.349 1.297 0 N-CA-C 108.867 -1.693 . . . . 0.0 108.867 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 82.84 16.52 70.04 Favored Glycine 0 C--N 1.353 1.512 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.455 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -80.54 155.95 73.51 Favored Pre-proline 0 N--CA 1.442 -0.865 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 179.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 35.7 Cg_exo -60.15 147.7 92.35 Favored 'Trans proline' 0 CA--C 1.501 -1.151 0 C-N-CA 121.959 1.772 . . . . 0.0 112.644 179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 33.8 m -74.29 139.81 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.843 0 N-CA-C 107.818 -1.178 . . . . 0.0 107.818 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -68.67 -39.72 80.5 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.26 -170.48 28.74 Favored Glycine 0 C--N 1.346 1.123 0 N-CA-C 107.785 -2.126 . . . . 0.0 107.785 -179.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 73.9 m -94.13 151.94 19.11 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 107.462 -1.311 . . . . 0.0 107.462 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -65.54 -39.11 91.39 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 110.2 -0.296 . . . . 0.0 110.2 -179.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 51.7 p90 -75.97 -21.72 56.68 Favored 'General case' 0 CA--C 1.507 -0.697 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.526 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -69.5 151.46 46.01 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.643 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.788 0 CA-C-O 117.775 -1.107 . . . . 0.0 108.603 -179.485 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 121.019 0.438 . . . . 0.0 110.661 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 20.7 ptmt -152.45 -155.16 0.58 Allowed 'General case' 0 N--CA 1.435 -1.204 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -64.75 136.77 57.28 Favored 'General case' 0 CA--C 1.498 -1.042 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.1 t -109.11 121.68 62.58 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.383 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.494 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.65 -35.7 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.888 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 -178.486 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -143.85 150.81 39.03 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.574 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.75 3.22 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -178.821 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 59.2 mtmt -45.65 107.74 0.11 Allowed 'General case' 0 CA--C 1.502 -0.884 0 CA-C-O 121.758 0.79 . . . . 0.0 110.069 -179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.574 HG13 ' O ' ' A' ' 57' ' ' THR . 19.2 m -122.11 162.17 21.98 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.469 0 N-CA-C 106.099 -1.815 . . . . 0.0 106.099 178.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.0 mt -102.23 136.73 41.54 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.57 157.29 26.63 Favored Glycine 0 CA--C 1.487 -1.708 0 N-CA-C 107.862 -2.095 . . . . 0.0 107.862 -179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.3 m -105.28 129.58 53.6 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.614 HG22 HG12 ' A' ' 75' ' ' ILE . 86.0 t -76.8 117.28 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 -179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -91.39 -39.5 11.97 Favored 'General case' 0 CA--C 1.486 -1.511 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 64.5 m95 -143.96 137.55 27.84 Favored 'General case' 0 CA--C 1.496 -1.111 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.489 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 45.8 t80 -153.91 115.6 4.21 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 177.282 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -107.59 120.13 41.36 Favored 'General case' 0 CA--C 1.496 -1.096 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 73.2 t -65.47 -39.9 86.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -179.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.1 mtm180 -62.88 -39.96 96.06 Favored 'General case' 0 C--N 1.352 0.702 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -178.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.458 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.0 m120 -73.75 -30.77 62.98 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 -179.322 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 84.52 14.08 71.67 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.274 -1.93 . . . . 0.0 108.274 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.458 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.8 p90 -157.55 166.78 32.02 Favored 'General case' 0 CA--C 1.495 -1.144 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.69 -167.41 24.11 Favored Glycine 0 CA--C 1.49 -1.49 0 N-CA-C 107.491 -2.244 . . . . 0.0 107.491 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -129.07 136.84 50.8 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 -179.487 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.614 HG12 HG22 ' A' ' 63' ' ' VAL . 85.7 mt -120.92 129.41 75.72 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.115 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 179.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -95.98 124.98 40.21 Favored 'General case' 0 CA--C 1.496 -1.106 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 78.5 mtp180 -70.23 134.76 48.36 Favored 'General case' 0 CA--C 1.495 -1.16 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 35.0 m120 -88.72 -1.27 57.99 Favored 'General case' 0 CA--C 1.502 -0.897 0 C-N-CA 119.804 -0.758 . . . . 0.0 109.051 -179.259 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -100.4 -34.76 9.82 Favored 'General case' 0 N--CA 1.444 -0.763 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.082 -179.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.0 p -115.03 -12.84 11.93 Favored 'General case' 0 CA--C 1.501 -0.932 0 C-N-CA 120.136 -0.626 . . . . 0.0 110.235 -178.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 67.5 mmtt 66.87 28.31 8.75 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -104.66 148.36 26.64 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -87.83 139.11 30.86 Favored 'General case' 0 N--CA 1.441 -0.906 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -127.18 143.3 40.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.05 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -86.98 131.35 34.11 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -178.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.473 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.7 p -121.98 154.01 26.35 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.103 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.473 ' N ' HG22 ' A' ' 86' ' ' VAL . 32.1 t-80 -140.82 165.41 27.57 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 -178.215 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -66.34 -20.83 66.19 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 60.4 p -83.42 1.23 42.54 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -95.67 -4.96 43.37 Favored 'General case' 0 N--CA 1.441 -0.886 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 21.9 mm -78.45 120.22 28.97 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.19 -1.411 . . . . 0.0 107.19 -179.483 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -94.25 -44.79 7.8 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 120.23 -0.588 . . . . 0.0 109.456 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -114.47 142.79 45.93 Favored 'General case' 0 CA--C 1.497 -1.091 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 -177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -120.01 155.85 32.06 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 106.451 -1.685 . . . . 0.0 106.451 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 18.9 t-20 -69.63 132.2 89.31 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 107.3 -1.371 . . . . 0.0 107.3 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -58.11 -37.17 96.74 Favored 'Trans proline' 0 CA--C 1.504 -1.022 0 C-N-CA 122.051 1.834 . . . . 0.0 114.727 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -67.09 -42.49 84.53 Favored 'General case' 0 CA--C 1.504 -0.817 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -178.301 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 62.2 mtpt -143.11 126.83 17.05 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.6 p90 -81.62 114.89 20.62 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.452 HD22 ' HB1' ' A' ' 139' ' ' ALA . 89.9 mt -128.02 143.62 51.08 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.03 -1.471 . . . . 0.0 107.03 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 90.5 mtm180 -107.57 16.74 23.46 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -179.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 89.5 p -104.64 164.6 11.64 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 -178.506 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.65 160.69 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.101 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.803 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -77.23 133.62 13.56 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 -179.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -78.0 123.7 27.13 Favored 'General case' 0 N--CA 1.435 -1.216 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 179.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 2.39 67.74 Favored Glycine 0 C--N 1.353 1.481 0 N-CA-C 109.244 -1.542 . . . . 0.0 109.244 179.419 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -92.92 153.44 18.79 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 179.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.2 m -95.68 125.43 40.25 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 105.516 -2.031 . . . . 0.0 105.516 178.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 22.9 m -129.51 162.87 36.2 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.962 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 -178.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -110.1 141.09 43.44 Favored 'General case' 0 CA--C 1.497 -1.068 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.407 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.2 p90 -159.56 161.46 35.2 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 119.049 -1.061 . . . . 0.0 109.839 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -98.48 154.09 18.14 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 56.4 t -115.07 125.69 72.45 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.188 0 N-CA-C 106.922 -1.511 . . . . 0.0 106.922 -179.053 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.76 159.67 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.399 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.534 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -68.75 142.02 55.07 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 -179.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -133.91 172.79 21.55 Favored Glycine 0 CA--C 1.493 -1.296 0 N-CA-C 107.319 -2.313 . . . . 0.0 107.319 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 25.0 pt-20 -70.47 -17.38 62.98 Favored 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 109.059 -0.719 . . . . 0.0 109.059 -179.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -96.4 6.27 49.12 Favored 'General case' 0 CA--C 1.499 -0.988 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 113.95 -78.7 0.26 Allowed Glycine 0 CA--C 1.491 -1.411 0 N-CA-C 107.749 -2.141 . . . . 0.0 107.749 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.16 133.02 55.18 Favored 'General case' 0 CA--C 1.498 -1.057 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.932 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -125.94 135.32 51.73 Favored 'General case' 0 N--CA 1.438 -1.027 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.86 147.36 29.37 Favored 'General case' 0 N--CA 1.44 -0.954 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -148.69 154.95 40.36 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 179.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.5 t30 60.38 54.23 3.97 Favored 'General case' 0 C--N 1.359 0.98 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 94.2 t -84.53 119.76 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.116 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.4 p -138.67 167.83 21.12 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.39 -1.708 . . . . 0.0 106.39 179.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.39 175.28 54.83 Favored Glycine 0 CA--C 1.496 -1.126 0 N-CA-C 106.852 -2.499 . . . . 0.0 106.852 179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -68.1 133.97 30.33 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 C-N-CA 121.144 1.23 . . . . 0.0 112.167 -179.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 93.04 -5.81 75.9 Favored Glycine 0 C--N 1.348 1.232 0 N-CA-C 108.379 -1.888 . . . . 0.0 108.379 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 91.44 9.71 62.85 Favored Glycine 0 C--N 1.354 1.561 0 N-CA-C 108.955 -1.658 . . . . 0.0 108.955 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 30.9 m -75.91 154.35 84.94 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -70.04 156.87 61.59 Favored 'Trans proline' 0 CA--C 1.499 -1.242 0 C-N-CA 121.582 1.522 . . . . 0.0 112.447 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 2.3 m -75.07 132.03 34.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.867 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.5 tt0 -67.67 -40.89 84.44 Favored 'General case' 0 CA--C 1.502 -0.903 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 -179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 134.36 -164.1 24.59 Favored Glycine 0 CA--C 1.492 -1.346 0 N-CA-C 107.026 -2.43 . . . . 0.0 107.026 -179.452 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.0 t -119.17 -168.58 1.59 Allowed 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 -179.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -62.63 -43.12 99.62 Favored 'General case' 0 CA--C 1.502 -0.88 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 -179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -136.27 136.16 39.59 Favored 'General case' 0 N--CA 1.436 -1.131 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -144.6 155.67 43.75 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 106.972 -1.492 . . . . 0.0 106.972 -179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.715 0 CA-C-O 117.863 -1.065 . . . . 0.0 108.257 179.947 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 29.8 t0 . . . . . 0 N--CA 1.487 1.389 0 CA-C-O 121.035 0.445 . . . . 0.0 110.48 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.38 170.66 7.79 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 107.88 -1.155 . . . . 0.0 107.88 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 70.9 mmtt -73.42 147.71 43.96 Favored 'General case' 0 CA--C 1.494 -1.204 0 CA-C-O 122.047 0.927 . . . . 0.0 109.028 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -109.49 122.24 63.8 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.37 0 N-CA-C 105.355 -2.091 . . . . 0.0 105.355 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.547 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -91.5 -36.29 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.801 0 N-CA-C 107.764 -1.198 . . . . 0.0 107.764 -178.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.631 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.19 152.24 38.92 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.603 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.29 -173.27 3.03 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 -179.379 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -41.98 105.92 0.05 Allowed 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.561 -179.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.603 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -121.4 161.95 21.03 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.373 0 N-CA-C 106.374 -1.714 . . . . 0.0 106.374 178.195 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.8 mt -104.39 134.56 47.39 Favored 'General case' 0 N--CA 1.432 -1.354 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 179.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.67 158.23 26.98 Favored Glycine 0 CA--C 1.485 -1.783 0 N-CA-C 107.867 -2.093 . . . . 0.0 107.867 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 96.1 m -106.69 130.99 54.33 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.572 HG22 HG12 ' A' ' 75' ' ' ILE . 81.1 t -75.12 102.5 2.46 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.084 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 31.0 mmmt -71.82 -42.45 66.98 Favored 'General case' 0 CA--C 1.496 -1.11 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 -179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 90.7 m95 -147.12 141.85 26.73 Favored 'General case' 0 CA--C 1.498 -1.055 0 C-N-CA 119.538 -0.865 . . . . 0.0 108.866 -178.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.428 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 59.0 t80 -150.29 121.83 7.98 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 177.526 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -99.07 116.98 32.53 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 75.1 t -64.08 -41.63 93.08 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.732 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -179.152 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 -61.17 -45.74 93.39 Favored 'General case' 0 N--CA 1.447 -0.62 0 O-C-N 122.369 -0.207 . . . . 0.0 110.662 -178.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -76.5 -31.4 57.7 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 -178.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.6 14.88 77.24 Favored Glycine 0 C--N 1.348 1.205 0 N-CA-C 107.597 -2.201 . . . . 0.0 107.597 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.2 m-85 -131.51 159.45 38.09 Favored 'General case' 0 CA--C 1.496 -1.128 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.5 -173.63 32.42 Favored Glycine 0 CA--C 1.49 -1.483 0 N-CA-C 108.122 -1.991 . . . . 0.0 108.122 -179.62 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -129.06 137.6 51.38 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.572 HG12 HG22 ' A' ' 63' ' ' VAL . 85.9 mt -119.62 127.87 75.87 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 179.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -95.8 123.14 39.25 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 77.8 mtp180 -68.83 131.99 46.04 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 107.467 -1.309 . . . . 0.0 107.467 -179.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -89.73 -1.34 57.98 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.806 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.3 m-20 -97.9 -30.08 12.95 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.971 -0.692 . . . . 0.0 110.248 -179.001 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.1 t -126.68 -5.89 6.34 Favored 'General case' 0 C--N 1.355 0.821 0 C-N-CA 119.449 -0.901 . . . . 0.0 110.379 -178.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 12.1 mptt 64.07 44.86 4.38 Favored 'General case' 0 C--N 1.358 0.966 0 CA-C-O 121.945 0.879 . . . . 0.0 109.551 179.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -122.39 148.97 44.44 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 178.597 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -90.96 138.84 31.29 Favored 'General case' 0 CA--C 1.502 -0.875 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -178.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.1 t -127.02 142.79 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 106.138 -1.801 . . . . 0.0 106.138 179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -87.27 135.96 33.11 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 107.038 -1.468 . . . . 0.0 107.038 -178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 87' ' ' HIS . 11.7 p -122.92 153.92 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.096 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.283 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.477 ' N ' HG22 ' A' ' 86' ' ' VAL . 79.4 m80 -127.45 157.92 38.75 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 -179.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 -69.58 -20.16 63.65 Favored 'General case' 0 CA--C 1.506 -0.748 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 10.7 t -86.0 2.44 46.32 Favored 'General case' 0 CA--C 1.502 -0.89 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -94.32 -6.36 44.54 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 -179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.2 mt -80.98 116.68 25.7 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.8 tptt -85.44 -43.26 13.76 Favored 'General case' 0 N--CA 1.443 -0.805 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.207 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -117.5 141.77 47.95 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 -177.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m120 -119.21 155.16 32.2 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 106.681 -1.6 . . . . 0.0 106.681 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 16.7 t-20 -68.3 133.31 91.35 Favored Pre-proline 0 N--CA 1.443 -0.795 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 179.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -69.78 -26.39 27.52 Favored 'Trans proline' 0 CA--C 1.503 -1.057 0 C-N-CA 121.553 1.502 . . . . 0.0 114.393 -179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -70.27 -40.9 74.09 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 -179.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 36.8 mtmm -140.44 118.97 12.25 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.9 p90 -83.65 114.13 21.34 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 179.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.501 HD22 ' HB3' ' A' ' 139' ' ' ALA . 85.2 mt -127.91 147.63 50.47 Favored 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 11.3 mpt_? -98.44 16.0 23.06 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 64.4 m -115.23 153.47 30.81 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 -178.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 19.5 m -102.5 173.44 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.5 -0.953 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -86.78 127.39 8.38 Favored Glycine 0 C--N 1.35 1.342 0 N-CA-C 108.108 -1.997 . . . . 0.0 108.108 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 17.2 t70 -77.7 123.89 27.26 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.07 2.28 71.57 Favored Glycine 0 C--N 1.354 1.532 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -92.87 152.32 19.47 Favored 'General case' 0 CA--C 1.495 -1.161 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.0 m -95.26 126.89 40.89 Favored 'General case' 0 N--CA 1.435 -1.19 0 N-CA-C 105.522 -2.029 . . . . 0.0 105.522 178.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.7 m -128.67 163.1 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.978 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 -178.172 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -109.06 131.58 54.93 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 -178.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.505 ' CE2' HG21 ' A' ' 75' ' ' ILE . 47.4 p90 -154.96 161.53 41.37 Favored 'General case' 0 CA--C 1.504 -0.818 0 C-N-CA 118.93 -1.108 . . . . 0.0 110.316 -178.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 -96.02 151.48 19.41 Favored 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 178.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.631 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.9 t -114.06 124.38 70.65 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.214 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 -179.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.4 159.83 32.25 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.461 0 N-CA-C 105.844 -1.91 . . . . 0.0 105.844 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 87.0 mt-10 -69.91 144.33 52.48 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 119.576 -0.849 . . . . 0.0 108.773 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.74 -179.23 18.65 Favored Glycine 0 CA--C 1.494 -1.252 0 N-CA-C 108.226 -1.949 . . . . 0.0 108.226 -179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -69.23 -25.18 64.17 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.65 10.07 24.56 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -179.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 103.02 -71.45 0.29 Allowed Glycine 0 CA--C 1.49 -1.522 0 N-CA-C 107.298 -2.321 . . . . 0.0 107.298 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.34 131.6 54.29 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 89.0 tt0 -124.46 135.48 53.27 Favored 'General case' 0 N--CA 1.437 -1.095 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 179.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -83.01 146.47 28.73 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.8 152.97 40.38 Favored 'General case' 0 N--CA 1.439 -0.978 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 179.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.3 m-20 57.23 53.46 7.72 Favored 'General case' 0 C--N 1.36 1.061 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 93.0 t -79.76 120.39 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.928 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 -179.252 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 71.8 p -138.12 168.26 20.09 Favored 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.42 172.8 53.92 Favored Glycine 0 C--N 1.348 1.228 0 N-CA-C 106.641 -2.584 . . . . 0.0 106.641 179.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.466 ' O ' HG22 ' A' ' 131' ' ' VAL . 52.1 Cg_endo -69.26 136.74 35.12 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 121.232 1.288 . . . . 0.0 112.157 -179.817 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.66 -5.68 79.91 Favored Glycine 0 C--N 1.35 1.319 0 N-CA-C 108.537 -1.825 . . . . 0.0 108.537 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.94 8.58 64.86 Favored Glycine 0 C--N 1.356 1.664 0 N-CA-C 108.637 -1.785 . . . . 0.0 108.637 179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.466 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.5 m -76.96 155.19 82.9 Favored Pre-proline 0 N--CA 1.439 -0.989 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.688 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_endo -68.88 154.4 71.05 Favored 'Trans proline' 0 CA--C 1.499 -1.268 0 C-N-CA 121.463 1.442 . . . . 0.0 112.139 179.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 35.1 m -74.65 140.18 17.96 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 -179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.12 -39.18 82.81 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 91.3 -167.36 31.37 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 107.666 -2.174 . . . . 0.0 107.666 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 69.7 m -79.68 170.0 17.16 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -59.88 -44.19 94.33 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 80.7 t80 -147.25 130.22 16.28 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 106.27 -1.752 . . . . 0.0 106.27 178.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.501 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.12 65.13 1.21 Allowed 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 -178.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 179.67 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.429 0 CA-C-O 121.128 0.49 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.94 157.69 16.21 Favored 'General case' 0 CA--C 1.497 -1.061 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -96.23 130.36 43.32 Favored 'General case' 0 CA--C 1.494 -1.209 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 64.5 t -102.4 120.71 52.51 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.407 0 N-CA-C 104.972 -2.233 . . . . 0.0 104.972 178.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -88.05 -35.9 8.71 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.899 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.159 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.662 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.94 152.59 39.67 Favored 'General case' 0 CA--C 1.493 -1.228 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.579 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.2 OUTLIER -94.21 -173.3 3.05 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 -179.177 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.43 ' H ' HG22 ' A' ' 57' ' ' THR . 99.1 mttt -44.55 106.49 0.07 Allowed 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 115.474 -0.785 . . . . 0.0 110.378 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.579 HG13 ' O ' ' A' ' 57' ' ' THR . 19.6 m -122.13 162.83 21.19 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.43 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 85.1 mt -103.08 137.12 41.67 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 106.844 -1.539 . . . . 0.0 106.844 179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.38 159.59 27.75 Favored Glycine 0 CA--C 1.487 -1.684 0 N-CA-C 107.823 -2.111 . . . . 0.0 107.823 -179.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.3 m -106.65 129.6 54.53 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.546 HG22 HG12 ' A' ' 75' ' ' ILE . 58.5 t -76.22 103.0 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.183 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 179.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.6 tptt -71.28 -44.92 64.28 Favored 'General case' 0 N--CA 1.436 -1.137 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -179.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.5 m95 -147.2 140.41 25.29 Favored 'General case' 0 CA--C 1.497 -1.084 0 C-N-CA 119.562 -0.855 . . . . 0.0 108.934 -179.068 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.505 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.6 t80 -146.2 119.24 8.79 Favored 'General case' 0 N--CA 1.431 -1.381 0 N-CA-C 104.808 -2.293 . . . . 0.0 104.808 176.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . 0.405 ' HB2' ' HB2' ' A' ' 70' ' ' ASN . 34.2 m120 -100.87 122.29 43.19 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 -179.017 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.4 t -64.96 -42.09 93.84 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.701 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.193 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -66.57 -28.21 68.34 Favored 'General case' 0 CA--C 1.507 -0.707 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.088 -177.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 98.8 m-20 -85.83 -30.07 23.25 Favored 'General case' 0 CA--C 1.499 -1.005 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -178.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 81.63 14.53 77.86 Favored Glycine 0 C--N 1.349 1.264 0 N-CA-C 108.271 -1.932 . . . . 0.0 108.271 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.0 p90 -157.0 166.57 32.99 Favored 'General case' 0 CA--C 1.497 -1.083 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.505 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -163.95 -162.56 15.08 Favored Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -129.31 139.61 51.7 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.546 HG12 HG22 ' A' ' 63' ' ' VAL . 87.6 mt -120.0 129.46 75.42 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -95.84 125.42 40.39 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.456 HH21 HG11 ' A' ' 59' ' ' VAL . 78.7 mtp180 -69.16 132.46 46.57 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.733 -1.21 . . . . 0.0 107.733 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -85.28 -7.63 58.91 Favored 'General case' 0 CA--C 1.504 -0.827 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -100.07 -31.09 11.6 Favored 'General case' 0 N--CA 1.442 -0.85 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.711 -178.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 4.2 m -116.56 -15.13 10.87 Favored 'General case' 0 CA--C 1.504 -0.821 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.91 -177.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt 64.34 45.38 3.85 Favored 'General case' 0 CA--C 1.495 -1.147 0 CA-C-O 122.104 0.954 . . . . 0.0 108.781 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -124.12 149.1 46.62 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -87.54 137.54 32.25 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -126.13 142.07 43.86 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.046 0 N-CA-C 106.143 -1.799 . . . . 0.0 106.143 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -84.97 132.41 34.35 Favored 'General case' 0 CA--C 1.504 -0.819 0 N-CA-C 107.568 -1.271 . . . . 0.0 107.568 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.8 p -124.18 152.72 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.236 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.461 ' N ' HG22 ' A' ' 86' ' ' VAL . 43.9 t-80 -136.53 158.12 45.19 Favored 'General case' 0 N--CA 1.438 -1.032 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -178.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.0 pt20 -63.67 -20.93 66.1 Favored 'General case' 0 CA--C 1.509 -0.609 0 O-C-N 122.182 -0.324 . . . . 0.0 110.53 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 6.8 t -84.33 2.01 42.32 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -101.64 -3.12 28.86 Favored 'General case' 0 CA--C 1.501 -0.905 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.7 mt -84.77 118.54 32.05 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.105 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 39.8 ttpt -92.3 -40.52 10.89 Favored 'General case' 0 N--CA 1.441 -0.892 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 -178.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -123.68 147.15 47.69 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 -178.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -151.85 -179.3 7.34 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 106.201 -1.777 . . . . 0.0 106.201 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 56.2 t-20 -68.25 122.75 85.42 Favored Pre-proline 0 N--CA 1.444 -0.745 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 -179.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.0 -21.36 18.39 Favored 'Trans proline' 0 C--N 1.319 -0.994 0 C-N-CA 121.619 1.546 . . . . 0.0 114.217 179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -67.55 -39.99 84.96 Favored 'General case' 0 CA--C 1.502 -0.882 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -178.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -128.01 129.21 46.36 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 15.2 p90 -74.82 114.73 13.61 Favored 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . . . . . . . . . 90.7 mt -125.44 145.41 50.08 Favored 'General case' 0 CA--C 1.491 -1.296 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -112.09 15.64 20.51 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 179.174 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 60.6 m -128.15 164.17 23.05 Favored 'General case' 0 CA--C 1.498 -1.035 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 25.8 m -123.59 164.44 21.44 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.098 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -88.41 137.86 14.61 Favored Glycine 0 CA--C 1.49 -1.512 0 N-CA-C 108.409 -1.877 . . . . 0.0 108.409 -179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -77.97 152.33 33.21 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.2 0.17 89.48 Favored Glycine 0 C--N 1.35 1.341 0 N-CA-C 109.11 -1.596 . . . . 0.0 109.11 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 58.6 mt-10 -92.83 149.72 21.09 Favored 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.1 m -97.29 127.21 43.05 Favored 'General case' 0 N--CA 1.435 -1.213 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 17.1 m -128.0 160.81 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.012 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -109.7 129.52 55.6 Favored 'General case' 0 CA--C 1.5 -0.978 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -179.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 75' ' ' ILE . 48.8 p90 -155.25 161.32 41.17 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 118.644 -1.222 . . . . 0.0 110.587 -178.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 62.0 m-20 -95.19 153.1 17.82 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.662 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.7 t -114.97 124.72 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.13 0 N-CA-C 106.362 -1.718 . . . . 0.0 106.362 -179.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.4 m -126.18 162.71 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.407 0 N-CA-C 105.955 -1.869 . . . . 0.0 105.955 179.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -68.21 145.81 53.95 Favored 'General case' 0 CA--C 1.495 -1.139 0 C-N-CA 119.396 -0.922 . . . . 0.0 109.274 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -143.2 179.45 20.71 Favored Glycine 0 CA--C 1.495 -1.172 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 -179.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.9 mp0 -65.28 -35.1 79.99 Favored 'General case' 0 CA--C 1.504 -0.822 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -84.8 10.78 10.58 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.61 -69.88 0.24 Allowed Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 107.776 -2.129 . . . . 0.0 107.776 179.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.0 132.03 54.65 Favored 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -124.46 136.02 53.7 Favored 'General case' 0 N--CA 1.438 -1.057 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.26 147.96 29.68 Favored 'General case' 0 CA--C 1.502 -0.889 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.87 151.73 39.17 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 56.79 53.13 8.58 Favored 'General case' 0 C--N 1.361 1.098 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 87.2 t -79.95 119.9 30.29 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.858 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -178.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 73.2 p -138.2 165.59 26.3 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.77 173.11 55.07 Favored Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.847 -2.501 . . . . 0.0 106.847 178.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.553 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.44 133.31 25.83 Favored 'Trans proline' 0 C--N 1.307 -1.615 0 C-N-CA 121.342 1.361 . . . . 0.0 112.285 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.0 1.36 89.74 Favored Glycine 0 C--N 1.35 1.311 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 -179.668 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 85.11 11.62 75.71 Favored Glycine 0 C--N 1.355 1.603 0 N-CA-C 109.117 -1.593 . . . . 0.0 109.117 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.553 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.4 m -78.2 152.58 79.23 Favored Pre-proline 0 N--CA 1.441 -0.901 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 67.5 Cg_endo -72.94 155.94 52.71 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.713 1.609 . . . . 0.0 112.524 179.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.2 m -80.41 152.44 4.49 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.815 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 79.2 mt-30 -67.57 -39.98 84.91 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 116.91 178.95 17.84 Favored Glycine 0 C--N 1.347 1.15 0 N-CA-C 107.191 -2.364 . . . . 0.0 107.191 -179.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 32.1 t -85.56 157.14 20.47 Favored 'General case' 0 CA--C 1.499 -0.993 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.13 -42.1 97.93 Favored 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 93.2 t80 -102.12 129.61 48.52 Favored 'General case' 0 N--CA 1.439 -1.023 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . . . . . . . . . . . -144.9 158.5 43.78 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 106.966 -1.494 . . . . 0.0 106.966 -178.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.727 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 -179.903 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.068 0.461 . . . . 0.0 110.557 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.484 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER -82.16 141.99 32.6 Favored 'General case' 0 N--CA 1.436 -1.152 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 179.924 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.484 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 68.6 mttm -81.92 134.57 35.4 Favored 'General case' 0 N--CA 1.437 -1.116 0 N-CA-C 108.164 -1.051 . . . . 0.0 108.164 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 70.3 t -109.82 120.66 61.36 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.436 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 178.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.542 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.01 -36.04 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.857 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -178.068 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.686 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.12 152.58 39.52 Favored 'General case' 0 CA--C 1.492 -1.253 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 179.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.12 -173.31 3.07 Favored 'General case' 0 CA--C 1.491 -1.292 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 -179.029 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -44.51 106.17 0.07 Allowed 'General case' 0 CA--C 1.504 -0.795 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.265 -179.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 19.5 m -122.89 162.65 22.69 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 178.474 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 84.5 mt -102.43 137.61 40.44 Favored 'General case' 0 N--CA 1.433 -1.304 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.48 157.29 26.58 Favored Glycine 0 CA--C 1.488 -1.602 0 N-CA-C 107.591 -2.204 . . . . 0.0 107.591 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.0 m -108.0 129.09 55.15 Favored 'General case' 0 CA--C 1.501 -0.942 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.61 HG22 HG12 ' A' ' 75' ' ' ILE . 74.5 t -76.89 106.74 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.415 ' HG2' ' CD1' ' A' ' 65' ' ' TRP . 88.6 tttt -74.22 -46.01 44.5 Favored 'General case' 0 N--CA 1.436 -1.171 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . 0.415 ' CD1' ' HG2' ' A' ' 64' ' ' LYS . 94.9 m95 -150.14 144.44 25.69 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.554 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.98 118.88 8.71 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 105.14 -2.17 . . . . 0.0 105.14 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -100.89 122.91 44.28 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 -178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.518 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.9 t -65.59 -40.91 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 -179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 80.0 ttt180 -61.16 -43.76 98.37 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.457 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 28.1 m120 -72.78 -31.31 64.78 Favored 'General case' 0 CA--C 1.499 -0.984 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -178.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.13 13.8 76.24 Favored Glycine 0 C--N 1.348 1.229 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.457 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 44.6 p90 -157.31 166.75 32.27 Favored 'General case' 0 CA--C 1.496 -1.101 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 -179.738 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.554 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -158.94 -163.83 13.56 Favored Glycine 0 CA--C 1.488 -1.614 0 N-CA-C 107.66 -2.176 . . . . 0.0 107.66 -179.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -128.18 138.23 52.39 Favored 'General case' 0 CA--C 1.496 -1.123 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 -179.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.61 HG12 HG22 ' A' ' 63' ' ' VAL . 94.4 mt -120.14 128.73 75.98 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -91.15 121.8 33.24 Favored 'General case' 0 CA--C 1.494 -1.191 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 1.8 ttm180 -66.87 130.45 43.18 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.8 t30 -88.42 5.79 40.61 Favored 'General case' 0 N--CA 1.443 -0.792 0 C-N-CA 119.661 -0.815 . . . . 0.0 109.295 -178.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -102.34 -43.07 5.79 Favored 'General case' 0 N--CA 1.443 -0.791 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.593 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 67.5 p -114.02 -7.71 13.09 Favored 'General case' 0 CA--C 1.502 -0.888 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.594 -179.056 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 2.6 mptp? 67.39 23.66 9.11 Favored 'General case' 0 CA--C 1.502 -0.876 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -93.52 146.85 23.48 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -72.48 140.75 48.43 Favored 'General case' 0 C--N 1.355 0.834 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 31.9 t -129.62 141.41 46.55 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.009 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -93.87 132.82 37.91 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -178.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.484 HG22 ' N ' ' A' ' 87' ' ' HIS . 8.6 p -125.03 154.08 32.76 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.289 0 N-CA-C 107.308 -1.368 . . . . 0.0 107.308 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.484 ' N ' HG22 ' A' ' 86' ' ' VAL . 35.1 t-80 -139.17 159.02 43.13 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 21.6 pt20 -64.92 -17.96 64.8 Favored 'General case' 0 C--N 1.352 0.696 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 69.2 p -89.59 1.79 55.51 Favored 'General case' 0 CA--C 1.498 -1.053 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.03 -4.98 31.23 Favored 'General case' 0 CA--C 1.501 -0.922 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 -179.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.0 mt -83.13 118.66 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.969 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.6 tttm -91.7 -42.74 9.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -178.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -119.3 149.16 42.27 Favored 'General case' 0 CA--C 1.495 -1.162 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 -178.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -147.86 165.02 31.87 Favored 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 106.468 -1.679 . . . . 0.0 106.468 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -70.76 124.04 90.24 Favored Pre-proline 0 N--CA 1.444 -0.76 0 N-CA-C 107.321 -1.362 . . . . 0.0 107.321 -179.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -68.96 -25.96 31.88 Favored 'Trans proline' 0 CA--C 1.503 -1.038 0 C-N-CA 121.486 1.457 . . . . 0.0 113.783 179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.1 mtt85 -70.61 -38.7 74.0 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 9.1 mttp -133.6 95.72 3.54 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 106.746 -1.575 . . . . 0.0 106.746 -179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 82.9 t80 -78.59 120.36 23.18 Favored 'General case' 0 CA--C 1.494 -1.207 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.452 ' HB3' ' HB3' ' A' ' 139' ' ' ALA . 77.1 mt -125.28 156.96 37.77 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 -178.742 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 27.3 mmt85 -98.69 16.38 22.24 Favored 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.518 ' HB3' HG22 ' A' ' 68' ' ' VAL . 92.3 p -137.69 165.44 26.38 Favored 'General case' 0 CA--C 1.497 -1.084 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 -177.752 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.428 HG21 HG21 ' A' ' 63' ' ' VAL . 32.7 m -112.02 163.16 9.25 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.077 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -81.32 135.2 14.13 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 108.594 -1.803 . . . . 0.0 108.594 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -75.06 144.41 42.99 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 179.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 84.06 1.93 89.56 Favored Glycine 0 C--N 1.352 1.448 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -92.67 147.74 22.63 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.8 m -97.14 126.76 42.53 Favored 'General case' 0 N--CA 1.434 -1.226 0 N-CA-C 104.852 -2.277 . . . . 0.0 104.852 178.138 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 15.8 m -126.62 161.32 33.23 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.978 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -177.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -109.52 130.19 55.52 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 -178.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 43.9 p90 -155.63 161.6 40.78 Favored 'General case' 0 CA--C 1.502 -0.892 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.491 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 61.1 m-20 -95.3 152.67 18.18 Favored 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 178.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.686 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 60.7 t -113.22 123.98 69.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.45 162.32 33.08 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.442 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -68.04 134.17 50.22 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.31 13.99 Favored Glycine 0 C--N 1.352 1.449 0 N-CA-C 108.186 -1.965 . . . . 0.0 108.186 -179.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -70.07 -26.24 63.91 Favored 'General case' 0 CA--C 1.505 -0.753 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.616 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -90.15 10.11 25.74 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.39 -72.11 0.25 Allowed Glycine 0 CA--C 1.489 -1.589 0 N-CA-C 107.27 -2.332 . . . . 0.0 107.27 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.73 135.96 54.94 Favored 'General case' 0 CA--C 1.496 -1.117 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.2 pt-20 -139.28 152.66 47.43 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -85.73 149.96 24.92 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -145.23 150.34 36.53 Favored 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 57.69 53.59 7.05 Favored 'General case' 0 C--N 1.36 1.022 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 82.9 t -78.9 121.66 32.48 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.931 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -178.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 67.0 p -137.84 166.45 23.98 Favored 'General case' 0 CA--C 1.5 -0.972 0 N-CA-C 106.714 -1.588 . . . . 0.0 106.714 179.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.17 173.51 54.45 Favored Glycine 0 C--N 1.348 1.247 0 N-CA-C 106.943 -2.463 . . . . 0.0 106.943 178.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.508 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.3 Cg_endo -69.56 133.97 27.25 Favored 'Trans proline' 0 C--N 1.307 -1.622 0 C-N-CA 121.287 1.325 . . . . 0.0 112.092 -179.668 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.28 -5.18 82.92 Favored Glycine 0 C--N 1.349 1.252 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.94 9.54 65.78 Favored Glycine 0 C--N 1.355 1.616 0 N-CA-C 108.686 -1.766 . . . . 0.0 108.686 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.9 m -78.84 153.74 77.96 Favored Pre-proline 0 N--CA 1.441 -0.896 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -71.53 155.12 59.91 Favored 'Trans proline' 0 C--N 1.315 -1.228 0 C-N-CA 121.652 1.568 . . . . 0.0 112.547 179.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 m -83.57 144.35 10.17 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.91 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 63.3 tt0 -67.47 -40.04 85.3 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . 0.451 ' HA3' HD12 ' A' ' 100' ' ' LEU . . . 100.27 -171.66 23.53 Favored Glycine 0 C--N 1.35 1.317 0 N-CA-C 107.337 -2.305 . . . . 0.0 107.337 -179.207 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.4 t -80.72 -175.32 5.22 Favored 'General case' 0 N--CA 1.444 -0.753 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -61.3 -46.26 91.02 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 81.1 t80 -153.53 128.85 9.82 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 178.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.452 ' HB3' ' HB3' ' A' ' 100' ' ' LEU . . . -147.85 64.54 1.11 Allowed 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.702 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 179.81 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.2 t0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 121.041 0.448 . . . . 0.0 110.506 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 11.3 tptt -103.71 134.41 47.08 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -70.93 135.95 48.25 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.404 ' O ' HG13 ' A' ' 54' ' ' VAL . 13.2 p -113.47 129.23 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 178.369 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.55 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -96.44 -34.81 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.891 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -178.042 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.679 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -146.39 152.19 38.68 Favored 'General case' 0 CA--C 1.493 -1.225 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.602 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.5 -173.5 3.06 Favored 'General case' 0 CA--C 1.491 -1.291 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -178.981 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.6 mtmt -44.48 108.25 0.11 Allowed 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.469 -179.541 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.602 HG13 ' O ' ' A' ' 57' ' ' THR . 26.7 m -123.21 161.14 25.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 177.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 76.7 mt -102.19 138.05 39.64 Favored 'General case' 0 N--CA 1.433 -1.28 0 N-CA-C 106.776 -1.565 . . . . 0.0 106.776 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.91 158.58 27.43 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 108.099 -2.0 . . . . 0.0 108.099 -179.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 92.9 m -107.23 130.36 54.75 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.516 HG22 HG12 ' A' ' 75' ' ' ILE . 58.1 t -76.12 105.25 4.86 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 179.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -74.98 -47.56 28.66 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 -179.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 24.9 m0 -142.67 138.85 30.92 Favored 'General case' 0 CA--C 1.496 -1.124 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -178.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.526 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 38.0 t80 -149.7 118.15 6.49 Favored 'General case' 0 N--CA 1.434 -1.273 0 N-CA-C 105.365 -2.087 . . . . 0.0 105.365 177.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -100.36 122.58 43.35 Favored 'General case' 0 CA--C 1.498 -1.04 0 N-CA-C 107.57 -1.27 . . . . 0.0 107.57 -179.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.58 -41.81 93.33 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.722 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 -179.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.86 -39.89 95.27 Favored 'General case' 0 C--N 1.352 0.7 0 O-C-N 122.334 -0.229 . . . . 0.0 110.605 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.8 m120 -74.3 -31.26 62.43 Favored 'General case' 0 CA--C 1.499 -1.019 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -178.661 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.22 14.98 75.54 Favored Glycine 0 C--N 1.349 1.257 0 N-CA-C 108.004 -2.039 . . . . 0.0 108.004 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.3 p90 -157.09 166.13 34.14 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.526 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.91 -161.65 14.32 Favored Glycine 0 CA--C 1.492 -1.375 0 N-CA-C 107.722 -2.151 . . . . 0.0 107.722 -179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -129.3 139.95 51.59 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.516 HG12 HG22 ' A' ' 63' ' ' VAL . 89.7 mt -119.43 129.12 75.7 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -94.27 125.12 38.71 Favored 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 106.803 -1.554 . . . . 0.0 106.803 -179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.471 HH21 HG11 ' A' ' 59' ' ' VAL . 77.1 mtp180 -69.29 131.46 44.89 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 -179.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -83.46 -10.11 58.58 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -98.27 -31.27 12.15 Favored 'General case' 0 N--CA 1.442 -0.835 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.722 -177.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -114.68 -15.72 11.91 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 119.78 -0.768 . . . . 0.0 109.904 -177.771 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.9 mmtm 64.57 44.05 4.13 Favored 'General case' 0 CA--C 1.496 -1.128 0 CA-C-O 121.938 0.875 . . . . 0.0 108.696 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -124.86 149.38 47.55 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -87.03 138.06 31.82 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -126.43 144.17 37.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.056 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 86.8 t80 -85.3 132.77 34.2 Favored 'General case' 0 N--CA 1.442 -0.87 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -178.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.439 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.2 p -125.45 150.8 30.9 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.267 0 N-CA-C 107.08 -1.452 . . . . 0.0 107.08 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.439 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.8 t-80 -130.03 156.46 44.44 Favored 'General case' 0 N--CA 1.438 -1.038 0 N-CA-C 106.421 -1.696 . . . . 0.0 106.421 -178.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 26.9 pt20 -64.8 -18.48 65.14 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 -179.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 71.2 p -90.31 1.65 56.32 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.11 -6.67 27.92 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 70.9 mt -85.56 119.54 34.23 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.155 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -96.49 -41.43 8.58 Favored 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 -178.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.51 132.64 35.56 Favored 'General case' 0 CA--C 1.5 -0.971 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -178.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -127.45 159.96 32.94 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 179.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 58.9 t-20 -77.51 121.01 83.73 Favored Pre-proline 0 N--CA 1.444 -0.77 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -61.43 -31.66 88.32 Favored 'Trans proline' 0 C--N 1.318 -1.036 0 C-N-CA 121.929 1.753 . . . . 0.0 114.173 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.0 mtp180 -65.34 -41.99 93.35 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.457 -177.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 58.9 mtpt -138.02 134.42 34.77 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 -179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.459 ' O ' HD23 ' A' ' 100' ' ' LEU . 18.6 p90 -75.16 114.53 13.77 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.85 HD22 ' HB3' ' A' ' 139' ' ' ALA . 81.6 mt -130.08 143.28 50.7 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 89.8 mmt-85 -113.65 15.94 18.74 Favored 'General case' 0 CA--C 1.5 -0.974 0 N-CA-C 107.04 -1.467 . . . . 0.0 107.04 179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -124.8 161.73 25.84 Favored 'General case' 0 CA--C 1.496 -1.099 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 -178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 31.8 m -116.9 164.02 13.56 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.984 0 N-CA-C 106.815 -1.55 . . . . 0.0 106.815 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -92.01 139.23 14.61 Favored Glycine 0 CA--C 1.491 -1.426 0 N-CA-C 108.351 -1.899 . . . . 0.0 108.351 -179.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -71.36 142.59 50.38 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 179.385 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 90.89 -6.39 81.88 Favored Glycine 0 C--N 1.351 1.38 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 40.0 mt-10 -83.0 145.87 29.09 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.7 m -100.13 125.58 46.27 Favored 'General case' 0 N--CA 1.434 -1.252 0 N-CA-C 105.053 -2.202 . . . . 0.0 105.053 178.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 24.0 m -129.98 162.09 38.39 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 -178.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -109.77 139.8 44.41 Favored 'General case' 0 CA--C 1.498 -1.041 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.5 p90 -158.4 161.83 37.55 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 118.816 -1.153 . . . . 0.0 110.299 -178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 54.0 m-20 -97.18 151.7 19.56 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 178.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.679 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 61.8 t -111.88 124.07 68.26 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.259 0 N-CA-C 106.225 -1.768 . . . . 0.0 106.225 -179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.0 m -127.37 162.88 31.71 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.517 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 179.76 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.65 140.62 55.49 Favored 'General case' 0 CA--C 1.5 -0.956 0 N-CA-C 108.758 -0.831 . . . . 0.0 108.758 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.51 -178.85 16.02 Favored Glycine 0 C--N 1.347 1.171 0 N-CA-C 107.981 -2.048 . . . . 0.0 107.981 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -70.72 -16.97 62.82 Favored 'General case' 0 C--N 1.353 0.747 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -96.76 10.73 37.97 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.36 -72.61 0.32 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 106.771 -2.532 . . . . 0.0 106.771 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -122.15 135.68 54.82 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.362 -1.347 . . . . 0.0 107.362 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 26.5 pt-20 -138.48 154.81 48.83 Favored 'General case' 0 CA--C 1.5 -0.95 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 179.005 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -88.48 149.18 23.79 Favored 'General case' 0 N--CA 1.437 -1.093 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.2 151.5 36.83 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.246 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 64.9 t30 60.35 52.51 4.78 Favored 'General case' 0 C--N 1.361 1.106 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 79.1 t -83.21 120.16 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 107.453 -1.314 . . . . 0.0 107.453 -178.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 81.9 p -136.43 165.35 26.03 Favored 'General case' 0 CA--C 1.498 -1.039 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -76.3 175.53 52.69 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.997 -2.441 . . . . 0.0 106.997 179.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.473 ' O ' HG22 ' A' ' 131' ' ' VAL . 39.3 Cg_endo -67.68 125.41 13.21 Favored 'Trans proline' 0 C--N 1.306 -1.667 0 C-N-CA 121.214 1.276 . . . . 0.0 112.09 -179.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.23 2.84 87.64 Favored Glycine 0 C--N 1.348 1.209 0 N-CA-C 108.373 -1.891 . . . . 0.0 108.373 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 83.48 15.75 70.44 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.171 -1.571 . . . . 0.0 109.171 179.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.473 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.5 m -81.03 154.96 72.82 Favored Pre-proline 0 N--CA 1.441 -0.923 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 131' ' ' VAL . 31.4 Cg_exo -61.49 150.64 84.34 Favored 'Trans proline' 0 CA--C 1.502 -1.125 0 C-N-CA 122.241 1.961 . . . . 0.0 112.758 178.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.405 ' H ' HG22 ' A' ' 133' ' ' VAL . 3.9 m -85.41 147.56 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.855 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.4 tt0 -66.37 -41.04 90.02 Favored 'General case' 0 CA--C 1.502 -0.869 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 100.67 -178.53 28.72 Favored Glycine 0 C--N 1.348 1.245 0 N-CA-C 107.919 -2.072 . . . . 0.0 107.919 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 50.3 m -75.33 172.16 12.94 Favored 'General case' 0 CA--C 1.503 -0.841 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -61.38 -40.04 92.9 Favored 'General case' 0 C--N 1.358 0.942 0 N-CA-C 107.972 -1.122 . . . . 0.0 107.972 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.3 t80 -139.22 126.95 21.95 Favored 'General case' 0 N--CA 1.434 -1.225 0 N-CA-C 106.146 -1.798 . . . . 0.0 106.146 178.311 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.85 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -148.03 159.07 44.28 Favored 'General case' 0 N--CA 1.435 -1.225 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -179.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.684 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.572 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 . . . . . 0 N--CA 1.489 1.484 0 CA-C-O 120.952 0.406 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -106.03 172.33 6.86 Favored 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -73.68 139.83 45.66 Favored 'General case' 0 CA--C 1.497 -1.066 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 68.0 t -102.28 120.12 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.544 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.52 -36.51 8.73 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.694 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 -178.397 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.01 152.86 40.8 Favored 'General case' 0 CA--C 1.492 -1.276 0 N-CA-C 107.745 -1.206 . . . . 0.0 107.745 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.594 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.2 t -94.9 -174.74 3.35 Favored 'General case' 0 CA--C 1.492 -1.265 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.255 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 41.7 pttt -42.93 107.09 0.07 Allowed 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 122.243 1.02 . . . . 0.0 110.766 -179.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.594 HG13 ' O ' ' A' ' 57' ' ' THR . 17.2 m -122.38 162.81 21.62 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.344 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -103.2 135.93 43.94 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 179.817 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.22 158.46 26.85 Favored Glycine 0 CA--C 1.486 -1.725 0 N-CA-C 107.589 -2.205 . . . . 0.0 107.589 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.8 m -107.14 130.06 54.75 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 107.479 -1.304 . . . . 0.0 107.479 -179.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.557 HG22 HG12 ' A' ' 75' ' ' ILE . 63.3 t -76.1 102.06 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.142 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 59.9 tptt -72.85 -44.04 61.88 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 -179.524 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 96.6 m95 -144.16 139.36 28.74 Favored 'General case' 0 CA--C 1.496 -1.099 0 C-N-CA 119.675 -0.81 . . . . 0.0 108.955 -178.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.494 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 50.2 t80 -151.18 121.49 7.3 Favored 'General case' 0 CA--C 1.493 -1.247 0 N-CA-C 105.585 -2.005 . . . . 0.0 105.585 177.074 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 -113.35 122.08 46.32 Favored 'General case' 0 CA--C 1.5 -0.958 0 N-CA-C 107.342 -1.355 . . . . 0.0 107.342 -179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.3 t -63.86 -39.82 86.82 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -63.28 -39.68 95.25 Favored 'General case' 0 C--N 1.353 0.732 0 O-C-N 122.27 -0.269 . . . . 0.0 110.322 -178.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.426 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 24.5 m120 -72.93 -30.97 64.29 Favored 'General case' 0 CA--C 1.499 -0.996 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 83.56 13.77 75.1 Favored Glycine 0 C--N 1.348 1.218 0 N-CA-C 107.934 -2.067 . . . . 0.0 107.934 -179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.426 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 46.9 p90 -158.89 168.22 27.36 Favored 'General case' 0 CA--C 1.495 -1.171 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -159.5 -167.79 20.63 Favored Glycine 0 CA--C 1.488 -1.636 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.72 137.34 51.54 Favored 'General case' 0 CA--C 1.496 -1.131 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 -179.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.557 HG12 HG22 ' A' ' 63' ' ' VAL . 90.0 mt -122.12 129.55 75.27 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.158 0 N-CA-C 106.705 -1.591 . . . . 0.0 106.705 179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 35.3 m120 -96.49 129.24 43.9 Favored 'General case' 0 CA--C 1.494 -1.187 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.513 HH21 HG11 ' A' ' 59' ' ' VAL . 78.4 mtp180 -68.63 133.0 47.83 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 106.818 -1.549 . . . . 0.0 106.818 179.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.6 t30 -88.87 -5.29 58.12 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -100.74 -29.45 12.27 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.257 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 5.4 m -119.47 -14.88 9.11 Favored 'General case' 0 C--N 1.355 0.819 0 C-N-CA 119.772 -0.771 . . . . 0.0 110.071 -177.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 74.9 mmtt 63.8 47.87 3.42 Favored 'General case' 0 CA--C 1.495 -1.155 0 CA-C-O 122.131 0.967 . . . . 0.0 109.051 -179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -123.3 151.53 42.31 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.286 -1.375 . . . . 0.0 107.286 178.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -85.45 137.4 32.94 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.8 t -130.21 142.02 44.85 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.966 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 179.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -89.78 132.26 35.31 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -179.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.497 HG22 ' N ' ' A' ' 87' ' ' HIS . 9.4 p -120.89 155.5 24.38 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.106 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 -179.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.497 ' N ' HG22 ' A' ' 86' ' ' VAL . 29.3 t-80 -139.36 163.85 31.4 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 106.927 -1.509 . . . . 0.0 106.927 -178.47 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -62.92 -36.71 84.3 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 65.3 p -76.84 1.47 17.33 Favored 'General case' 0 CA--C 1.501 -0.926 0 O-C-N 122.004 -0.435 . . . . 0.0 110.172 -178.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -92.18 -11.52 35.28 Favored 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.7 mt -84.18 119.36 33.11 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.03 0 N-CA-C 106.756 -1.572 . . . . 0.0 106.756 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -94.34 -42.44 8.9 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.876 -178.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -103.73 138.73 39.95 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 -177.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 33.4 m120 -125.86 150.3 47.99 Favored 'General case' 0 CA--C 1.5 -0.949 0 N-CA-C 106.468 -1.678 . . . . 0.0 106.468 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -70.08 132.44 88.33 Favored Pre-proline 0 C--N 1.353 0.732 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 179.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -70.07 -27.96 24.37 Favored 'Trans proline' 0 CA--C 1.503 -1.048 0 C-N-CA 121.752 1.634 . . . . 0.0 114.616 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.2 mtp180 -70.75 -39.29 73.37 Favored 'General case' 0 CA--C 1.499 -0.997 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 -179.495 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 21.6 mttp -140.07 105.67 5.11 Favored 'General case' 0 CA--C 1.491 -1.315 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.9 p90 -80.03 114.01 18.63 Favored 'General case' 0 N--CA 1.435 -1.221 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 139' ' ' ALA . 88.9 mt -129.82 149.97 51.33 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 42.0 mmt180 -98.78 15.02 26.71 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 179.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.2 t -104.29 162.26 13.35 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 -179.16 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 28.6 m -119.56 163.95 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.088 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -75.88 124.81 7.58 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.583 -1.807 . . . . 0.0 108.583 -179.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -78.05 122.64 25.84 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 91.14 1.85 71.96 Favored Glycine 0 C--N 1.352 1.465 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -93.0 152.92 19.04 Favored 'General case' 0 CA--C 1.494 -1.189 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 98.3 m -92.91 127.14 38.32 Favored 'General case' 0 N--CA 1.436 -1.16 0 N-CA-C 105.428 -2.064 . . . . 0.0 105.428 178.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 16.3 m -127.94 162.7 33.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -178.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.11 131.78 54.74 Favored 'General case' 0 CA--C 1.499 -0.999 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -178.392 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.417 ' CE2' HG21 ' A' ' 75' ' ' ILE . 50.5 p90 -154.67 161.05 41.74 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.182 -179.198 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -97.0 152.4 18.77 Favored 'General case' 0 CA--C 1.495 -1.168 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.649 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 57.1 t -113.52 124.42 70.15 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.174 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 -179.261 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -124.48 159.4 30.51 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.48 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 179.121 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -69.34 144.39 53.49 Favored 'General case' 0 CA--C 1.495 -1.152 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -137.24 174.61 21.64 Favored Glycine 0 CA--C 1.495 -1.197 0 N-CA-C 107.625 -2.19 . . . . 0.0 107.625 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -68.32 -27.38 66.23 Favored 'General case' 0 CA--C 1.504 -0.806 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.633 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -89.09 4.22 49.15 Favored 'General case' 0 CA--C 1.502 -0.891 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -179.103 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 117.6 -79.57 0.3 Allowed Glycine 0 CA--C 1.492 -1.345 0 N-CA-C 107.894 -2.082 . . . . 0.0 107.894 179.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.86 131.93 54.69 Favored 'General case' 0 CA--C 1.497 -1.078 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 -178.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.99 135.04 53.37 Favored 'General case' 0 CA--C 1.498 -1.025 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.61 146.56 30.03 Favored 'General case' 0 N--CA 1.44 -0.957 0 N-CA-C 107.532 -1.284 . . . . 0.0 107.532 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -147.3 152.87 38.98 Favored 'General case' 0 CA--C 1.497 -1.075 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 179.687 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 65.0 t30 60.42 55.05 3.62 Favored 'General case' 0 C--N 1.359 1.015 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 95.6 t -82.37 120.19 33.34 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.944 0 N-CA-C 107.801 -1.185 . . . . 0.0 107.801 -179.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 72.8 p -137.91 166.88 22.95 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.63 174.0 54.03 Favored Glycine 0 C--N 1.349 1.289 0 N-CA-C 106.716 -2.554 . . . . 0.0 106.716 179.095 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.461 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.8 Cg_endo -69.21 135.37 31.58 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 121.217 1.278 . . . . 0.0 112.06 -179.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 91.53 -6.03 80.32 Favored Glycine 0 C--N 1.349 1.274 0 N-CA-C 108.247 -1.941 . . . . 0.0 108.247 -179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 90.82 8.56 65.13 Favored Glycine 0 C--N 1.355 1.61 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 128' ' ' PRO . 35.7 m -76.88 153.71 83.01 Favored Pre-proline 0 N--CA 1.441 -0.878 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -70.52 154.23 64.86 Favored 'Trans proline' 0 CA--C 1.5 -1.19 0 C-N-CA 121.603 1.535 . . . . 0.0 112.367 179.257 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.41 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.5 m -80.09 135.41 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.96 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 -179.336 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 62.8 tt0 -67.52 -39.79 85.1 Favored 'General case' 0 CA--C 1.501 -0.904 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 103.57 -159.6 16.78 Favored Glycine 0 C--N 1.348 1.227 0 N-CA-C 107.193 -2.363 . . . . 0.0 107.193 -179.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.6 t -93.51 -169.5 2.14 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.7 tptp -61.85 -44.97 95.76 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 60.5 t80 -153.59 135.31 14.47 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 106.288 -1.745 . . . . 0.0 106.288 179.381 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.419 ' O ' HD22 ' A' ' 100' ' ' LEU . . . -145.7 65.42 1.23 Allowed 'General case' 0 CA--C 1.498 -1.031 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 -178.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.261 1.7 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.571 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 28.1 t0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 120.742 0.306 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . 0.523 ' HE3' ' H ' ' A' ' 53' ' ' LYS . 0.0 OUTLIER 66.13 -169.49 0.2 Allowed 'General case' 0 C--N 1.358 0.963 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.869 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . 0.523 ' H ' ' HE3' ' A' ' 52' ' ' LYS . 98.7 mttt -85.37 137.26 33.06 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.9 t -98.12 119.32 45.97 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.329 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 178.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.498 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -90.41 -36.36 8.27 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.721 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -178.54 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.637 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -144.53 151.1 38.62 Favored 'General case' 0 CA--C 1.493 -1.226 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.552 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -94.34 -174.47 3.36 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.283 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 39.2 pttt -45.02 106.39 0.07 Allowed 'General case' 0 N--CA 1.443 -0.781 0 CA-C-O 122.077 0.941 . . . . 0.0 110.602 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.552 HG13 ' O ' ' A' ' 57' ' ' THR . 17.7 m -125.05 163.13 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.492 -1.283 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 178.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.5 mt -100.83 139.36 36.63 Favored 'General case' 0 N--CA 1.435 -1.197 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 160.56 27.45 Favored Glycine 0 CA--C 1.49 -1.495 0 N-CA-C 107.926 -2.07 . . . . 0.0 107.926 -179.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 94.0 m -107.11 130.81 54.64 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.641 HG22 HG12 ' A' ' 75' ' ' ILE . 98.8 t -77.18 114.77 18.03 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.999 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 58.1 mtpt -70.79 -41.72 71.3 Favored 'General case' 0 CA--C 1.492 -1.288 0 N-CA-C 107.421 -1.326 . . . . 0.0 107.421 179.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -171.58 148.83 2.54 Favored 'General case' 0 N--CA 1.435 -1.18 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.495 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 40.2 t80 -143.11 122.11 12.81 Favored 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 105.505 -2.035 . . . . 0.0 105.505 179.061 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 49.3 t-20 -97.47 121.68 39.66 Favored 'General case' 0 CA--C 1.5 -0.947 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.609 HG22 ' HB3' ' A' ' 102' ' ' SER . 75.3 t -63.38 -40.21 88.18 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 -179.355 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 89.7 mtm180 -63.48 -40.34 96.84 Favored 'General case' 0 C--N 1.352 0.683 0 CA-C-N 116.718 -0.219 . . . . 0.0 110.566 -178.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.452 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 25.2 m120 -73.95 -31.36 62.99 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 -179.048 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.53 14.89 75.03 Favored Glycine 0 C--N 1.347 1.146 0 N-CA-C 107.82 -2.112 . . . . 0.0 107.82 -179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.452 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.65 166.12 33.68 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -162.28 -163.38 14.93 Favored Glycine 0 CA--C 1.488 -1.612 0 N-CA-C 107.454 -2.258 . . . . 0.0 107.454 -179.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -127.92 139.04 52.84 Favored 'General case' 0 CA--C 1.498 -1.038 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.641 HG12 HG22 ' A' ' 63' ' ' VAL . 88.2 mt -126.3 129.25 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.125 0 N-CA-C 106.165 -1.791 . . . . 0.0 106.165 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 4.4 m-20 -100.01 135.13 41.9 Favored 'General case' 0 CA--C 1.494 -1.199 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 80.7 mtp180 -70.54 135.47 48.57 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -85.87 -4.42 59.16 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 94.7 m-20 -97.53 -38.48 9.55 Favored 'General case' 0 CA--C 1.506 -0.749 0 C-N-CA 119.885 -0.726 . . . . 0.0 110.413 -178.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 64.1 p -113.94 -12.05 12.71 Favored 'General case' 0 CA--C 1.5 -0.943 0 C-N-CA 120.052 -0.659 . . . . 0.0 110.472 -178.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.2 mmtm 65.8 28.85 10.79 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 -179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -96.89 149.46 21.85 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 107.386 -1.339 . . . . 0.0 107.386 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -83.85 139.53 32.59 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 -179.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.1 t -131.44 142.37 43.47 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.016 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 90.0 t80 -92.4 132.13 37.01 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 -179.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.48 HG22 ' N ' ' A' ' 87' ' ' HIS . 7.6 p -122.09 154.43 26.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.233 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 -179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.48 ' N ' HG22 ' A' ' 86' ' ' VAL . 34.4 t-80 -137.15 157.94 45.54 Favored 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.469 -1.678 . . . . 0.0 106.469 -178.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.1 pt20 -64.75 -18.26 64.89 Favored 'General case' 0 CA--C 1.508 -0.669 0 O-C-N 122.211 -0.306 . . . . 0.0 110.402 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 70.1 p -89.26 1.86 55.12 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -99.32 -4.68 31.21 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 73.1 mt -83.39 118.46 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.997 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 -179.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 60.9 tptt -87.01 -42.88 12.76 Favored 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.415 -177.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -108.41 138.9 43.93 Favored 'General case' 0 CA--C 1.498 -1.024 0 C-N-CA 119.929 -0.708 . . . . 0.0 109.348 -177.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 24.9 m120 -130.31 159.04 38.15 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 106.269 -1.752 . . . . 0.0 106.269 179.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -72.54 140.6 81.94 Favored Pre-proline 0 C--N 1.353 0.747 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 179.694 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -78.31 -27.53 5.31 Favored 'Trans proline' 0 C--N 1.314 -1.271 0 C-N-CA 121.671 1.581 . . . . 0.0 113.567 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 29.3 mmt85 -70.38 -41.31 73.24 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 38.9 mtmm -138.63 138.03 37.46 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 21.9 p90 -82.73 116.21 21.99 Favored 'General case' 0 N--CA 1.437 -1.096 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.631 HD22 ' HB3' ' A' ' 139' ' ' ALA . 82.7 mt -121.66 136.54 54.94 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.062 -1.458 . . . . 0.0 107.062 179.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 1.5 mpt_? -113.37 16.83 18.85 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.609 ' HB3' HG22 ' A' ' 68' ' ' VAL . 84.1 p -126.95 162.01 26.99 Favored 'General case' 0 CA--C 1.498 -1.046 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' N ' ' A' ' 104' ' ' GLY . 6.6 p -120.05 155.32 23.01 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.024 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.456 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.04 146.12 36.0 Favored Glycine 0 CA--C 1.497 -1.053 0 N-CA-C 109.964 -1.254 . . . . 0.0 109.964 -177.933 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -78.1 135.27 37.67 Favored 'General case' 0 N--CA 1.438 -1.033 0 N-CA-C 107.199 -1.408 . . . . 0.0 107.199 179.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 81.98 1.58 90.33 Favored Glycine 0 C--N 1.351 1.366 0 N-CA-C 108.946 -1.662 . . . . 0.0 108.946 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -84.08 138.14 33.21 Favored 'General case' 0 N--CA 1.426 -1.655 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 94.7 m -88.19 129.41 35.34 Favored 'General case' 0 CA--C 1.495 -1.145 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 27.5 m -128.32 160.31 38.58 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.007 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -110.09 128.85 55.68 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -156.17 161.01 40.37 Favored 'General case' 0 CA--C 1.501 -0.907 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.314 -178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -98.4 153.18 18.76 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 105.523 -2.029 . . . . 0.0 105.523 178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.637 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.6 t -114.62 125.52 71.95 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.191 0 N-CA-C 106.718 -1.586 . . . . 0.0 106.718 -179.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 31.4 m -123.99 159.57 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.543 0 N-CA-C 106.036 -1.839 . . . . 0.0 106.036 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 17.4 mt-10 -69.61 140.06 53.69 Favored 'General case' 0 CA--C 1.498 -1.028 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -135.37 179.5 17.65 Favored Glycine 0 CA--C 1.494 -1.246 0 N-CA-C 107.924 -2.07 . . . . 0.0 107.924 -179.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 49.5 mp0 -65.19 -35.52 81.33 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -84.47 6.99 21.3 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 111.38 -73.76 0.21 Allowed Glycine 0 CA--C 1.492 -1.369 0 N-CA-C 108.346 -1.901 . . . . 0.0 108.346 178.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -120.68 131.56 54.63 Favored 'General case' 0 CA--C 1.497 -1.087 0 N-CA-C 108.199 -1.038 . . . . 0.0 108.199 -178.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -126.22 135.22 51.32 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.41 147.4 29.8 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -144.95 151.59 38.87 Favored 'General case' 0 CA--C 1.498 -1.045 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 82.1 m-20 57.24 52.47 8.84 Favored 'General case' 0 C--N 1.362 1.124 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -179.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 86.3 t -80.51 119.45 30.09 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 70.8 p -137.34 168.63 19.26 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 179.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.54 178.34 53.36 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 106.275 -2.73 . . . . 0.0 106.275 178.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.522 ' O ' HG22 ' A' ' 131' ' ' VAL . 54.9 Cg_endo -69.76 135.33 30.19 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 C-N-CA 121.299 1.333 . . . . 0.0 112.135 -179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 85.8 0.66 87.55 Favored Glycine 0 C--N 1.348 1.219 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.51 9.97 74.48 Favored Glycine 0 C--N 1.355 1.634 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.522 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.8 m -76.63 155.54 83.37 Favored Pre-proline 0 N--CA 1.441 -0.894 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -70.13 160.93 47.85 Favored 'Trans proline' 0 C--N 1.315 -1.202 0 C-N-CA 121.633 1.555 . . . . 0.0 112.245 179.015 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.412 HG22 ' H ' ' A' ' 133' ' ' VAL . 2.6 m -69.42 137.69 23.7 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.79 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.04 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.3 tt0 -64.97 -41.69 95.22 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 110.5 -174.41 17.27 Favored Glycine 0 C--N 1.347 1.168 0 N-CA-C 107.259 -2.336 . . . . 0.0 107.259 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.4 t -102.87 -165.39 1.17 Allowed 'General case' 0 CA--C 1.504 -0.816 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 -179.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 41.1 ttmt -62.06 -44.09 97.44 Favored 'General case' 0 CA--C 1.501 -0.906 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 91.0 t80 -141.38 132.15 25.77 Favored 'General case' 0 N--CA 1.437 -1.123 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 179.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.631 ' HB3' HD22 ' A' ' 100' ' ' LEU . . . -146.26 156.38 43.33 Favored 'General case' 0 N--CA 1.436 -1.153 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 -179.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.264 1.825 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 179.654 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 . . . . . 0 N--CA 1.487 1.379 0 CA-C-O 121.01 0.433 . . . . 0.0 110.399 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -103.84 172.18 6.95 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -74.0 139.67 44.94 Favored 'General case' 0 N--CA 1.438 -1.041 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 67.6 t -103.6 120.0 53.02 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.409 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.521 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -89.38 -36.25 8.5 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.727 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -178.348 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.657 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.86 152.21 39.11 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.581 ' O ' HG13 ' A' ' 59' ' ' VAL . 7.9 t -95.22 -173.72 3.01 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 -179.254 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.1 mtmt -43.56 104.91 0.04 OUTLIER 'General case' 0 CA--C 1.503 -0.827 0 CA-C-O 121.666 0.746 . . . . 0.0 110.103 -179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.581 HG13 ' O ' ' A' ' 57' ' ' THR . 16.5 m -124.95 161.84 28.09 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.379 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 178.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 82.7 mt -100.6 139.25 36.54 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.69 160.47 27.4 Favored Glycine 0 CA--C 1.487 -1.704 0 N-CA-C 107.634 -2.186 . . . . 0.0 107.634 -179.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 95.5 m -106.59 129.83 54.45 Favored 'General case' 0 CA--C 1.499 -0.994 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.529 HG22 HG12 ' A' ' 75' ' ' ILE . 95.7 t -72.16 117.09 15.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.051 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 -179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 62.7 mtpt -68.39 -44.26 75.48 Favored 'General case' 0 CA--C 1.492 -1.261 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 179.294 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 65.7 p-90 -175.6 154.29 1.58 Allowed 'General case' 0 N--CA 1.436 -1.165 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 179.149 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.469 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 43.1 t80 -142.72 121.12 12.37 Favored 'General case' 0 N--CA 1.434 -1.241 0 N-CA-C 105.541 -2.022 . . . . 0.0 105.541 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 53.9 t-20 -95.23 120.5 35.56 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.081 -1.452 . . . . 0.0 107.081 -179.418 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . 0.535 HG22 ' OG ' ' A' ' 102' ' ' SER . 69.3 t -62.99 -40.27 88.38 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.736 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 -179.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 43.3 ttm180 -62.17 -43.92 97.75 Favored 'General case' 0 C--N 1.353 0.72 0 N-CA-C 110.409 -0.219 . . . . 0.0 110.409 -178.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.46 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.4 m120 -72.41 -31.63 65.67 Favored 'General case' 0 CA--C 1.499 -1.01 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -178.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 82.6 14.91 74.82 Favored Glycine 0 C--N 1.347 1.16 0 N-CA-C 107.692 -2.163 . . . . 0.0 107.692 -179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.46 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 43.2 p90 -157.82 166.46 32.66 Favored 'General case' 0 CA--C 1.497 -1.077 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -164.83 -161.47 13.86 Favored Glycine 0 CA--C 1.488 -1.61 0 N-CA-C 107.367 -2.293 . . . . 0.0 107.367 -179.14 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -128.87 141.58 51.24 Favored 'General case' 0 CA--C 1.496 -1.102 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.529 HG12 HG22 ' A' ' 63' ' ' VAL . 88.4 mt -122.99 126.4 73.67 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.218 0 N-CA-C 105.941 -1.874 . . . . 0.0 105.941 179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 67.0 t30 -87.98 120.73 29.6 Favored 'General case' 0 CA--C 1.493 -1.233 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 -179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -76.35 127.62 33.23 Favored 'General case' 0 CA--C 1.496 -1.107 0 N-CA-C 106.441 -1.689 . . . . 0.0 106.441 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -79.81 -4.09 50.59 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -70.59 -42.25 71.28 Favored 'General case' 0 N--CA 1.437 -1.098 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.484 HG22 ' O ' ' A' ' 80' ' ' THR . 17.5 m -141.83 -8.57 0.93 Allowed 'General case' 0 C--N 1.356 0.886 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.547 -178.524 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 9.8 mptt 63.0 42.28 7.57 Favored 'General case' 0 CA--C 1.498 -1.028 0 O-C-N 121.644 -0.66 . . . . 0.0 109.705 179.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.84 -8.57 36.98 Favored 'General case' 0 CA--C 1.493 -1.231 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.572 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.7 t0 74.83 133.74 0.05 OUTLIER 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 -179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.1 t -129.51 142.92 42.68 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.943 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 -179.362 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 89.8 t80 -88.99 132.94 34.5 Favored 'General case' 0 N--CA 1.442 -0.861 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 87' ' ' HIS . 10.4 p -122.67 154.87 27.93 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.176 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 -179.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.491 ' N ' HG22 ' A' ' 86' ' ' VAL . 36.0 t-80 -139.17 158.13 44.71 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 -178.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . . . . . . . . . 25.0 pt20 -65.18 -16.52 63.6 Favored 'General case' 0 C--N 1.351 0.637 0 O-C-N 122.222 -0.299 . . . . 0.0 110.268 -179.119 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 67.7 p -89.03 1.8 54.99 Favored 'General case' 0 CA--C 1.498 -1.032 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -179.588 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -100.74 -3.25 30.49 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 -179.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 75.1 mt -83.5 118.31 30.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 -179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 64.9 tttp -85.74 -43.37 13.42 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.106 -178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -115.13 140.74 48.82 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 108.928 -0.768 . . . . 0.0 108.928 -177.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 32.0 m120 -119.39 159.25 24.56 Favored 'General case' 0 CA--C 1.499 -1.003 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 35.6 t-20 -70.34 126.61 92.38 Favored Pre-proline 0 N--CA 1.444 -0.767 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -70.72 -25.18 24.46 Favored 'Trans proline' 0 C--N 1.317 -1.105 0 C-N-CA 121.49 1.46 . . . . 0.0 114.332 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -70.22 -41.15 73.98 Favored 'General case' 0 CA--C 1.503 -0.844 0 N-CA-C 109.055 -0.721 . . . . 0.0 109.055 -179.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -140.06 130.82 25.86 Favored 'General case' 0 CA--C 1.492 -1.286 0 N-CA-C 106.417 -1.698 . . . . 0.0 106.417 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -76.42 114.99 15.74 Favored 'General case' 0 N--CA 1.438 -1.054 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.727 HD22 ' HB1' ' A' ' 139' ' ' ALA . 84.6 mt -125.91 140.83 52.31 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -179.863 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 26.6 mmm180 -107.89 15.99 23.92 Favored 'General case' 0 CA--C 1.499 -1.014 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.535 ' OG ' HG22 ' A' ' 68' ' ' VAL . 50.3 m -125.52 162.65 24.43 Favored 'General case' 0 CA--C 1.498 -1.044 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 -178.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.496 HG12 HG11 ' A' ' 133' ' ' VAL . 35.1 m -119.0 163.72 15.94 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.946 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 -179.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . -73.65 139.47 26.5 Favored Glycine 0 C--N 1.352 1.418 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -178.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.4 134.46 36.57 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.1 1.86 90.44 Favored Glycine 0 C--N 1.353 1.486 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 178.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -86.64 161.38 18.51 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 -179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 97.0 m -103.37 127.95 50.59 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 106.046 -1.835 . . . . 0.0 106.046 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.99 161.43 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 -178.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -109.58 130.46 55.51 Favored 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -156.43 161.17 40.11 Favored 'General case' 0 CA--C 1.504 -0.822 0 C-N-CA 118.61 -1.236 . . . . 0.0 110.44 -178.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 65.8 m-20 -94.38 152.12 18.87 Favored 'General case' 0 CA--C 1.493 -1.213 0 N-CA-C 105.585 -2.006 . . . . 0.0 105.585 178.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.657 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.2 t -115.03 124.25 71.49 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.279 -1.748 . . . . 0.0 106.279 -179.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -125.2 159.53 32.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.433 0 N-CA-C 106.02 -1.844 . . . . 0.0 106.02 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -69.44 141.96 53.93 Favored 'General case' 0 CA--C 1.498 -1.02 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 -179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -141.12 -179.22 18.2 Favored Glycine 0 C--N 1.347 1.183 0 N-CA-C 108.136 -1.985 . . . . 0.0 108.136 -179.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.8 mp0 -68.73 -26.15 65.11 Favored 'General case' 0 CA--C 1.504 -0.804 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.04 10.25 22.33 Favored 'General case' 0 CA--C 1.5 -0.953 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 102.52 -71.35 0.32 Allowed Glycine 0 CA--C 1.49 -1.491 0 N-CA-C 107.281 -2.328 . . . . 0.0 107.281 179.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.41 130.16 53.44 Favored 'General case' 0 N--CA 1.436 -1.133 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 -179.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -122.76 135.37 54.54 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 179.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.33 146.73 30.21 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -143.65 150.16 38.34 Favored 'General case' 0 N--CA 1.439 -1.018 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 179.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 56.99 52.64 8.95 Favored 'General case' 0 C--N 1.361 1.081 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 96.9 t -78.54 121.51 31.68 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.914 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 66.6 p -137.16 167.23 21.96 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.19 176.36 54.69 Favored Glycine 0 C--N 1.35 1.326 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 179.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.53 ' O ' HG22 ' A' ' 131' ' ' VAL . 48.4 Cg_endo -68.82 134.87 31.16 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 121.293 1.329 . . . . 0.0 112.034 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 84.33 1.06 89.52 Favored Glycine 0 C--N 1.349 1.268 0 N-CA-C 108.192 -1.963 . . . . 0.0 108.192 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 81.97 15.9 73.78 Favored Glycine 0 C--N 1.355 1.597 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 179.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.53 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.1 m -81.72 156.11 70.52 Favored Pre-proline 0 N--CA 1.44 -0.972 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 -179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.09 152.87 68.5 Favored 'Trans proline' 0 CA--C 1.501 -1.146 0 C-N-CA 122.216 1.944 . . . . 0.0 112.583 178.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.496 HG11 HG12 ' A' ' 103' ' ' VAL . 2.6 m -67.08 136.88 25.88 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.767 0 N-CA-C 108.361 -0.978 . . . . 0.0 108.361 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 98.8 mt-30 -67.8 -40.33 83.9 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 106.51 -170.23 16.13 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 106.767 -2.533 . . . . 0.0 106.767 -178.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -116.85 178.33 4.38 Favored 'General case' 0 CA--C 1.502 -0.904 0 N-CA-C 107.301 -1.37 . . . . 0.0 107.301 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -63.86 -39.58 94.54 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.2 t80 -116.27 131.35 56.97 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 179.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.727 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -145.24 154.53 42.48 Favored 'General case' 0 N--CA 1.434 -1.257 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -178.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.263 1.769 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.514 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 . . . . . 0 N--CA 1.489 1.486 0 CA-C-O 121.074 0.464 . . . . 0.0 110.625 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -104.36 171.43 7.34 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LYS . . . . . . . . . . . . . 30.2 mtpp -73.91 142.76 45.94 Favored 'General case' 0 CA--C 1.496 -1.113 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 -179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 54' ' ' VAL . 11.2 p -104.61 125.83 59.46 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.275 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 178.353 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.533 HG13 HG12 ' A' ' 113' ' ' VAL . 0.0 OUTLIER -94.75 -35.22 5.96 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 -178.344 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.656 ' HB3' ' HB ' ' A' ' 113' ' ' VAL . . . -145.23 151.68 38.78 Favored 'General case' 0 CA--C 1.492 -1.26 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . 0.555 ' O ' HG13 ' A' ' 59' ' ' VAL . 0.3 OUTLIER -93.96 -173.72 3.21 Favored 'General case' 0 CA--C 1.49 -1.342 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 -179.19 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 58.3 mtmt -46.21 106.26 0.08 Allowed 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 121.775 0.798 . . . . 0.0 110.145 -179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 57' ' ' THR . 18.1 m -121.79 163.04 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.324 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 178.52 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' LEU . . . . . . . . . . . . . 83.2 mt -101.92 138.59 38.68 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 179.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.98 161.04 28.12 Favored Glycine 0 CA--C 1.487 -1.671 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 -179.54 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' THR . . . . . . . . . . . . . 93.9 m -105.72 129.58 53.9 Favored 'General case' 0 CA--C 1.498 -1.052 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.575 HG22 HG12 ' A' ' 75' ' ' ILE . 88.8 t -79.29 112.11 16.94 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.155 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 -179.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 60.0 tptt -65.72 -44.95 84.48 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 179.559 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -172.59 157.03 3.78 Favored 'General case' 0 N--CA 1.437 -1.109 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.529 ' HA ' ' HA3' ' A' ' 73' ' ' GLY . 35.9 t80 -145.5 120.81 10.24 Favored 'General case' 0 N--CA 1.434 -1.246 0 N-CA-C 105.169 -2.16 . . . . 0.0 105.169 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -101.67 120.87 41.02 Favored 'General case' 0 N--CA 1.437 -1.08 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -179.053 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' VAL . . . . . . . . . . . . . 76.6 t -65.4 -40.08 87.26 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.759 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -62.92 -39.97 96.18 Favored 'General case' 0 CA--C 1.506 -0.726 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -178.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.428 ' HB3' ' CE2' ' A' ' 72' ' ' TYR . 26.5 m120 -73.87 -30.54 62.69 Favored 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 85.0 13.66 71.28 Favored Glycine 0 N--CA 1.437 -1.244 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . 0.428 ' CE2' ' HB3' ' A' ' 70' ' ' ASN . 48.6 p90 -158.49 167.51 29.45 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.803 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.529 ' HA3' ' HA ' ' A' ' 66' ' ' PHE . . . -155.01 -170.72 20.98 Favored Glycine 0 CA--C 1.488 -1.652 0 N-CA-C 107.255 -2.338 . . . . 0.0 107.255 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -128.27 138.15 52.3 Favored 'General case' 0 CA--C 1.497 -1.08 0 N-CA-C 107.807 -1.182 . . . . 0.0 107.807 -179.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.575 HG12 HG22 ' A' ' 63' ' ' VAL . 86.4 mt -122.83 130.39 74.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.057 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 20.5 m120 -96.01 128.4 42.88 Favored 'General case' 0 CA--C 1.495 -1.167 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 79.5 mtp180 -70.77 132.32 45.16 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.7 m-20 -84.61 -8.99 58.7 Favored 'General case' 0 CA--C 1.504 -0.801 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.7 m-20 -98.9 -31.53 11.79 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 119.883 -0.727 . . . . 0.0 110.712 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 3.6 m -115.43 -15.46 11.51 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.795 -0.762 . . . . 0.0 109.936 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.8 mmtm 64.3 44.54 4.26 Favored 'General case' 0 CA--C 1.497 -1.096 0 CA-C-O 121.921 0.867 . . . . 0.0 108.741 -179.459 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -121.57 151.78 39.96 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -83.68 140.12 32.35 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 -179.58 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 39.3 t -129.76 141.73 45.71 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' PHE . . . . . . . . . . . . . 85.4 t80 -89.41 131.41 35.49 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' VAL . . . . . . . . . . . . . 4.1 p -118.73 149.23 21.22 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.148 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.404 ' CD2' ' H ' ' A' ' 88' ' ' GLN . 9.0 t-160 -127.52 168.55 14.78 Favored 'General case' 0 N--CA 1.44 -0.955 0 N-CA-C 107.74 -1.207 . . . . 0.0 107.74 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLN . . . . . 0.404 ' H ' ' CD2' ' A' ' 87' ' ' HIS . 98.4 mt-30 -69.99 -23.82 63.21 Favored 'General case' 0 CA--C 1.503 -0.833 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . . . . . . . . . 68.6 p -83.74 1.29 43.47 Favored 'General case' 0 CA--C 1.497 -1.065 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 -179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ALA . . . . . . . . . . . . . . . -91.13 -9.18 46.51 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 28.4 mm -78.11 116.97 22.59 Favored 'Isoleucine or valine' 0 C--N 1.354 0.798 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 124' ' ' ASN . 61.0 tptt -95.93 -45.34 6.98 Favored 'General case' 0 CA--C 1.501 -0.938 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -121.16 148.48 44.16 Favored 'General case' 0 CA--C 1.495 -1.169 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -154.18 178.8 9.58 Favored 'General case' 0 N--CA 1.432 -1.325 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASN . . . . . . . . . . . . . 83.0 m-20 -76.58 132.9 71.38 Favored Pre-proline 0 N--CA 1.443 -0.803 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -72.19 -26.51 17.77 Favored 'Trans proline' 0 C--N 1.316 -1.135 0 C-N-CA 121.576 1.517 . . . . 0.0 113.515 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 41.7 ptt180 -74.64 -30.25 61.56 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.8 mmtm -140.79 108.05 5.51 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 25.5 p90 -79.59 118.1 21.12 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LEU . . . . . 0.498 HD22 ' HB1' ' A' ' 139' ' ' ALA . 79.6 mt -120.56 148.04 44.39 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ARG . . . . . . . . . . . . . 41.0 mmt180 -105.51 16.93 24.69 Favored 'General case' 0 CA--C 1.499 -0.987 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 82.7 p -134.03 164.46 27.27 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -177.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.536 HG21 HG11 ' A' ' 109' ' ' VAL . 14.2 p -121.29 160.87 22.03 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.104 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 -179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . 0.526 ' N ' HG22 ' A' ' 103' ' ' VAL . . . -74.37 136.39 21.15 Favored Glycine 0 CA--C 1.495 -1.21 0 N-CA-C 109.103 -1.599 . . . . 0.0 109.103 -178.365 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.34 147.94 32.24 Favored 'General case' 0 N--CA 1.44 -0.972 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 179.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 82.75 -1.35 88.36 Favored Glycine 0 C--N 1.352 1.436 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 179.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -93.63 161.96 14.14 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 96.7 m -105.73 128.26 53.58 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.536 HG11 HG21 ' A' ' 103' ' ' VAL . 17.7 m -128.88 161.77 37.41 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.017 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 42.3 tt0 -109.66 130.4 55.52 Favored 'General case' 0 CA--C 1.498 -1.027 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' PHE . . . . . 0.471 ' CE2' HG21 ' A' ' 75' ' ' ILE . 49.5 p90 -155.15 160.51 40.98 Favored 'General case' 0 CA--C 1.503 -0.843 0 C-N-CA 118.757 -1.177 . . . . 0.0 110.172 -178.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -97.17 155.63 16.75 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 179.109 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.656 ' HB ' ' HB3' ' A' ' 56' ' ' ALA . 59.9 t -117.16 125.45 73.95 Favored 'Isoleucine or valine' 0 CA--C 1.493 -1.212 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -179.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.3 m -124.95 160.01 30.84 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.426 0 N-CA-C 106.048 -1.834 . . . . 0.0 106.048 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -69.03 141.19 54.91 Favored 'General case' 0 CA--C 1.498 -1.03 0 N-CA-C 108.274 -1.009 . . . . 0.0 108.274 -179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -139.07 -179.1 17.04 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 108.124 -1.99 . . . . 0.0 108.124 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -68.64 -26.21 65.22 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -89.78 9.54 26.93 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 108.336 -0.986 . . . . 0.0 108.336 -179.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 104.04 -71.64 0.26 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 107.463 -2.255 . . . . 0.0 107.463 179.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -121.18 130.46 53.72 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 88.5 tt0 -123.86 134.74 53.51 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -81.99 146.53 29.68 Favored 'General case' 0 CA--C 1.5 -0.951 0 N-CA-C 107.578 -1.268 . . . . 0.0 107.578 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -146.22 152.25 38.9 Favored 'General case' 0 N--CA 1.437 -1.117 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ASN . . . . . 0.421 ' HA ' ' HB2' ' A' ' 92' ' ' LYS . 82.3 m-20 58.46 57.86 3.65 Favored 'General case' 0 C--N 1.358 0.95 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' VAL . . . . . . . . . . . . . 83.1 t -83.87 119.99 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.982 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 -179.305 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' THR . . . . . . . . . . . . . 76.2 p -135.95 168.04 20.09 Favored 'General case' 0 CA--C 1.498 -1.036 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.64 174.34 54.88 Favored Glycine 0 C--N 1.349 1.302 0 N-CA-C 106.75 -2.54 . . . . 0.0 106.75 178.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.533 ' O ' HG22 ' A' ' 131' ' ' VAL . 55.5 Cg_endo -69.75 134.49 28.13 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 C-N-CA 121.363 1.375 . . . . 0.0 112.002 -179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 90.36 -6.03 82.52 Favored Glycine 0 C--N 1.349 1.284 0 N-CA-C 108.103 -1.999 . . . . 0.0 108.103 -179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 88.31 9.21 70.2 Favored Glycine 0 C--N 1.354 1.564 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.533 HG22 ' O ' ' A' ' 128' ' ' PRO . 34.3 m -81.37 157.41 70.42 Favored Pre-proline 0 N--CA 1.44 -0.937 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -59.88 149.01 86.2 Favored 'Trans proline' 0 CA--C 1.501 -1.141 0 C-N-CA 122.057 1.838 . . . . 0.0 112.649 178.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 5.9 m -75.88 152.85 6.13 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -179.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -64.24 -40.98 97.14 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' GLY . . . . . . . . . . . . . . . 95.11 172.01 37.01 Favored Glycine 0 C--N 1.348 1.195 0 N-CA-C 107.985 -2.046 . . . . 0.0 107.985 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 45.4 t -72.46 149.11 44.47 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -61.99 -39.53 92.52 Favored 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -119.68 128.23 53.62 Favored 'General case' 0 N--CA 1.437 -1.102 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 178.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ALA . . . . . 0.498 ' HB1' HD22 ' A' ' 100' ' ' LEU . . . -146.34 160.27 42.26 Favored 'General case' 0 N--CA 1.435 -1.207 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 -178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.262 1.72 0 CA-C-O 117.962 -1.018 . . . . 0.0 108.642 179.562 . . . . . . . . 0 0 . 1 stop_ save_